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Though the GluK4 kainate receptor subunit shows limited homology and a 
restricted expression pattern relative to other kainate receptor subunits, its 
ablation results in distinct behavioral and molecular phenotypes.  
 
To study the function of GluK4, I generated a global GluK4 knockout mouse line 
by crossing a germline-expressed cre transgenic mouse line with a GluK4-floxed 
mouse line in which exon 16 of GRIK4, the gene encoding GluK4, was flanked by 
lox-P sites (floxed). Thorough characterization of GluK4 expression in the 
resulting knockout mice using RT-PCR and a custom-designed anti-GluK4 
antibody revealed that GRIK4 mRNA expression persisted though GluK4 protein 
expression was ablated.  
 
In keeping with genome-wide studies in humans that have implicated GluK4 in 
bipolar disorder and schizophrenia, I found that GluK4 mice displayed reduced 
anxiety, increased risk-taking behavior, reduced depressive behavior, impaired 
sensorimotor gating, and hyperlocomotion relative to wild-type mice. GluK4 
knockout mice also demonstrated impaired fear memory and spatial memory.  
 Furthermore, my findings indicate that GluK4 is a key mediator of excitotoxic 
neurodegeneration: GluK4 knockout mice showed robust neuroprotection in the 
Cornu Ammonis 3 (CA3) region of the hippocampus following intrahippocampal 
injection of kainate, a potent excitotoxin, and widespread neuroprotection 
throughout the hippocampus following hypoxia-ischemia. Molecular and 
biochemical analysis of kainate- and sham-treated wild-type and GluK4 knockout 
hippocampal tissue revealed that GluK4 may act through the c-Jun N-terminal 
Kinase (JNK) pathway to regulate the molecular cascades that lead to 
excitotoxicity. Finally, I found preliminary evidence to suggest that GluK4 may 
regulate hippocampal seizure activity following intraperitoneal injection of 
kainate. 
 
Together, these findings suggest that GluK4 may be relevant to the 
understanding and treatment of human neuropsychiatric and neurodegenerative 
disorders.  
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CHAPTER 1: INTRODUCTION 
Glutamate is the principal excitatory neurotransmitter in the central nervous 
system (CNS), and imbalances in glutamatergic transmission have profound 
behavioral and physiological consequences. Hypoactivity of the glutamate 
system has been implicated in human affective disorders such as schizophrenia, 
based initially on clinical observations that glutamate antagonists can mimic 
certain symptoms of the disease (Krystal et al., 1994). Conversely, hyperactivity 
of the glutamate system can result in excitotoxic neurodegeneration, a form of 
neuronal cell death that often accompanies ischemic stroke (Lucas and 
Newhouse, 1957; Olney, 1969). 
 
Glutamate Receptor Physiology 
Both normal and pathological aspects of excitatory neurotransmission are 
contingent upon the interactions between glutamate and its receptors. Glutamate 
receptors can be broadly classified as metabotropic or ionotropic. Metabotropic 
receptors are G-protein-coupled, and ligand binding results in the activation of 
downstream signaling pathways. Ionotropic receptors are ligand-gated ion 
channels. Three subtypes of ionotropic receptors – N-methyl-D-aspartate 
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and 
kainate receptors – were initially distinguished by the eponymous glutamate 
analogs for which they show the highest affinity (Lodge, 2009). Though kainate 
receptors were the last of the three subtypes to be identified (Bettler et al., 1990), 
pharmacological isolation of kainate receptor activity from that of NMDA and 
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AMPA receptors in vitro, coupled with the genetic ablation of kainate receptor 
subunits in vivo, have indicated that they play an essential role in regulating the 
overall excitability of neuronal networks.  
 
Like AMPA and NMDA receptors, kainate receptors are permeable to sodium, 
potassium, and calcium, though permeability to the latter varies with kainate 
receptor subunit mRNA editing (Köhler et al., 1993). Nevertheless, kainate 
receptors display a distinct electrophysiological profile upon activation: they 
mediate excitatory post-synaptic currents (EPSCs) of smaller amplitude than 
AMPA or NMDA receptors, with slow decay kinetics (Castillo et al., 1997; Vignes 
and Collingridge, 1997). In response to repetitive stimulation, these postsynaptic 
kainate receptors contribute to temporal summation of synaptic input, where 
EPSC amplitude increases progressively after each stimulus and neuronal 
excitability is enhanced (Frerking and Ohliger-Frerking, 2002). Kainate receptors 
are also located pre-synaptically, where they act as autoreceptors. At 
glutamatergic synapses, presynaptic kainate receptors modulate excitatory 
transmission by facilitating or depressing glutamate release. At γ-Aminobutyric 
Acid (GABA)-ergic synapses, presynaptic kainate receptors modulate inhibitory 
transmission by facilitating or depressing the release of the inhibitor 
neurotransmitter GABA (Rodriguez-Moreno et al., 1997; Schmitz et al., 2000; 
Cossart et al., 2001). Furthermore, there is a growing body of evidence to 
suggest that kainate receptors can act in a non-canonical, metabotropic fashion. 
For instance, kainate receptors can control the excitability of hippocampal 
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pyramidal cells by inhibiting slow afterhyperpolarization (sAHP) (Melyan et al., 
2002), a post-synaptic, Ca2+-dependent K+ current that occurs after burst firing to 
limit further action potentials. The inhibition of sAHP by kainate receptors is 
independent of ionotropic action, and acts through a metabotropic signaling 
cascade (Melyan et al., 2002; Melyan and Lancaster, 2004). Thus, through their 
many, disparate functions, kainate receptors serve to fine-tune network 
excitability, synaptic plasticity, and, potentially, cognition. 
 
Kainate Receptor Subunits 
The function of kainate receptors is further specified by their subunit composition. 
The five kainate receptor subunit types – GluK1-5 – assemble as tetramers and 
share the same general secondary structure: an extracellular N-terminal domain; 
a transmembrane domain (M1); a p-loop (M2) domain that begins on the 
cytoplasmic face of the cell membrane and penetrates the membrane without 
traversing it, then re-emerges on the cytoplasmic face; a second and third 
transmembrane domain (M3 and M4); and, finally, the cytoplasmic C-terminal 
domain (Oswald et al., 2007) (Figure 1.1). The ligand-binding domain is 
comprised of the domain (S1) that falls between the N-terminal domain and the 
M1 domain, and the loop (S2) between M3 and M4 (Hollmann et al., 1994; Wo 
and Oswald, 1994). The N-terminal domain regulates subunit assembly 
(Leuschner and Hoch, 1999), the p-loop forms the receptor pore (Hughes, 1994), 
and the C-terminal domain contains cis-acting regulatory elements that can 
promote forward trafficking in the case of GluK2 and GluK3 (Yan et al., 2004), or 
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endoplasmic reticulum retention in the case of GluK1 and GluK5 (Ren et al., 
2003; Nasu-Nishimura et al., 2006). Depending on the subunit type, the C-
terminal domain can interact with several subsets of auxiliary proteins to regulate 
receptor trafficking, to stabilize receptors at the synapse, or to modify channel 
gating (Coussen and Mulle, 2006).  
 
Despite the similarities in their secondary structures, kainate receptor subunits 
differ in their agonist affinities: GluK1-3 have low-affinity agonist binding sites (Kd 
in the micromolar range), while GluK4 and GluK5 have high-affinity sites (Kd in 
the nanomolar range) (London and Coyle, 1979; Hampson et al., 1987). 
Furthermore, GluK4 and GluK5 share 68% sequence homology with each other, 
but only 45% with GluK1-3 (Werner et al., 1991; Herb et al., 1992; Sakimura et 
al., 1992). Low-affinity subunits can co-assemble to form functional homologous 
receptors, while high-affinity subunits must assemble with low-affinity subunits, 
as this conformation sterically hinders the endoplasmic reticulum retention motif 
that prevents high-affinity subunits from reaching the cell surface on their own 
(Herb et al., 1992; Sakimura et al., 1992).  
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FIGURE 1.1. General kainate receptor subunit structure. Kainate receptor 
subunits have three transmembrane domains, M1, M2, and M3. Interspersed 
between M1 and M3 is the pore-forming p-loop domain, M2. S1 and S2 form the 
ligand-binding domain. The N-terminal regulates subunit assembly, and the C-
terminal mediates receptor trafficking.  
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The GluK4 Kainate Receptor Subunit 
Unlike the other high-affinity subunit, GluK5, which is expressed throughout the 
CNS (Herb et al., 1992), GluK4 mRNA and protein expression are largely 
restricted to the CA3 region of the hippocampus (Werner et al., 1991; Darstein et 
al., 2003) (Figure 1.2a). Within the CA3, GluK4 mRNA is localized to the 
pyramidal cell layer, while GluK4 protein is localized to the stratum lucidum 
(Werner et al., 1991; Darstein et al., 2003). The stratum lucidum is comprised of 
the axons arising from granule cells in the dentate gyrus (DG) region of the 
hippocampus, and their synapses onto CA3 pyramidal cell dendrites (Amaral and 
Witter, 1989). The association between DG granule cells and CA3 pyramidal 
cells is known as the mossy fiber pathway (Amaral and Witter, 1989) (Figure 
1.2b). CA3 pyramidal cells then project to the Cornu Ammonis 1 (CA1) region of 
the hippocampus via Schaffer collaterals, or form recurrent collaterals within the 
stratum oriens of the CA3 (Amaral and Witter, 1989) (Figure 1.2b). Pyramidal 
cells within the CA3 also receive input from the entorhinal cortex (EC) through 
the perforant path (Lopes da Silva and Arnolds, 1978). 
 
Outside of the CA3, GluK4 protein also shows limited expression within the 
polymorphic layer (hilus) of the DG region of the hippocampus, the pyramidal 
layer of the CA1 region of the hippocampus, Purkinje cells in the cerebellum, 
scattered neurons in layers II and V of the cortex, and the central terminals of 
dorsal root ganglion (DRG) neurons in the spinal dorsal horn (Fogarty et al., 
2000; Darstein et al., 2003; Lucifora et al., 2006) (Figure 1.2a).  
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Within the hippocampus, GluK4 co-precipitates with GluK2, but not GluK3, and is 
expressed both pre- and post-synaptically (Darstein et al., 2003). 
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FIGURE 1.2. Hippocampal subregions and connectivity. (A) The 
hippocampus is comprised of 4 major subregions: Cornu Ammonis 1 (CA1; blue), 
Cornu Ammonis 2 (CA2; light gray), Cornu Ammonis 3 (CA3; green), and dentate 
gyrus (DG; yellow). Pyramidal cells form the stratum pyramidal (SP) of the CA1, 
CA2, and CA3 subregions. Dentate granule cells form the stratum granulosum 
(SG) of the dentate gyrus. The stratum oriens (SO), stratum lucidum (SL), and 
stratum radiatum (SR) are indicated for the CA3, and contain various fibers of 
passage. (B) Mossy fibers originating from the SG synapse onto pyramidal cell 
fibers in the SL to form the mossy fiber pathway. Pyramidal cells within the CA3 
can form recurrent connections. Projections from the CA3 to the CA1 form the 
Schaffer collaterals.  
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The restricted expression pattern of GluK4 suggests that receptors containing 
this subunit may have distinct signaling properties and physiological functions. 
Initial electrophysiological studies using GluK4 knockout mice have revealed that 
GluK4 ablation results in both pre- and post-synaptic deficits. The mossy fiber 
presynaptic fiber volley induced by kainate, a strong kainate receptor agonist, is 
reduced in GluK4 knockout mice relative to wild-type mice (Catches et al., 2012). 
GluK4 knockout mice also display decreased EPSC amplitude (Fernandes et al., 
2009) and impaired mossy fiber long-term potentiation (LTP) (Catches et al., 
2012). Meanwhile, mossy fiber LTP is decreased in GluK4/GluK5 double-
knockout mice (Fernandes et al., 2009), but unaffected in GluK5 knockout mice 
(Contractor et al., 2003), indicating that GluK4 plays a key role in LTP.  
 
GluK4 in Learning and Memory 
LTP, a form of synaptic plasticity, occurs when synaptic transmission is 
enhanced between a pre- and post-synaptic cell (Bliss and Collingridge, 1993). 
According to classical Hebbian theory, this process constitutes the cellular basis 
of learning and memory (Brown et al., 1990). LTP is typically dependent on 
ionotropic NMDA receptor activity (Morris, 2003); however, LTP at mossy fiber 
synapses within the CA3 is unique in that it is largely NMDA receptor-
independent, and is instead mediated by kainate receptors (Bortolotto et al., 
2003). Previous studies in which the mossy fiber pathway has been disrupted in 
mice by chemical inactivation or frank lesions to the CA3 have demonstrated the 
importance of this region to several learning and memory paradigms, including 
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fear conditioning and the Morris Water Maze (MWM) (Stupien et al., 2003; 
Florian and Roullet, 2004; Kesner, 2007).  
Given the importance of GluK4 to mossy fiber LTP, and the importance of mossy 
fiber LTP to learning and memory, I sought to elucidate the role of GluK4 in 
memory. First, I generated a global GluK4 knockout mouse line by crossing a 
transgenic cre line in which cre is expressed in germline cells (The Jackson 
Laboratory), and a second mouse line in which exon 16 of GRIK4, the gene 
encoding GluK4, was floxed (a generous gift of the Contractor Laboratory at 
Northwestern University) (Fernandes et al., 2009). Though GRIK4 mRNA 
expression persisted in this line, GluK4 protein expression was undetectable. I 
then compared the performance of wild-type and GluK4 knockout mice in a 
battery of memory-based tasks. I found, using two forms of a Y-maze task, that 
short-term working memory was intact in GluK4 knockout animals. However, 
GluK4 knockout animals showed impaired fear memory acquisition during a fear 
conditioning task, and impaired spatial memory acquisition and recall during a 
MWM task. GluK4 is therefore essential to certain types of associative, but not 
working, learning and memory.     
 
GluK4 in Neuropsychiatric Disorders 
Learning and memory deficits are often co-morbid with mood disorders (Palomo 
et al., 2008), and, indeed, there is mounting evidence from human and animal 
studies to suggest a role for aberrant GluK4 expression in schizophrenia and 
bipolar disorder. Expression of the NMDA receptor subunit NMDAR1, the AMPA 
 11 
subunit GluR1, and the kainate subunits GluK3 and GluK4 were all found to be 
decreased at the mRNA level in post-mortem brain tissue from schizophrenics 
relative to tissue from normal controls (Porter et al., 1997; Sokolov, 1998). 
Neuroleptic treatment in schizophrenic patients restored subunit expression to 
normal levels (Sokolov, 1998). Additionally, a genome-wide association study 
identified separate single-nucleotide polymorphisms (SNPs) in GRIK4, the gene 
encoding the ionotropic glutamate kainate receptor subunit GluK4, that confer 
susceptibility to schizophrenia and protection against bipolar disorder, 
respectively (Pickard et al., 2006). This association study was initially undertaken 
on the basis of clinical observations in a schizophrenic patient who was found to 
have a chromosomal breakpoint that disrupted GRIK4 (Pickard et al., 2006). 
Furthermore, a deletion mutation within the 3’ untranslated region (UTR) of 
GRIK4 not only confers protection against bipolar disorder (Pickard et al., 2008), 
but also increases GluK4 mRNA and protein expression (Pickard et al., 2008; 
Knight et al., 2011), and enhances hippocampal activation during a face 
processing task as assessed by function magnetic resonance imaging (Whalley 
et al., 2009a). Finally, GluK2, the kainate receptor subunit that co-precipitates 
with GluK4 in the CA3, has also been implicated in bipolar disorder: GluK2 
knockout mice display a complex behavioral phenotype that is consistent with 
certain facets of the disorder.  
 
Taken together, these data suggest that deficits in GluK4 expression may 
contribute to the etiology of schizophrenia and bipolar disorder. I therefore sought 
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to characterize the phenotype of the GluK4 knockout mouse line in behavioral 
tasks relating to mood and affect. I found that GluK4 knockout mice show 
increased exploration of the anxiogenic center zone of an open field, decreased 
arousal in an acoustic startle test, and decreased immobility in a forced swim test 
relative to wild-type mice, suggesting that GluK4 may mediate anxiety and 
depression. Additionally, GluK4 knockout mice showed increased locomotion 
relative to wild-type mice, which phenocopies the psychomotor agitation 
observed in schizophrenia and bipolar disorder. GluK4 mice also exhibited 
decreased prepulse inhibition (PPI), an indication of impaired sensorimotor 
gating and a hallmark of patients with schizophrenia and patients in the manic 
phase of bipolar disorder (Perry and Braff, 1994; Perry et al., 2001). 
 
GluK4 in Excitotoxicity 
In contrast to behavioral disorders such as schizophrenia, which are associated 
with insufficient glutamatergic neurotransmission, excitotoxic neurodegeneration 
occurs under pathological conditions where there is excessive glutamate release, 
such as ischemia and, on a much slower time scale, Alzheimer’s disease (Jacob 
et al., 2007). The CA3 region of the hippocampus, where GluK4 expression is 
greatest, is highly – and selectively – vulnerable to cell death in some models of 
excitotoxicity (Nadler, 1981; Ben-Ari, 1985). Thus, I reasoned that GluK4 might 
be involved in excitotoxic neuronal death. Indeed, GluK4 ablation was 
neuroprotective in the CA3 following intrahippocampal (IH) kainate injections. 
Following hypoxia-ischemia (HI), a murine model of stroke in which animals are 
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subjected to unilateral common carotid artery transection and prolonged hypoxia, 
GluK4 knockout mice showed marked neuroprotection throughout the 
hippocampus. 
 
Using microdissected CA3 tissue from wild-type and GluK4 knockout animals 
that had been injected with kainate or vehicle control (phosphate-buffered saline; 
PBS), I performed a microarray experiment to analyze the downstream effectors 
of GluK4 following excitotoxic insult, and to probe the molecular underpinnings of 
neuroprotection in GluK4 knockout animals. From these data and subsequent 
biochemical analysis, I found that several pro-apoptotic pathways, most notably 
the JNK pathway, were selectively up-regulated in wild-type, but not GluK4 
knockout tissue, following kainate injection. The JNK pathway has been widely 
implicated in excitotoxic cell death. Mice deficient in JNK3, the neuronal isoform 
of JNK, show strong resistance to neurodegeneration following middle cerebral 
artery occlusion (MCAO), a murine model of ischemia, and to intraperitoneal (IP) 
kainate injection (Brecht et al., 2005). Peptides and small molecules that target 
various components of the JNK pathway are also effective in preventing 
neurodegeneration following MCAO (Bogoyevitch et al., 2004). Furthermore, the 
GluK2 and GluK5 kainate receptor subunits can directly activate the JNK 
pathway by forming a signaling complex with post-synaptic density protein 95 
(PSD-95) and mixed lineage kinase 3 (MLK3) (Tian et al., 2005; Jiang et al., 
2007). In the context of ischemia, the assembly of this signaling complex 
promotes MLK3 autophosphorylation and thereby initiates the kinase cascade 
 14 
that leads to JNK activation (Liu et al., 2006). It is therefore likely that GluK4 
activation leads to excitotoxic neurodegeneration through the JNK pathway. 
 
Furthermore, I found that JNK pathway activation was increased following vehicle 
injection in GluK4 mice compared to wild-type mice, indicating that GluK4 could 
play a dual role in JNK pathway activation: under basal conditions, GluK4 may 
suppress JNK pathway activation, while under excitotoxic conditions, GluK4 may 
promote JNK pathway activation. The precise nature of the relationship between 
GluK4 and JNK pathway activation remains to be fully elucidated; however, I 
propose several lines of reasoning that may underlie my observations.     
 
GluK4 in Seizure Generation 
In addition to triggering excitotoxic neurodegeneration, excessive glutamate 
release is thought to underlie medial temporal lobe epilepsy (mTLE) (Sharma et 
al., 2007). Kainate administration recapitulates many of the features of mTLE, 
including convulsions, hippocampal lesions, and mossy fiber sprouting, 
suggesting that kainate receptors may play a role in the pathogenesis of this 
disease (Sharma et al., 2007). Furthermore, GluK2 knockout mice are resistant 
to kainate-induced seizures (Mulle et al., 1998). I therefore investigated seizure 
susceptibility in GluK4 knockout mice relative to wild-type mice, but found that 
the paradigm used to instigate and evaluate seizure activity was too variable to 
yield significant results. Nevertheless, trends in the data suggest that GluK4 
knockout mice may be less susceptible to seizures than wild-type mice at high 
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doses of kainate, but more susceptible to seizures at low doses of kainate. These 
observations suggest another biphasic role for GluK4, where it may serve to 
suppress seizure activity under mildly seizurogenic conditions, but may promote 
seizure activity under highly seizurogenic conditions.  
 
The work described herein reveals that a single glutamate receptor subunit with 
highly restricted expression serves as a key modulator of anxiety, depressive-like 
behavior, memory, and sensorimotor gating on one hand, and excitotoxic cell 
death cascades on the other. GluK4 may therefore provide a foothold in 
understanding the mechanisms – and treatment – of human neuropsychiatric and 
neurodegenerative disorders. 
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CHAPTER 2: MATERIALS AND METHODS 
Animal Use 
For all experiments, mice were 8 – 12 week old males maintained on a 12-hour 
light/dark cycle with food and water provided ad libitum. All animal procedures 
were approved by the Institutional Animal Care and Use Committee at the 
Rockefeller University. 
 
Genotyping  
GRIK4 recombination was assessed in DNA preparations from tail samples of 
wild-type and GluK4 knockout animals using the primers detailed in Table 2.1 
and the following polymerase chain reaction (PCR) conditions: 3 minutes at 
94˚C; 30 seconds at 94˚C, 30 seconds at 62˚C, and 30 seconds at 72˚C 
repeated for 35 consecutive cycles; and finally 8 minutes at 72˚C. These same 
primers and PCR conditions were also used to assess recombination of the 
GRIK4 allele in DNA preparations of lung and hippocampus tissue.  
 
To assess the presence of the Cre transgene in the F1 generation of GluK4 
knockout animals, the primers detailed in Table 2.1 and the following PCR 
conditions were used: 3 minutes at 94˚C; 30 seconds at 94˚C, 1 minute at 51˚C, 
and 1 minute at 72˚C repeated for 35 consecutive cycles; and 2 minutes at 72˚C.  
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TABLE 2.1. GluK4- and cre-specific primers used to genotype GluK4 knockout 
mice 
Primer name Purpose Sequence 
GluK4 P1 Assessing recombination of GRIK4 allele GCAGGCTGAACTCTGAGTTT 
GluK4 P2 Assessing recombination of GRIK4 allele CCAGAGACAGCACTAGGTGC 
GluK4 P6 Assessing recombination of GRIK4 allele GCCTGGGCTAGAGTGAGAC 
Cre forward Assessing presence of Cre transgene CCGGTGAACGTGCAAAACAGGCTCTA 
Cre reverse Assessing presence of Cre transgene CTTCCAGGCGCGAGTTGATAGC 
 
 
GRIK4 RT-PCR 
GRIK4 mRNA expression in wild-type versus GluK4 knockout animals was 
expressed by quantitative (q) and non-quantitative reverse-transcriptase (RT) 
PCR. mRNA was extracted from fresh-dissected hippocampal tissue using 
TRIzol (Ambion) according to the manufacturer’s instructions, and resuspended 
in nuclease-free water. Samples were then DNAse-treated using a DNA-free kit 
(Ambion). cDNA was synthesized from the purified RNA samples using a 
Superscript III kit (Invitrogen) according to the manufacturer’s instructions, with 
the following specifications: for non-quantitative RT-PCR, random hexamers 
were used as primers, and 0.1M DTT was added to the reaction; for real-time 
qRT-PCR, dNTPs were used as primers and DTT was excluded from the 
reaction. dNTPs were used for quantitative PCR because they selectively amplify 
poly-adenylated (i.e., mature) RNA. Meanwhile, the purpose of the non-
quantitative PCR experiment was to determine whether any RNA – mature or not 
– was produced in GluK4 knockout animals, so I chose to use random hexamers, 
which do not distinguish between immature and mature RNA in these 
experiments. DTT acts as an enzyme stabilizing agent in RT-PCR reactions, but 
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can interfere with downstream reactions involving SYBR-green and was 
therefore excluded from real-time qRT-PCR experiments. For both quantitative 
and non-quantitative reactions, the following PCR conditions were used to 
generate cDNA from the template RNA samples: 50 minutes at 50˚C; 5 minutes 
at 85˚C, after which RNAse H was added to each reaction to remove any 
remaining template RNA; and 20 minutes at 37˚C. Reactions in which reverse 
transcriptase was omitted were used as negative controls.  
 
For non-quantitative experiments, PCR reactions were carried out using a 
standard PCR machine (Eppendorf). The primers used were designed to amplify 
distinct, 200 – 300 base pair (bp) regions of GluK4 transcript such that all regions 
of the transcript were represented (Table 2.2). Each primer set was used in a 
separate reaction mixture with wild-type or GluK4 knockout template cDNA, or 
negative controls. All reactions were amplified at the same time using the 
following PCR conditions: 3 minutes at 94˚C; 30 seconds at 94˚C, 1 minute at 
55˚C, and 30 seconds at 72˚C repeated for 25 cycles; and 10 minutes at 72˚C. 
Reaction products were run on a 2% agarose gel and visualized by UV 
transillumination.  
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TABLE 2.2. Primers used to assess GRIK4 expression using non-quantitative 
RT-PCR in wild-type and GluK4 knockout mice 
 
 
 
  
Primer name Purpose Sequence 
GluK4 exons 2 to 4 forward Non-quantitative analysis of GRIK4 mRNA expression, exons 2 to 4 
TTCTGGTTCTCATTGTCCCG 
 
GluK4 exons 2 to 4 reverse Non-quantitative analysis of GRIK4 mRNA expression, exons 2 to 4 
AAGATGTCCACTTCGACCTTG 
 
GluK4 exons 4 to 6 forward Non-quantitative analysis of GRIK4 mRNA expression, exons 4 to 6 
AGGTCGAAGTGGACATCTTTG 
 
GluK4 exons 4 to 6 reverse Non-quantitative analysis of GRIK4 mRNA expression, exons 4 to 6 GGTGAATCTCTGGAGTTGGAAC 
GluK4 exons 6 to 8 forward Non-quantitative analysis of GRIK4 mRNA expression, exons 6 to 8 
CCAGCAACACCGACATCA 
 
GluK4 exons 6 to 8 reverse Non-quantitative analysis of GRIK4 mRNA expression, exons 6 to 8 
GACACCATCCCCAGTTCAG 
 
GluK4 exons 7 to 9 forward Non-quantitative analysis of GRIK4 mRNA expression, exons 7 to 9 
CGGGATGACAAGACAGCTAC 
 
GluK4 exons 7 to 9 reverse Non-quantitative analysis of GRIK4 mRNA expression, exons 7 to 9 
GCATGGGATTGGTTGAAAATGG 
 
GluK4 exons 9 to 11 forward Non-quantitative analysis of GRIK4 mRNA expression, exons 9 to 11 
AGAACTGTGACCATGTGCC 
 
GluK4 exons 9 to 11 reverse Non-quantitative analysis of GRIK4 mRNA expression, exons 9 to 11 
ACCTTCCAATTCTACCATGCG 
 
GluK4 exons 10 to 13 
forward 
Non-quantitative analysis of GRIK4 
mRNA expression, exons 10 to 13 
CAGCCTCATGAACTACCTTCG 
 
GluK4 exons 10 to 13 
reverse 
Non-quantitative analysis of GRIK4 
mRNA expression, exons 10 to 13 
TCATTGCCTTCCATCTCCTG 
 
GluK4 exons 13 to 15 
forward 
Non-quantitative analysis of GRIK4 
mRNA expression, exons 13 to 15 
AAGGCAATGACCGATATGAGG 
 
GluK4 exons 13 to 15 
reverse 
Non-quantitative analysis of GRIK4 
mRNA expression, exons 13 to 15 
CTGCGTCCCATATGAACTCTG 
 
GluK4 exons 15 to 16 
forward 
Non-quantitative analysis of GRIK4 
mRNA expression, exons 15 to 16 
CTTCTAGCTTATCTGGCGGTC 
 
GluK4 exons 15 to 16 
reverse 
Non-quantitative analysis of GRIK4 
mRNA expression, exons 15 to 16 
ACACAGCGGGTAGACAAAG 
 
GluK4 exons 16 to 17 
forward 
Non-quantitative analysis of GRIK4 
mRNA expression, exons 16 to 17 
CGGTGTAATCTCCTGGTCAAC 
 
GluK4 exons 16 to 17 
reverse 
Non-quantitative analysis of GRIK4 
mRNA expression, exons 16 to 17 
ATACTCAATGGCAGTCTGGTC 
 
GluK4 exons 18 to 20 
forward 
Non-quantitative analysis of GRIK4 
mRNA expression, exons 18 to 20 
AAGGGCTATGGGATTGGC 
 
GluK4 exons 18 to 20 
reverse 
Non-quantitative analysis of GRIK4 
mRNA expression, exons 18 to 20 
CTGATGCTTCTGAGTGTCTGAG 
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For quantitative experiments, the PCR reactions were carried out using a 
Lightcycler 480 (Roche). Each reaction contained wild-type or GluK4 knockout 
cDNA, or negative controls. Primers used are outlined in Table 2.3, and were 
designed to amplify regions upstream, downstream, and surrounding exon 16 of 
GRIK4 mRNA. SYBR green (Applied Biosystems) was used as an index of PCR 
product amplification. All reactions were performed in triplicate. Crossing 
threshold (CT) values were averaged between technical replicates, and 
normalized to reactions in which the appropriate cDNA template was amplified 
using primers specific for mouse β-actin (Table 2.3). All subsequent analysis of 
fold-change was performed using REST-MCS software (Pfaffl et al., 2002). 
 
TABLE 2.3. Primers used to assess GRIK4 expression using quantitative RT-
PCR in wild-type and GluK4 knockout mice.  
 
 
 
 
 
Primer name Purpose Sequence 
GluK4 exons 3 to 4 forward Quantitative analysis of GRIK4 mRNA expression, exons 3 to 4 TCCTGCTTGGCTCTTGAT 
GluK4 exons 3 to 4 reverse Quantitative analysis of GRIK4 mRNA expression, exons 3 to 4 GCGGTTGATACGGTTCTTGG 
GluK4 exon 16 forward Quantitative analysis of GRIK4 mRNA expression, exon 16 CGGTGTAATCTCCTGGTCAAC 
GluK4 exon 16 reverse Quantitative analysis of GRIK4 mRNA expression, exon 16 ACACAGCGGGTAGACAAAG 
GluK4 exons 20 to 21 
forward 
Quantitative analysis of GRIK4 
mRNA expression, exons 20 to 21 
TCTTTGTGGTTCTTATTTGTGG
C 
GluK4 exons 20 to 21 
reverse 
Quantitative analysis of GRIK4 
mRNA expression, exons 20 to 21 CAGTTCTGTCACCATCTCCTG 
Mouse β-actin Normalization CTAAGGCCAACCGTGAAAAG 
Mouse β-actin Normalization ACCAGAGGCATACAGGGACA 
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GRIK4 mRNA Size Assessment and Sequencing 
Purified hippocampal cDNA from 3 wild-type and 3 GluK4 knockout animals was 
amplified by PCR using a forward primer targeted against the sense strand of 
exon 13 (see Table 2.2, primer “GluK4 exons 13 to 15 forward”), and a reverse 
primer targeted against the anti-sense strand of exon 20 (see Table 2.2, primer 
“GluK4 exons 18 to 20 reverse”). The PCR conditions were as follows: 5 minutes 
at 95˚C; 1 minute at 54˚C; 3 minutes at 72˚C; 30 seconds at 95˚C, 1 minute at 
54˚C, and 2 minutes at 72˚C, repeated for 35 cycles; and 2 minutes at 72˚C. The 
resulting PCR products were run on an agarose gel to compare the size of wild-
type versus GluK4 knockout transcript.  
 
Wild-type and GluK4 knockout PCR products were also sequenced by an outside 
facility (Genewiz) using the forward primer, and, in separate reactions, the 
reverse primer to generate ~1000 bp sequences. Sequences were aligned to the 
known GRIK4 mRNA sequence (RefSeq Accession number NM_175481.3) 
using DNASTAR software. 
 
Generation of Custom Anti-GluK4 Antibody 
A custom GluK4 antibody was generated in rabbits at an outside facility 
(Covance) using an immunizing peptide corresponding to amino acids 939 – 956 
of the C terminal end of the mouse GluK4 protein, 
SPARSEESLEWDKTTNSSEPE. The resulting immune sera were purified 
against the immunizing peptide to ensure optimal specificity.  
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Western Blotting to Detect GluK4 
Fresh-dissected hippocampi from wild-type and GluK4 knockout mice were 
homogenized in lysis buffer (25 mM Tris-Cl pH 7.4, 95 mM NaCl, 2% SDS, 10 
mM EDTA) supplemented with protease and phosphatase inhibitor cocktails 
(Sigma). Protein concentration was determined by spectrophotometer using a 
bicinchonic acid (BCA) kit (Thermoscientific) according to the manufacturer’s 
instructions. Samples were treated with mercaptoethanol and boiled for 5 
minutes at 100˚C. Samples were then run on a denaturing 6% Tris-Glycine gel, 
transferred to a PVDF membrane, and blocked in a 5% milk solution dissolved in 
Tris-buffered saline with Tween-20. Blots were probed with either the custom-
generated GluK4 antibody (1:2000) or an Abcam GluK4 antibody (ab10101; 
1:2000). Following overnight incubation in primary antibody, blots were washed, 
incubated in the appropriate secondary antibody, washed again, incubated in 
chemiluminescent reagent (PerkinElmer), and exposed to film. Band intensity 
was quantified using Adobe Photoshop software and normalized to GAPDH 
(1:2000, 5% bovine serum albumen; Abcam) from the same blot.  
 
Novel-arm Y-maze  
For this and all subsequent behavioral trials, animals were single-housed in the 
room in which they were to be tested for at least 5 days prior to the initiation of 
the trials, and experimenters were blind to the genotype of the animals during 
testing and scoring.  
 
 23 
Mice were placed in a 3-armed Y-maze in which one arm was closed off by an 
opaque barrier, and allowed to explore for 5 minutes. The mice were then 
removed from the maze and placed in their home cage for 2 minutes, during 
which time the barrier was removed from the third arm and the bedding in the 
maze was mixed. Finally, mice were placed back in the maze and observed for 5 
minutes. The percent time spent in each arm once the barrier was removed was 
scored using Ethovision software (Noldus) and analyzed using a two-tailed 
Student’s T-test. This and all further behavioral analyses were performed with 
Graph Pad Prism software.   
 
Spontaneous Alternation Y-maze 
Mice were allowed to freely explore an open-armed Y-maze for 10 minutes. The 
order of arm entry was scored by two independent observers, blind to the 
genotype of the animals. Alternation was assessed by dividing the number of arm 
entry triads in which each arm was visited by the total number of arm visits minus 
2, and percent alternation was compared between genotypes using a two-tailed 
Student’s T-test.  
 
Fear Conditioning 
Fear conditioning experiments took place in a conditioning chamber 
(MedAssociates) equipped with a speaker, a house light, and a video camera, 
and all trials were video-recorded for subsequent scoring. On the first day of the 
test (day 1), mice were placed in a conditioning chamber that had been cleaned 
 24 
with an ammonia-based solution and were allowed to habituate to the chamber 
for 6 minutes. The final minute of the habituation period was scored to assess 
baseline freezing behavior. Mice then received three tone-footshock pairings 
(tone, 20 seconds, 85 decibels (dB), 3.5 kilohertz (kHz); footshock, 2 seconds, 
0.7 milliamperes (mA)) separated by an inter-trial interval of 60 seconds. After 24 
hours (day 2), mice were exposed to the context in which they had initially 
received the shock on day 1 (“context stimulus”) for 5 minutes, and the sessions 
were video-recorded. The chamber environment was then altered by placing 
patterned contact paper on the walls, wire mesh on the floors, and yellow filters 
on the lights. The ammonia-based cleaning solution was replaced with an 
unscented disinfectant, and the chambers were scented with pure vanilla extract. 
Two hours after exposure to the context stimulus, mice were placed in the altered 
chambers and exposed to the tone (“cued stimulus”) without the footshock for 
two minutes. Freezing behavior for all trials on days 1 and 2 was scored in 5-
second bins. One-way ANOVAs were used to analyze post-shock freezing for 
each tone-shock pairing on day 1. Two-way ANOVAs with Bonferroni post hoc 
tests were used to compare freezing behavior between genotypes during one-
minutes time bins in the contextual task on day 2, and to compare pre-tone and 
tone-elicited freezing behavior during the cued task on day 2. 
 
Incremental Hot Plate 
Mice were placed on an incremental hot plate apparatus (IITC Life Science) set 
to increase in temperature from 43˚C to 57˚C at a rate of 2.5˚C per minute. A 
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two-tailed Student’s T-test was used to compare paw-withdrawal latency 
between wild-type and GluK4 knockout mice. 
 
Morris Water Maze (MWM) 
MWM experiments were performed in a 1-meter pool filled with room 
temperature water made opaque with non-toxic white tempera paint. Distal visual 
cues consisting of black and white geometric shapes were placed throughout the 
testing room. Mice were initially tested in four 1-minute trials per day for two 
consecutive days in a visual platform paradigm, where the platform was 1 cm 
above the water level, to assess visual acuity, swimming ability, and motivation to 
escape from the water. Mice were then tested in a hidden platform paradigm, 
where the platform was submerged 1 cm below the water level, for four trials per 
day for four consecutive days. Trials proceeded until mice reached the platform 
or, if they were unable to locate it, for 60 seconds, at which point they were 
placed on the platform by the experimenter. The pool quadrant in which the mice 
were placed was varied across trials for both the hidden and visual platform 
assays. Following the final trial on the 4th and final day of hidden platform testing, 
a probe trial was carried out to assess spatial memory. The platform was 
removed from the pool and the mice were allowed to explore the pool for 2 
minutes.   
 
All trials were video recorded and scored using Ethovision software. For visual 
platform trials, the latency to reach the platform was compared between 
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genotypes on each testing day using a two-way analysis of variance (ANOVA) 
with a Bonferroni post-hoc correction. For hidden platform trials, path length and 
velocity were averaged across all trials for each mouse and compared by 
Student’s T-test. For the probe trials, the difference in quadrant preference 
between genotypes was assessed by two-way ANOVA with a Bonferroni post-
hoc test. Search strategy in hidden platform trials was assessed from traces of 
the trajectory from pool entry to platform for each mouse by an experimenter 
blind to the genotype of the mice. Assessment criteria were based on those 
outlined by Brody and Holtzman (2006). Strategies were categorized as spatial, 
non-spatial systematic, or repetitive looping. These strategies are further 
described in Chapter 4. Overall differences in search strategies between 
genotypes were assessed for each hidden platform day using a Chi-Square test. 
 
Forced Swim Test 
Mice were placed in a 4-L transparent beaker that was filled to 20 cm of its 25 cm 
height with room temperature water and observed for 6 minutes. All trials were 
video-recorded for later scoring. The total amount of time that a mouse spent 
immobile over the course of the 6-minute trial was scored by hand every 5 
seconds from video recordings and analyzed in one-minute bins. Immobility was 
defined as a lack of movement, except for that which was necessary to stay 
afloat. The total time spent immobile over the course of the trial was analyzed by 
a two-tailed Student’s T-test. The contribution of time, genotype, and the 
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interaction between time and genotype to overall variation was assessed by two-
way ANOVA coupled with a Bonferroni post-hoc test for multiple comparisons. 
 
Open Field Test  
Two open field paradigms were used: one to assess anxiety, and one to assess 
locomotor behavior. In the anxiety paradigm (referred to in the text as “short / lit”), 
the open field test was conducted in an evenly lit 46 cm x 46 cm arena with a 
white floor and black walls. Mice were individually placed in the arena such that 
they were facing a wall, and observed for 5 minutes. The arena was cleaned with 
70% ethanol between trials. All trials were tracked and scored with Ethovision 
software (Noldus).  For scoring purposes, the arena was divided into central and 
peripheral zones, where the center and periphery represented 36% and 64% of 
the total area of the arena, respectively. Scored measures included total number 
of center entries, percent time spent in center versus periphery, total distance 
traveled, and average velocity. Differences in each measure between wild-type 
and GluK4-knockout mice were analyzed by two-tailed Student’s T-tests. 
 
In the locomotor paradigm (referred to in the text as “long / dark”), the open field 
test was conducted in a completely dark room. Light meter readings indicated 
that ambient light levels were 0 relative light units (RLU). The open field 
chambers used in this paradigm (Accuscan) were equipped with a laser 
photobeam tracking system to assess vertical and horizontal beam breaks. The 
arena was divided into central and peripheral zones such that the center 
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represented 40% of the total area, and the periphery represented 60% of the 
total area (the constraints of the tracking software made it impossible to exactly 
reproduce the zone distributions of the short / lit paradigm). Animals were 
observed for 1 hour, and behavior was scored in 5-minute bins using Fusion 3.2 
Software (Accuscan). Scored measures included number of center entries, 
percent time spent in the center zone, and distance traveled. Differences in each 
measure over time between wild-type and GluK4-knockout mice were assessed 
by a two-way repeated measures ANOVA with Bonferroni post-hoc analysis. 
 
Acoustic Startle and Prepulse Inhibition (PPI) 
Mice were tested in SR-LAB startle response system chambers (San Diego 
Instruments) equipped with a speaker and a Plexiglas restraint chamber mounted 
on a piezoelectric accelerometer unit. Stimuli were presented in five blocks, and 
each stimulus was followed by a non-stimulus period of white noise (background) 
of 65 dB. In the first block, animals were presented with 5 single pulses of 120 dB 
to test their basal startle response. In the second block, animals were presented 
with 4 pulses of 80, 90, 100, 110, and 120 dB, ordered pseudo-randomly, to 
assess startle threshold. In the third block, animals were presented with 120 dB 
pulses preceded by a prepulse that was 3, 6, or 12 dB louder than the 
background. Each prepulse / pulse combination was presented 9 times, in 
pseudo-random order. Single 120 dB pulses were also presented 9 times, 
interspersed with prepulse  / pulse pairs. In the fourth block, pulse intensity was 
maintained at 120 dB, prepulse was maintained at 6 dB above background, and 
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the inter-stimulus interval (ISI) between the prepulse and pulse was varied. The 
ISIs assayed were 25, 50, 100, 200, and 500 milliseconds (ms), and each ISI 
was presented 3 times in pseudo-random order, interspersed with 120 dB single 
pulses. In the fifth block, animals were again presented with 5 single pulses of 
dB. The startle response, Vmax, was recorded using SR-LAB software (San 
Diego Instruments).  
 
To assess the startle threshold, the startle response to each tone intensity in the 
second block was averaged for each mouse, and compared between genotypes 
across tones using a two-way repeated-measures ANOVA with a Bonferroni 
post-hoc test. In the third block, the percent PPI was calculated for each prepulse 
intensity using the following equation: 100 – ((average Vmax for prepulse 
intensity in question / average Vmax within block 3 for single 120 dB pulse) * 
100). Percent PPI was compared between genotypes across prepulse intensity 
by two-way repeated-measures ANOVA with a Bonferroni post-hoc test. In the 
fourth block, the percent PPI was calculated for each ISI using the following 
equation: 100 – ((average Vmax for ISI in question / average Vmax within block 4 
for single 120 dB pulse) * 100). Percent PPI was then compared between 
genotypes across ISI by two-way repeated-measures ANOVA with a Bonferroni 
post-hoc test.  
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Stereotaxic Injections 
For IH stereotaxic injections, animals were anesthetized with 2.5% avertin (0.02 
mL/g of body weight) and atropine (0.6 mg/kg of body weight). Animals were then 
placed in a stereotaxic apparatus (Stoetling) and injected over the course of 60 
seconds with 300 nanoliters (nL) PBS or 0.15 nanomoles (nm) kainate in 300 nL 
PBS. Injection coordinates were as follows: -2.5 mm from Bregma on the 
anterior-posterior axis; 1.7 mm from the midline on the medial-lateral axis; and 
1.7 mm dorsal-ventral from the surface of the skull. For stereology experiments, 
animals were injected unilaterally. For microarray and biochemistry experiments, 
animals were injected bilaterally. Injections were performed with a 2.5 µL 
Hamilton syringe equipped with a 33-gauge blunt needle and controlled by an 
automated microinjection pump (World Precision Instruments). After injection, the 
needle was retracted by 0.1 mm and left in place for 2 minutes to allow injected 
material to diffuse. Animals were then injected IP with 0.03 mL buprenex (0.03 
mg/kg of body weight) for analgesia and 500 mL sterile 0.9% saline for 
rehydration, and they were allowed to recover on a heating pad.  
 
Hypoxia-Ischemia (HI) 
Animals were maintained under deep isoflurane anesthesia during surgery.  The 
left common carotid artery was exposed and gently separated from the vagus 
nerve. The artery was then ligated at two points several millimeters apart with 6-0 
silk sutures, and transected between the ligation points. Following surgery, mice 
were injected IP with 0.03 mL Buprenex (buprenorphine HCl; 0.03 mg/kg of body 
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weight) and 500 mL sterile 0.9% saline, and allowed to recover for 40 minutes on 
a heating pad. Animals were then transferred to a hypoxic chamber maintained 
at 8% O2 and 92% N2 for 45 minutes at 37˚C (Vannucci et al., 2001). 
 
Stereology 
24 hours after IH kainate injection or HI, animals were perfused with 15 mL ice-
cold 0.9% saline followed by 15 mL of ice-cold 4% paraformaldehyde (PFA). 
Brains were post-fixed overnight in 4% PFA, cryoprotected for 24 hours in 30% 
sucrose in 0.1 M phosphate buffer, frozen in powdered dry ice, and stored at -
80˚C. Thin sections were collected on a cryostat and stored at -20˚C in freezing 
medium (30% glycerol, 30% ethylene glycol, 40% 0.1 M phosphate buffer) until 
use. For tissue from IH-injected animals, 20 µm sections were collected in 12-
well plates such that each plate contained a range of sections that were 240 µm 
apart. Extensive tissue damage sustained by HI-treated animals made it 
necessary to slice tissue at 30 µm, such that sections were 360 µm apart in each 
well of a 12-well plate. 
 
Fixed free-floating brain sections from one well were mounted on glass slides 
using a gelatin-based mounting medium and dried overnight at room 
temperature. Sections were stained in a solution of 0.00005% Fluorojade C 
(FJC) and 0.0001% 4’,6-Diamidino-2-Phenylindole (DAPI) (Schmued et al., 
2005), and visualized using an Axiovert 200 inverted epifluorescence microscope 
(Carl Zeiss, Inc.). All sections were imaged at high resolution and 50x 
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magnification. Exposure time and gain were consistent for each stain between all 
sections from all animals.  
 
Cell death was quantified using NIH Image J software. Hippocampal subregions 
were identified and outlined by observation of DAPI staining. Subregion outlines 
were overlaid onto corresponding FJC images. The FJC images were split into 
their component red, green, and blue color channels, and the green channel was 
selected for further processing. Images were calibrated in µm, and then 
thresholded using the triangle algorithm to highlight FJC-positive cells. This 
algorithm was chosen because it consistently yielded a higher signal-to-noise 
ratio than the other available algorithms. Image splitting, calibrating, and 
thresholding were all carried out using an automated macro to ensure that image 
processing was consistent across sections. Experimenters were blind to the 
genotype and treatment of the animals during image processing. The area of 
FJC-positive staining within each hippocampal subregion was recorded and 
normalized to the total number of slices quantified. Differences in FJC area 
between genotypes were analyzed for each subregion using a two-tailed 
Student’s T-test.   
 
Microarray Sample Preparation and Array Hybridization 
24 hours after bilateral IH injection of PBS or kainate, animals were killed by 
cervical dislocation. The hippocampus from the left hemisphere was quickly 
removed and left intact, while the hippocampus from the right hemisphere was 
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microdissected with sterile tools on ice to isolate the hippocampal subfields. 
Tissue was immediately frozen in sterile tubes on dry ice and stored at -80˚C 
until use.  
 
Total RNA and total protein were isolated simultaneously using TRIzol according 
to the manufacturer’s instructions. Briefly, tissue samples were homogenized in 
TRIzol and incubated for 10 minutes at room temperature. Following the addition 
of chloroform, samples were centrifuged at 12,000 x g for 15 minutes at 4˚C. The 
aqueous layer, containing total RNA, and the organic layer, containing total 
protein, were collected separately for further processing. The aqueous layer was 
incubated at 20˚C for 1 hour in isopropanol supplemented with glycogen, 
centrifuged at 12,000 x g for 15 minutes at 4˚C, washed with 70% ethanol, and 
pelleted at 7,500 x g for 5 minutes at 4˚C. The RNA pellet was then air-dried for 5 
minutes at room temperature, and resuspended in nuclease-free water at 55˚C. 
Meanwhile, the organic layer was cleared of DNA by ethanol precipitation 
followed by sedimentation at 2000 x g for 5 minutes at 4˚C. The proteins in the 
resulting supernatant were precipitated with isopropanol, sedimented at 12,000 x 
g for 10 minutes at 4˚C, and washed 3 times in 0.3 M guanidine hydrochloride in 
95% ethanol. The protein pellet was then incubated in ethanol for 20 minutes at 
room temperature, centrifuged at 7,500 x g for 5 minutes at 4˚C, vacuum-dried 
for 5 minutes, and dissolved in a buffer containing 25 mM Tris-HCl, 95 mM NaCl, 
2% SDS, and 10 mM EDTA supplemented with protease and phosphatase 
inhibitors. Protein samples were stored at -80˚C until use. 
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All RNA samples were purified with an RNeasy mini kit (Qiagen) according to the 
manufacturer’s instructions. The quality and concentration of all RNA samples 
was determined using a Bioanalyzer (Agilent). Any sample with an RNA integrity 
number below 8, or a concentration below 40 nanograms (ng) / µL – the minimal 
criteria required for microarray analysis – was subjected to further purification 
with an RNeasy MinElute kit (Qiagen).   
 
One-step RT-PCR using was performed on all hippocampal and CA3 RNA 
samples with primers specific to heat shock protein 27 (Hsp27; RefSeq 
accession number NM_103560; Table 2.4) to investigate whether the samples 
that were supposed to receive kainate had actually received it. Hsp27 is a heat-
shock-protein-encoding gene that is highly up-regulated in the context of 
excitotoxicity (Hunsberger et al., 2005; van der Weerd et al., 2010). CA3 samples 
were further analyzed by one-step RT-PCR using CA1- and DG-specific primers 
(Table 2.4) to assess contamination from neighboring hippocampal sub-regions. I 
assessed multiple primer pairs directed against a host of region specific genes 
that were first identified by Lein et al. (Lein et al., 2004). These primer pairs were 
compared in CA3, DG, and CA1 samples, and the most robust and tissue-
specific primer pairs were selected for further analysis. The CA1-specific gene 
selected was nephroblastoma overexpressed gene (Nov; RefSeq Accession 
number NM_010930), and the DG-specific gene selected was desmoplakin (Dsp; 
RefSeq Accession number NM_023842.2).   
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TABLE 2.4. Primers used to evaluate microarray RNA samples.  
 
One-step RT-PCR was carried out using a OneStep RT-PCR kit (Qiagen). PCR 
conditions were optimized for each primer pair to determine the cycle number 
and template RNA concentration required to achieve optimal signal. All primer 
pairs ultimately required 30 PCR cycles, and 25 ng of RNA. The following PCR 
conditions were used: 30 minutes at 50˚C; 15 minutes at 95˚C; 45 seconds at 
94˚C, 45 seconds at 53˚C, and 1 minute at 72˚C, repeated for 30 cycles. The 
resulting PCR products were run on an agarose gel alongside a DNAladder 
(GeneRuler), and analyzed semiquantitatively: PCR band intensity was assessed 
using Photoshop, and normalized between gels using the same band on the 
accompanying DNA ladder. (Pilot experiments in which the one-step RT-PCR 
reactions were multiplexed with β-actin primers to facilitate within-sample 
normalization were largely unsuccessful: β-actin was far more abundant than any 
of the other genes amplified, and the PCR amplification of β-actin would saturate 
– and therefore prove useless for quantification – in far fewer cycles than the 
other genes.) In experiments where CA3 samples were assessed for 
Primer name Purpose Sequence 
Hsp27 forward Semi-quantitative analysis of Hsp27 expression as indication of kainate-induced excitotoxicity 
CTGGACGTCAACCACTTCG 
 
Hsp27 reverse Semi-quantitative analysis of Hsp27 expression as indication of kainate-induced excitotoxicity 
CTGCCTTTCTTCGTGCTTG 
 
DG forward Semi-quantitative analysis of Dsp expression as indication of DG contamination 
CCTGTGATGCGTATCAGAAAAG 
 
DG reverse Semi-quantitative analysis of Dsp expression as indication of DG contamination 
TGTAAAGGGCTCGCATTTG 
 
CA1 forward Semi-quantitative analysis of Nov expression as indication of CA1 contamination 
CCCGAGGAAGTAACAGACAAG 
 
CA1 reverse Semi-quantitative analysis of Nov expression as indication of CA1 contamination 
GAGACACTGAAACTCCACCTG 
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contamination by neighboring sub-regions, a positive control consisting of 
purified DG RNA or CA1 RNA amplified by the DG- or CA1-specific primer pair 
was included in each gel. CA3 samples with the lowest levels of contamination 
were selected for further processing. 
 
Purified RNA samples that had been assessed for contamination and kainate 
injection as appropriate were pooled in equal proportions. 3 samples were pooled 
for each of the 8 conditions described in Chapter 7, and submitted to the 
Genomics Resource Center at the Rockefeller University for amplification, 
labeling, and chip hybridization. Briefly, biotin-UTP-labeled cRNA was generated 
and amplified by T7 linear amplification using a MessageAmp Premier RNA 
Amplification kit (Applied Biosystems), and hybridized to a MouseRef-8 v.20 
Expression Bead Chip (Illumina). This chip includes probes for ~25,600 RefSeq 
transcripts, corresponding to 19,100 unique genes from the mouse genome. 
 
Microarray Data Analysis 
Raw signals from the Illumina chip were exported into Genespring software. All 
signals were thresholded as follows: the background was set to 70, the lower 
cutoff for a present call was set to 0.8, and the upper cutoff for an absent call was 
set to 0.6. Thresholded signals were then scaled to the median, and transformed 
to a log2 scale. Fold change was calculated as the ratio between conditions as 
appropriate. 
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For Database for Annotation, Visualization and Integrated Discovery (DAVID) 
analysis, fold change after kainate injection was calculated relative to PBS, and 
compared between genotypes to extract genes that were changed by greater 
than |2|-fold. This analysis resulted in three gene lists: genes that were changed 
by greater than |2|-fold in both genotypes, genes that were changed by greater 
than |2|-fold in wild-type samples alone, and genes that were changed by greater 
than |2|-fold in knockout samples alone. Each list was then input into DAVID and 
compared against the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway database (Huang et al., 2008). 
 
For Gene Set Enrichment Analysis (GSEA), all probe sets meeting the threshold 
conditions set in Genespring were ranked for each genotype according to their 
fold-change after kainate injection relative to PBS. Wild-type and GluK4 knockout 
gene lists were analyzed separately using the GSEAPreranked setting in GSEA, 
and compared at 100 permutations against the Biocarta pathway database 
(Subramanian et al., 2005). Gene sets from the Biocarta database that were 
larger than 800 genes, or smaller than 6 genes, were excluded from analysis. 
The chip annotations file that provides the gene names associated with the 
microarray probe identification numbers listed in the Genespring output was 
downloaded from the Illumina website (MouseRef8_V2_0_R2_11278551_A). For 
probes that were represented more than once on the microarray chip, the 
instance in which it yielded the highest fold-change value was selected for 
analysis (max_probe setting in GSEA).  
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Western Blotting to Detect JNK Pathway Components 
Western blotting to analyze JNK pathway components was performed as 
described above, with several modifications. Total protein and RNA were 
simultaneously extracted from fresh-dissected samples using TRIzol. 30 µg of 
CA3 protein per lane were treated with mercaptoethanol, boiled for 5 minutes, 
and loaded onto a 10% Tris-Glycine polyacrylamide gel. Proteins were 
transferred to a PVDF membrane, and membranes were blocked and incubated 
in primary as above. Anti-phosphorylated MKK4, anti-JNK, anti-phosphorylated 
JNK, anti-cJun, anti- phosphorylated cJun, and anti-phosphorylated ATF-2 
antibodies were all purchased from Cell Signaling and used at 1:1000 in the 
dilution buffer recommended by the manufacturer. Anti c-Fos was purchased 
from Calbiochem and used at 1:250 in 5% milk. Blots were then probed with 
secondary antibodies, incubated in chemiluminescent reagent, and quantified as 
above.  
 
Intraperitoneal (IP) Kainate Injections 
10 mM kainate solution in saline was prepared fresh each day that it was 
administered. Up to 6 mice were injected on a given experimental day, using one 
of several injection paradigms: (1) an initial dose of 30 mg/kg kainate, followed by 
two doses of 15 mg/kg at 45 minute intervals; (2) an initial dose of 15 mg/kg 
kainate followed by two doses of 5 mg/kg at 10 minute intervals; (3) an initial 
dose of 15 mg/kg, followed by a single dose of 5 mg/kg after 20 minutes; or (4) a 
single dose of 15 mg/kg. In injection paradigm (1), mice were observed for 4 
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hours following the initial injection; in all other paradigms, mice were observed for 
2 hours. After the observation period, all mice were rehydrated with 500 mL of 
sterile saline and allowed to recover on a heating pad overnight. 
 
Seizures were hand-scored during the observation period using a 0 – 6 scale first 
developed by Racine (Racine, 1972). The scale used for the experiments herein 
included slight modifications as described (McKhann et al., 2003; McLin and 
Steward, 2006). At level 0, mice do not show any abnormal behavior; at level 1, 
mice cease to explore, sniff, and groom, and become motionless; at level 2, mice 
adopt a rigid posture, stretching their bodies out and erecting their tails; at level 
3, mice begin to show myoclonic jerks of the head and neck, and may rear into a 
sitting position; at level 4, mice exhibit forelimb clonus, running clonus, or rearing 
and falling broken by periods of total stillness; at level 5, mice show continuous 
level 4 seizures; and at level 6, mice exhibit violent bouncing seizures that 
progress to a loss of posture tone and death if persisting.    
 
Data from injection paradigms that were repeated over several days were 
combined for analysis. The effects of genotype and time were compared by two-
way ANOVA with a Bonferroni post-hoc test. 
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CHAPTER 3: GENERATING GLUK4 KNOCKOUT ANIMALS 
Mouse Crosses 
GluK4 knockout animals were generated by crossing mice homozygous for a 
GRIK4 allele in which exon 16 was floxed (GluK4-floxed mice; generously 
provided by the Contractor Laboratory at Northwestern University) (Fernandes et 
al., 2009) with mice homozygous for a transgene encoding cre-recombinase 
under the control of an EIIA promoter (Figure 3.1). The EIIA promoter is active in 
the early mouse embryo, allowing for cre-mediated recombination in many 
tissues, including germ cells. Animals resulting from this cross transmit the 
recombined GRIK4 allele to their progeny in a global, cre-independent manner. 
All first filial generation (F1) offspring were heterozygous for the floxed, 
recombined (FR) GRIK4 allele as well as the EIIA cre transgene. Founder F1 
offspring were then mated to yield the allelic frequencies outlined in Table 3.1 by 
the second filial (F2) generation. 
 
F2 mice that were homozygous for the FR GRIK4 allele, regardless of Cre 
transgene status, (Table 3.1, highlighted rows) were selected for propagation of 
the GluK4 knockout line. All knockout animals had a mixed C57Bl/6 / 129SvE 
background. Animals homozygous for the wild-type (+) GRIK4 allele but 
maintained on the same background as GluK4 knockout mice are referred to 
herein as wild-type mice. 
 
 
 41 
 
 
FIGURE 3.1. Schematic of GluK4 knockout strategy. Exon 16 of GRIK4 was 
floxed GluK4-floxed mice. Crossing these mice with an EIIA-cre line, where cre is 
expressed in the germline, resulted in a global, cre-independent GluK4 knockout 
line.  
 
 
 
 
 
 
 
 
 
 
 
  
 42 
TABLE 3.1. Expected Mendelian ratios of F2 offspring resulting from crosses of 
founder F1 mice.  
EIIA Cre Transgene* GRIK4 allele** Expected percentage of 
offspring 
Cre/Cre FR/FR 6.25% 
Cre/Cre FR/+ 12.50% 
Cre/+ FR/FR 12.50% 
Cre/+ FR/+ 25.00% 
Cre/Cre +/+ 6.25% 
+/+ FR/FR 6.25% 
Cre/+ +/+ 12.50% 
+/+ FR/+ 12.50% 
Cre/Cre +/+ 6.25% 
  
* “+” refers to the wild-type allele, “Cre” refers to the EIIA Cre transgenic allele;  
** “+” refers to the wild-type allele, “FR” refers to the floxed, recombined allele. 
 
Assessing Global Cre-mediated GRIK Recombination 
Cre-mediated recombination of the floxed GRIK4 allele was assessed using a 
three-primer PCR strategy. A forward primer, P2, and a reverse primer, P1, were 
designed to flank the first (downstream) loxP site, such that P2 was downstream 
of the loxP site and P1 was upstream. The region recognized by P1 was located 
between the two loxP sites, such that it would be obviated by successful cre-
mediated recombination. A third reverse primer, P6, was targeted upstream of 
the second loxP site (Figure 3.2).  
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FIGURE 3.2. Schematic of genotyping strategy for GluK4 knockout mice. P2 
is a forward primer, and P1 and P6 are both reverse primers. (A) The wild-type 
allele yields a 264 bp P2-P1 PCR product and a 1500 bp P2-P6 product. (B) The 
floxed, unrecombined allele yields a 388 bp P2-P1 product, and a 1700 bp P2-P6 
product. (C) The floxed, recombined allele yields a 422 bp P2-P6 product. P1 is 
targeted against a region between the two loxP sites, such that successful 
recombination eliminates that region and, thus, the P2-P1 product.  
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Using this genotyping strategy, PCR products of the sizes outlined in Table 3.2 
were obtained for the various genotypes assessed. 
 
TABLE 3.2. Expected size of genotyping PCR products. 
 Wild-type F/F (homozygous floxed, unrecombined) 
GluK4 knockout 
(homozygous floxed, 
recombined) 
P2-P1 PCR product size 264 bp 388 bp N/A: P1 recognition site excised 
P2-P6 PCR product size 1500 bp 1700 bp 422 bp 
 
To determine whether cre-mediated recombination of GRIK4 had occurred 
globally, DNA extracts from hippocampus, cortex, lung, and tail from wild-type 
versus heterozygous  FR / + mice from the founder F1 generation were analyzed 
using the 3-primer PCR strategy described above. As predicted, the recombined 
GRIK4 allele was present in all FR / + heterozygote tissues, and absent in all 
wild-type tissues (Figure 3.3).  
 
  
 45 
 
 
FIGURE 3.3. Assessing cre-mediated recombination of GRIK4 in various 
tissues from GluK4-floxed, and GluK4 FR / + heterozygote mice. (A) The 
floxed, unrecombined allele, which appears here as a ~1700 bp band 
corresponding to the P2-P6 PCR product, is present in all tissues assessed in 
GluK4-floxed mice. The faint lower band (~400 bp) represents the P2-P1 PCR 
product, but is not favored in this reaction. (B) Recombination of the floxed 
GRIK4 allele has occurred in all GluK4 FR / + heterozygote tissues assessed. 
The upper band (~1500 bp) represents the floxed, unrecombined allele; the lower 
band (~400 bp) represents the recombined allele. 
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Characterizing GRIK4 mRNA Expression 
The GRIK4 gene yields a 3488 bp transcript with 21 exons (RefSeq accession 
number NM_175481.5). The coding region extends from positions 201 to 3071, 
which overlaps with exons 3 – 21. Exon 16, which is floxed in the GluK4-floxed 
animals provided by the Contractor laboratory, encodes the pore-forming M2 p-
loop region of GluK4 (Fernandes et al., 2009) (see Figure 1.1). 
 
The Contractor laboratory had shown previously that a global GluK4 knockout 
mouse, generated using a germline-expressed cre line similar to the EIIA cre line 
used here, was both a transcriptional and translational null (Fernandes et al., 
2009). However, they assessed GRIK4 mRNA expression using a primer pair 
designed to amplify the excised exon 16, and therefore did not exclude the 
possibility that a GRIK4 transcript containing the regions up- or downstream was 
still being expressed. 
 
To evaluate this possibility, I designed primer sets that were targeted throughout 
the GRIK4 transcript such that all exons within the coding region were 
represented (exons 2 – 20). I then used these primer sets to perform RT-PCR on 
RNA purified from wild-type and GluK4 knockout hippocampus homogenates. 
The PCR products were run on an agarose gel and visualized by UV illumination. 
Bands representing all amplified regions of GRIK4 were present in wild-type 
samples. Surprisingly, the same bands were also present in GluK4 knockout 
samples, with the exception of those with either a forward or a reverse primer in 
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exon 16 (Figure 3.4a). To ensure that the presence of bands in the GluK4 
knockout samples was not the result of genomic DNA contamination, I ran the 
same PCR reactions without including reverse transcriptase. No bands were 
observed in these conditions (Figure 3.4a). 
 
To further explore GRIK4 mRNA expression in GluK4 knockout animals, I ran 
RT-PCR on wild-type and GluK4 knockout hippocampal extracts using a forward 
primer located in exon 13, and a reverse primer in exon 20, such that the 
resulting PCR product would encompass exon 16. The predicted size of the PCR 
product from the wild-type GRIK4 allele is 940 bp, and a band of this size was 
indeed observed in wild-type samples. The band observed in knockout samples 
was approximately 200 bp smaller, a decrease corresponding to the predicted 
size of exon 16 (173 bp; Figure 3.4b). PCR products from wild-type and GluK4 
knockout samples were then sent to an outside facility (Genewiz) for sequencing. 
Aligning the resulting sequences with the predicted GRIK4 mRNA sequence 
indicated that GluK4 knockout samples were indeed missing exon 16, but that 
the surrounding regions were intact. Furthermore, sequencing revealed that the 
deletion of exon 16 was in frame, and that there were no premature stop codons 
in the sequenced region of GluK4 knockout mRNA. Taken together, these results 
indicate that GluK4 knockout animals are not, in fact, transcriptional knockouts. 
Instead, they produce a truncated GRIK4 mRNA product that is missing exon 16. 
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FIGURE 3.4. GRIK4 mRNA is intact in GluK4 knockout mice. (A) Non-
quantitative RT-PCR using primer pairs that, together, covered all coding exons 
of GRIK4, revealed that GRIK4 mRNA was intact in GluK4 knockout mice. Only 
the region corresponding to the floxed exon 16 is missing. (B) A product 
encompassing the region corresponding to exon 16 was ~200 bp smaller in 
GluK4 knockout samples than in wild-type samples, consistent with the size of 
exon 16. (C) Quantitative RT-PCR using primer pairs designed to amplify exons 
3-4, exons 20-21, or exon 16 indicated that GRIK4 mRNA is expressed at the 
same levels in wild-type and GluK4 knockout hippocampal tissue. Once again, 
only the region corresponding to exon 16 appeared to be missing. Bars represent 
mean ± SEM. * p < 0.05. WT, wild-type; KO, GluK4 knockout; + RT, reactions 
including reverse transcriptase; - RT, reactions excluding reverse transcriptase; 
Ex, exons. 
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The possibility remained, however, that the modified GRIK4 mRNA produced by 
the GluK4 knockout animals was expressed only at very low levels, rendering the 
animals functional – if not true – knockouts. To address this, I performed 
quantitative RT-PCR on hippocampal extracts from wild-type mice and GluK4 
knockout mice. Three primer sets were used in separate experiments: one set 
that amplified exons 3 – 4, corresponding to the coding region of the GRIK4 
transcript that is farthest downstream in the 5’ direction; one set that amplified 
exon 16; and one set that amplified exons 20 – 21, corresponding to the coding 
region of the GRIK4 transcript that is farthest upstream in the 3’ direction. cDNA 
levels in each reaction were detected by SYBRgreen in a Roche Lightcycler 480 
real time RT-PCR system. While expression of the amplified region surrounding 
exon 16 was significantly down-regulated (p = 0.042) and essentially abolished in 
GluK4 knockout samples relative to wild-type samples, expression of exons 3 – 4 
and exons 20 – 21 did not differ significantly from wild-type levels (p = 0.697 and 
p = 0.846, respectively; Figure 3.4c). These data indicate that GluK4 knockout 
animals are not transcriptional nulls: they produce a modified GRIK4 transcript 
that lacks exon 16, but is otherwise intact, and they express this modified 
transcript at the same levels that wild-type animals express the wild-type 
transcript.   
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Characterizing GluK4 Protein Expression 
The fact that GluK4 knockout animals were not transcriptional nulls raised the 
possibility that they were not true translational nulls, as they were reported to be 
by the Contractor laboratory (Fernandes et al., 2009). Initial attempts to assess 
whether GluK4 knockout animals expressed GluK4 protein yielded inconsistent 
results: western blots using commercially available GluK4 antibodies had such 
high background that it was difficult to disambiguate aspecific bands from those 
corresponding to GluK4.  
 
To obviate this issue, I commissioned the production of a custom, polyclonal 
GluK4 antibody (Covance). The immunizing peptide used to generate the 
antibody, SPARSEESLEWDKTTNSSEPE, corresponds to amino acids 939 – 
956 of the C terminal end of the mouse GluK4 protein. This peptide had 
previously been used in two separate studies to generate GluK4 antibodies 
(Fogarty et al., 2000; Darstein et al., 2003), and was chosen because its 
sequence has high homology between mouse, rat, and human isoforms of 
GluK4, but low homology to other ionotropic glutamate receptor subunits. The 
resulting polyclonal antibody was affinity-purified against the immunizing peptide 
to remove non-specific antibody species. Using this antibody, it was possible to 
distinguish a band corresponding to the predicted 108 kilodalton (kDa) molecular 
weight of GluK4 in wild-type hippocampal extracts. However, this band was not 
observed in GluK4 knockout extracts, nor were any additional bands that might 
correspond to modified forms of GluK4 (Figure 3.5a).  
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Because the custom GluK4 antibody recognizes the C-terminus of the GluK4 
protein, it was still possible that GluK4 knockout mice might express one or more 
modified forms of GluK4 in which the C-terminus was absent but other areas of 
the protein were intact. To assess this, western blots were performed on the 
same wild-type and GluK4 knockout hippocampal extracts using a commercially 
available antibody directed against amino acids 59 – 73 of the N-terminus of 
GluK4 (ab10101; Abcam). Like the other commercially available GluK4 
antibodies, this antibody yielded high background. However, upon over-exposing 
the blots, it was possible to observe a band corresponding to the size of GluK4 in 
wild-type extracts that was absent in GluK4 knockout extracts. No additional 
bands were observed in GluK4 knockout blots using this antibody (Figure 3.5b).       
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FIGURE 3.5. GluK4 protein is undetectable by western blot in GluK4 
knockout animals. Western blots of wild-type and GluK4 knockout whole-
hippocampus homogenates using a custom generated (A) or commercially 
available (B) anti-GluK4 antibody indicated that a band corresponding to the 
predicted size of GluK4 (108 kDa) was missing in GluK4 knockout mice.  
 
 
 
 
 
 
 
  
 54 
Taken together, these results suggest that GluK4 knockout animals are ultimately 
translational nulls, despite the fact that they are not transcriptional nulls. It is 
likely that the excision of exon 16, which corresponds to the pore-forming p-loop 
of GluK4, results in either an unstable protein that gets targeted for degradation, 
or a stable protein that is unable to pass a critical checkpoint during kainate 
receptor assembly, and thus gets targeted for degradation.  
 
  
 55 
CHAPTER 4: GLUK4 IN LEARNING AND MEMORY 
GluK4 knockout mice show reduced LTP (Catches et al., 2012), a cellular 
process that is crucial to learning and memory. GluK4 expression is also highest 
within the CA3 region of the hippocampus, an area that is involved in memory 
acquisition and retrieval (Hunsaker et al., 2009). I therefore investigated whether 
GluK4-deficient animals demonstrated learning or memory impairments.  
 
GluK4 Ablation Does Not Affect Performance in Novel-arm or Spontaneous 
Alternation Y-maze Tests 
Working (short-term) memory was assessed by novel-arm Y-maze and 
spontaneous alternation Y-maze. In the novel-arm Y-maze task, mice were 
initially placed in a 3-armed Y-maze in which one arm was blocked, and allowed 
to acclimatize. The block was then removed from the third arm, thereby creating 
a novel environment for the mice to explore. Because mice are inherently curious 
about novel environments, mice with intact working memory should spend 
proportionally more time in the novel arm than in the two arms that had initially 
been open (Hughes, 2004). Both wild-type (n = 5) and GluK4 knockout (n = 6) 
mice favored the novel arm to the other arms, with no significant difference in the 
percent time spent in the novel arm (Student’s T-test, p = 0.6721; Figure 4.1a) or 
either of the other arms (Student’s T-test, p = 0.8436 and p = 0.4399; Figure 
4.1a).  
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In the spontaneous alternation Y-maze task, mice were allowed to freely explore 
a 3-armed Y-maze. Because, once again, mice prefer novel environments, mice 
with intact working memory should continuously seek the least-recently-visited 
arm as they move about the maze, and should therefore alternate between the 
arms in triads – that is, arm A, followed by arm B, followed by arm C. The 
proportion of triads in each trial is measured as percent alternation. No significant 
difference in percent alternation was observed between wild-type and GluK4 
knockout mice (wild-type, n = 13; GluK4 knockout, n = 12; student’s T-test, p = 
0.4028; Figure 4.1b).  
 
Taken together, the data from the novel-arm Y-maze and the spontaneous 
alternation Y-maze suggest that GluK4 ablation does not affect working memory.   
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FIGURE 4.1. GluK4 knockout mice do not show working memory 
impairments in Y-maze tasks. (A) In a novel-arm Y-maze, wild-type (n = 5) and 
GluK4 knockout mice (n = 6) showed equal preference for the novel arm (Arm C; 
p = 0.6721). (B) In a spontaneous alternation Y-maze, wild-type (n = 13) and 
GluK4 knockout mice (n = 12) did not differ in their % alternation (p = 0.4028).  
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Fear Memory Acquisition is Impaired in GluK4 Knockout Mice 
In Pavlovian fear conditioning paradigms, mice learn to associate a neutral 
conditioned stimulus (CS) and an aversive unconditioned stimulus (US), such 
that the CS alone evokes a fear response. The CS can be defined as a cue, such 
as a tone, that accompanies the US, or the context in which the mice initially 
receive the US. Cued and contextual fear conditioning are thought to be 
amygdala- and hippocampus-dependent, respectively (Maren, 2008). Targeted 
disruption of the afferent mossy fiber pathway in the GluK4-rich CA3 region 
impairs the acquisition and consolidation of contextual fear memory (Daumas et 
al., 2004), a finding that raises the possibility that GluK4 might be involved in 
contextual fear conditioning. Furthermore, ablation of the GluK2 kainate receptor 
disrupts cued fear memory and reduces synaptic potentiation in the lateral 
amygdala (Ko et al., 2005).  
 
Based on this evidence, I investigated the role of GluK4 in both cued and 
contextual fear memory. The cued CS consisted of a tone (3.5 kHz, 85 dB; “cued 
stimulus”), and the contextual stimulus consisted of the initial environment in 
which the mice were presented with the US (“context stimulus”). The US 
consisted of a footshock delivered through floor rods connected to a shock 
generator. On day 1, mice were presented with three tone-shock pairings. Both 
wild-type and GluK4 knockout mice demonstrated immediate post-shock 
freezing, but while freezing behavior increased steadily during successive tone-
shock pairings in the wild-type cohort, it did not increase significantly in the 
 59 
knockout cohort (One-way ANOVA (tone): for wild-type mice F = 8.455, p = 
0.0020, n = 8; for GluK4 knockout mice F = 0.8476, p = 0.4426, n = 8; Figure 
4.2a). On day 2, mice were presented with either the context stimulus, or the 
cued stimulus in an altered context, both without the US. There were no 
significant differences in freezing between genotypes for the context stimulus 
paradigm (Two-way ANOVA, effect of genotype: F = 0.35, p = 0.5625; Figure 
4.2b) or the cued stimulus paradigm (Two-way ANOVA, effect of genotype: F = 
0.34, p = 0.5701; Figure 4.2c).  
 
Because GluK4 shows limited expression in the dorsal root ganglia of nociceptive 
spinal afferent neurons (Lucifora et al., 2006), I performed an incremental hot-
plate test to investigate the possibility that wild-type and GluK4 knockout animals 
had different pain thresholds and were therefore differentially sensitive to the 
footshock. Mice were tested in a hot-plate apparatus that increased in 
temperature at a rate of 2.5˚C/minute from 43˚ to 57˚C, and no difference in paw 
withdrawal latency was observed between genotypes (wild-type, n = 3; GluK4 
knockout, n = 5; Student’s T-test, p = 0.3555; Figure 4.2d) indicating that there 
was no difference in basal pain threshold between genotypes. Taken together, 
these data suggest that, while fear memory storage and retrieval are intact in 
GluK4 knockout mice, fear memory acquisition is significantly impaired.  
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FIGURE 4.2. GluK4 knockout mice show impaired fear memory acquisition, 
but not recall. (A) Freezing behavior increased progressively in the wild-type 
cohort (n = 8) after successive tone-shock pairings on day 1 (p = 0.0020), but not 
in the GluK4 knockout cohort (n = 8). These findings suggest that GluK4 mice 
have impaired fear memory acquisition. (B) Freezing behavior was not 
significantly different between genotypes over the course of the context stimulus 
trial on day 2 (p = 0.5625). (C) Freezing behavior was not significantly different 
during the pre-tone or tone periods of the cued stimulus trial on day 2 (p = 
0.5701). Fear memory recall was therefore intact in GluK4 knockout mice. (D) 
Wild-type and GluK4 knockout mice did not differ in their latency to withdraw their 
paws from an incremental hot plate, indicating that they do not have different 
basal pain thresholds. Bars represent mean ± SEM.    
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Spatial Learning and Memory are Impaired in GluK4 Knockout Mice 
Spatial memory, like fear memory, is also dependent in part on the CA3 region of 
the hippocampus: reversible inhibition of mossy fiber transmission results in 
impaired spatial memory acquisition in the MWM test of spatial reference 
memory (Florian and Roullet, 2004). Thus, I tested wild-type and GluK4 knockout 
mice in the MWM to assess whether GluK4 ablation results in spatial memory 
deficits.  
 
Mice were initially tested in a visual platform paradigm, where the platform was 
raised above the water surface, and no basal differences in visual or swimming 
abilities were observed between the genotypes (wild-type n = 13; GluK4 
knockout n = 12; two-way ANOVA for latency to reach platform, effect of 
genotype, F= 1.15, p = 0.2946; Figure 4.3a).  
 
Mice were then trained for 4 days in a hidden platform paradigm, where the 
platform was submerged below the water level, and, thus, no longer visible to the 
mice, such that they had to navigate to the platform location using distal spatial 
cues. Throughout hidden platform testing the GluK4 knockout cohort performed 
significantly worse than the wild-type cohort, demonstrating increased path 
length between the point of water entry and the escape platform (Student’s T-
test, p = 0.0231, Figure 4.3b) without any concomitant changes in velocity 
(Student’s T-test, p = 0.2407; Figure 4.3c).   
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FIGURE 4.3. MWM performance is impaired in GluK4 knockout mice during 
hidden platform trials. (A) The latency to reach the platform during the trials 
when the platform was visible above the waterline did not differ between wild-
type (n = 13) and GluK4 knockout mice (n = 12; p = 0.2946), indicating that 
vision, swimming ability, and motivation to escape the water were all equal 
between genotypes. (B) Pathlength to reach the hidden platform was increased 
in GluK4 knockout mice relative to wild-type mice over the course of the hidden 
platform trials (p = 0.0231), indicating that spatial memory is impaired in GluK4 
knockout mice. (C) There was no difference between genotypes in swimming 
velocity (p = 0.2407), suggesting that the increase in pathlength observed in the 
GluK4 knockout mice was not an artifact of hyperactivity. Bars represent mean ± 
SEM. VP, visual platform. 
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To parse the discrepancies in hidden platform performance between wild-type 
and GluK4 knockout mice, I compared the search strategies that they used to 
locate the platform based on the schema elaborated by Brody and Holtzman 
(Brody and Holtzman, 2006). Search strategies were classified as follows: spatial 
strategies, where mice swam directly to the escape platform or to the area 
surrounding the platform and searched intently in that region; non-spatial 
systematic strategies, where mice did not swim directly to the platform but 
instead scanned the pool without spatial bias until they found the platform; and 
strategies based on repetitive looping, where mice swam circularly at a fixed 
distance from the pool walls without spatial bias (Figure 4.4).  
 
Both wild-type and knockout mice favored non-spatial systematic strategies on 
day 1 of the hidden platform trials, presumably because they had not yet learned 
the position of the platform (Figure 4.5c). Wild-type mice decreased their reliance 
on non-spatial systematic strategies over time in favor of spatial strategies, and 
by day 4 they employed spatial search strategies almost exclusively (Figure 4.5d-
f). However, while GluK4 knockout mice also decreased their reliance on non-
spatial strategies to some extent, they employed non-spatial systematic 
strategies more frequently than wild-type mice by day 3, and this difference 
became very robust by day 4 (Chi-square test for overall difference in search 
strategy between genotypes, day 3 p = 0.021; day 4 p = 0.001; Figure 4.5e,f). 
These findings suggest that the increased path length demonstrated by the 
GluK4 cohort in the hidden platform test relative to the wild-type cohort is a 
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function of impaired spatial memory acquisition. While wild-type mice learned to 
use spatial search strategies over time, GluK4 knockout mice continued to use 
non-spatial search strategies to locate the platform.  
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FIGURE 4.4. Schematic of search strategies employed by mice in the MWM. 
Search strategies were classified as spatial direct (A), non-spatial systematic (B), 
or repetitive looping (C) as a measure of MWM performance and, hence, of 
spatial learning and memory.  
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FIGURE 4.5. GluK4 knockout mice use less efficient search strategies than 
wild-type mice to locate the hidden platform in the MWM. Representative 
search strategies are shown from wild-type (A) and GluK4 knockout mice (B) to 
locate the hidden platform. (C, D) Wild-type (n = 13) and GluK4 knockout mice (n 
= 12) both employed non-spatial systematic strategies on day 1 of the hidden 
platform trials. (E, F) Wild-type mice decreased their reliance on non-spatial 
systematic strategies in favor of spatial strategies to locate the hidden platform 
over the course of the trials, while GluK4 knockout mice continued to employ 
non-spatial systematic strategies. The overall difference in search strategy 
between wild-type and GluK4 knockout search strategy was significant on days 3 
and 4 (p = 0.021; p = 0.001, respectively). 
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To further assess the role of GluK4 in spatial memory, I performed a probe trial 
following hidden platform training in which the escape platform was removed 
from the pool altogether. Animals that have learned to navigate to the platform 
should spend more time in the quadrant of the pool (target quadrant) in which the 
platform was previously located during the hidden platform trials than in the other 
quadrants of the pool. A two-way ANOVA with Bonferroni post-hoc analysis for 
time spent in each quadrant revealed a significant effect of quadrant (F = 25.63, 
p < 0.0001), with a significant difference between genotypes in the time spent in 
the target quadrant (p < 0.05), indicating that GluK4 knockout mice showed 
decreased preference for the target quadrant when compared with knockout 
mice (Figure 4.6).  
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FIGURE 4.6. MWM probe trial performance is impaired in GluK4 knockout 
mice. Wild-type (n = 13) and GluK4 knockout mice (n = 12) differed significantly 
in their preference for the target quadrant, Q2 (p < 0.05), suggesting that GluK4 
knockout mice had not learned the location of the hidden platform and, thus, had 
impaired spatial memory recall. Bars represent mean ± SEM. Q1-4, quadrant 1-
4. 
 
 
 
  
 71 
It is possible that the impaired probe trial performance in the GluK4 knockout 
cohort is an effect of impaired spatial memory acquisition, as in the hidden 
platform trials. It is also possible that this impairment stems from the combined 
effects of impaired spatial memory acquisition, consolidation, and/or recall. 
Because memory acquisition is impaired in these mice, and memory acquisition 
precedes memory consolidation and recall, it is difficult to disambiguate the 
individual contributions of each phase of memory formation to the memory 
deficits induced by GluK4 ablation. Nevertheless, these experiments highlight the 
key role of GluK4 in spatial memory.  
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CHAPTER 5: GLUK4 IN MOOD AND NEUROPSYCHIATRIC DISORDERS 
Based on associational studies in humans implicating GluK4 in bipolar disorder 
and schizophrenia (Pickard et al., 2006; 2008), as well as a concurrent 
behavioral study in which GluK2 knockout animals were shown to be less 
anxious, more risk-taking, and less despairing than wild-type animals (Shaltiel et 
al., 2008), I sought to investigate the behavioral phenotype of GluK4 knockout 
animals. 
 
GluK4 Knockout Mice Display Reduced Despair in the Forced Swim Test 
First, I performed a forced swim test to assess depressive behavior in wild-type 
versus GluK4-deficient animals. Each mouse was placed in beaker of water from 
which it was unable to escape, and its mobility over time was recorded and 
scored. Immobility in this task is widely considered to be a manifestation of 
despair (Porsolt et al., 1977). I found that knockout mice spent less time 
immobile over the course of the trial (wild-type mean percent time spent immobile 
± SEM = 41.55 ± 2.88%, n = 6; knockout mean percent time spent immobile ± 
SEM = 20.82 ± 6.73% n = 5; Student’s T-test, p = 0.0145). A two-way ANOVA of 
mobility scored in 1-minute time bins revealed that genotype, time, and the 
interaction of genotype and time were all significant (F = 9.29, p = 0.0138; F = 
13.34, p < 0.0001; and F = 3.46, p = 0.0100, respectively; Figure 5.1). These 
results are again consistent with those observed in GluK2 knockout mice, and, 
moreover, suggest that GluK4 may play a modulatory role in baseline affect and 
mood.  
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FIGURE 5.1. GluK4 knockout mice show decreased despair-type 
manifestations in forced swim test. GluK4 knockout mice (n = 5) were 
consistently more mobile than wild-type mice (n = 6) over the course of a 6-
minute forced swim test (p = 0.0138). Bars represent mean ± SEM. * p < 0.05. 
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GluK4 Knockout Mice Demonstrate Reduced Anxiety, But Increased Locomotion, 
in the Open Field Test 
To assess anxiety and risk-taking behavior, wild-type and GluK4 knockout 
animals were observed in an open field test. In this task, mice are allowed to 
freely investigate an open, evenly lit field, and typically demonstrate robust 
thigmotaxis. I found that, while both wild-type and GluK4 knockout mice preferred 
the periphery to the center of the field, knockout mice spent proportionally more 
time in the center than wild-type mice did (wild-type, n = 13; GluK4 knockout, n = 
12; Student’s T-test, p = 0.007, Figure 5.2a). Knockout mice also entered the 
center more frequently than wild-type mice (Student’s T-test, p = 0.004; Figure 
5.2b).  
 
Additionally, knockout mice showed marked hyperactivity relative to the wild-type 
mice in the open field. The knockout mice traveled greater total distances 
(Student’s T-test, p = 0.0004; Figure 5.2c) over the course of the assay at higher 
average velocities than wild-type mice (wild-type mean velocity in cm/second ± 
SEM = 6.92 ± 0.42; knockout mean velocity in cm/second ± SEM = 9.75 ± 0.54; 
Student’s T-test, p = 0.0004).   
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FIGURE 5.2. GluK4 knockout mice show decreased aversion to center 
zone, and increased locomotion in short / lit open field. (A) Though both 
wild-type (n = 13) and GluK4 knockout mice (n = 12) preferred the periphery to 
the center zone of the open field during a 5-minute trial, the GluK4 knockout mice 
spent proportionally more time in the center zone of the open field (and, thus, 
proportionally less time in the periphery of the open field) than wild-type mice (p = 
0.007), suggesting that GluK4 knockout mice have decreased basal levels of 
anxiety relative to wild-type mice. (B) GluK4 knockout mice entered the center 
zone more frequently than wild-type mice over the course of the trial (p = 0.004). 
(C) GluK4 knockout mice traveled greater distances over the course of the trial 
than wild-type mice, suggesting that GluK4 knockout mice may be hyperactive (p 
= 0.0004). Bars represent mean ± SEM.  
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Because hyperactivity could confound the interpretation of the differences 
between wild-type and GluK4 knockout mice in center zone preference and 
center zone entries, making it difficult to disambiguate the relative contributions 
of anxiety and locomotion, I tested separate cohorts of wild-type and GluK4 
knockout mice in a second open field paradigm where the primary anxiogenic 
stimulus – light – was removed. The observation period was also extended to an 
hour to assess whether mice habituated to the open field environment. Thus, in 
this second paradigm (long / dark), I investigated whether hyperlocomotion was a 
function of anxiety or the novelty of the open field environment, rather than a 
constant feature of GluK4 knockout mouse behavior.  
 
I found that the distance traveled by wild-type and GluK4 knockout mice 
decreased over time as the mice habituated to the environment. However, GluK4 
knockout mice consistently traveled greater distances throughout the 1-hour 
observation period than wild-type mice, despite demonstrating habituation (Two-
way ANOVA: effect of genotype, F = 8.435, p = 0.0076; effect of time, F = 31.26, 
p < 0.0001; wild-type n = 15, knockout n = 12; Figure 5.3a). Hyperlocomotion in 
GluK4 knockout animals was therefore independent of the novelty of the 
environment.  
 
The number of center entries per time bin decreases progressively throughout 
the trial, in a similar fashion to total distance traveled. However, a two-way 
ANOVA revealed that the number of center entries in the GluK4 knockout cohort 
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is significantly higher than in the wild-type cohort (effect of genotype, F = 5.42, p 
= 0.0283; Figure 5.3b). Meanwhile, GluK4 mice appeared to spend more time in 
the center zone than wild-type mice, though the data for each time point were 
variable, and the difference was not quite significant by two-way ANOVA (effect 
of genotype, F = 4.00, p = 0.0564; Figure 5.3c). There was also a significant 
effect of time on the percent of time spent in the center zone: both wild-type and 
GluK4 knockout animals appear to have spent more time in the center zone as 
the trial progressed (F = 3.47, p = 0.0002).  
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FIGURE 5.3. GluK4 mice show decreased aversion to center zone, and 
increased locomotion in long / dark open field. (A) The distance traveled by 
GluK4 knockout mice (n = 12) was consistently greater than that traveled by wild-
type mice (n = 15; p = 0.0076). Nevertheless, both wild-type and GluK4 knockout 
cohorts habituate to the open field environment over the course of the 1-hour 
trial. (B) The frequency of center zone entry is greater in GluK4 knockout mice 
than in wild-type mice (0.0283). (C) The proportion of time spent in the center 
zone is different, though not quite significantly (p = 0.0564), between wild-type 
and GluK4 knockout mice over the course of the trial. Bars represent mean ± 
SEM.  
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Together, these results suggest several interpretations. One possibility is that 
hyperlocomotion accounts for the differences in center entries and percent time 
spent in center in both the first (short / lit) and the second (long / dark) open field 
paradigms, and that there is no difference in basal anxiety levels between wild-
type and GluK4 knockout mice. Another possibility is that in the first paradigm, it 
is the open area of the field itself that is serving as the primary anxiogenic 
stimulus, independently of the ambient illumination. Thus, the fact that wild-type 
and GluK4 knockout mice differed in center zone preference in both the first and 
second paradigms could still be attributed to basal differences in anxiety. This 
would also explain why the time spent in the center zone in the second paradigm 
increased in both wild-type and knockout cohorts: as they became more familiar 
with the environment, the center zone may have become less anxiogenic.  
 
GluK4 Ablation Affects PPI and the Acoustic Startle Response 
PPI is a cross-species indicator of sensorimotor gating, and involves a 
suppression of the startle response evoked by a loud tone when that tone is 
immediately preceded by a weaker tone (Geyer et al., 1990). Under normal 
conditions, PPI is thought to be a precognitive means of preventing sensory 
overload (van den Buuse, 2010). Meanwhile, impaired PPI is widely considered 
to be an endophenotype of schizophrenia – a disorder characterized by cognitive 
disorganization and an inability to distinguish between salient and non-salient 
environmental cues (Perry and Braff, 1994). The cellular basis of PPI is complex 
and involves many brain structures and neurotransmitter systems, among which 
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are the hippocampus and glutamate, respectively (Reijmers et al., 1995; Koch, 
1996). 
 
To assess the effect of GluK4 ablation on PPI, I evaluated wild-type and GluK4 
knockout mice in a multi-block PPI paradigm. First, the startle response to single 
pulses with intensities ranging from 80 – 120 dB was analyzed. Next, the pulse 
was preceded by a prepulse, and the pulse intensity was maintained at 120 dB, 
while the prepulse intensity was varied from 3 to 12 dB above the background 
white noise level of 65 dB. Finally, the prepulse and pulse were maintained at 6 
dB (above background) and 120 dB, respectively, and the ISI between the 
prepulse and the pulse was varied from 25 to 500 milliseconds.  
 
The overall response to single acoustic pulses of varying intensity was 
significantly different between wild-type and GluK4 knockout mice (two-way 
ANOVA, effect of genotype, F = 7.12, p = 0.0132; wild type n = 15, knockout n = 
12; Figure 5.4a). Post-hoc analysis of the individual pulse intensities revealed 
that the response to 80, 90, and 100 dB pulses was largely the same between 
genotypes, but that GluK4 knockout mice displayed significantly reduced startle 
intensities relative to wild-type mice at 110 dB (p < 0.01) and 120 dB (p < 
0.0001).  
 
PPI was measured as a percentage, representing the ratio of the magnitude of 
the startle response (Vmax) evoked by a pulse following a prepulse, over the 
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magnitude of the average baseline startle response to a single 120 dB pulse. 
Overall, the percent PPI was also significantly reduced in GluK4 knockout mice 
compared to wild-type mice (two-way ANOVA, effect of genotype, F = 8.52, p = 
0.0073; Figure 5.4b), indicating that GluK4 mice do not effectively inhibit the 
startle response following a prepulse. Post-hoc analysis indicated that this effect 
was significant at a prepulse intensity of 6 dB (p < 0.01) and 12 dB (p < 0.001) 
above background. Varying the ISI between the prepulse and the pulse did not 
yield a significant difference between wild-type and GluK4 knockout mice (two-
way ANOVA, effect of genotype, F = 2.34, p = 0.1387; Figure 5.4c).  
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FIGURE 5.4. The acoustic startle response and PPI are impaired in GluK4 
knockout mice. (A) GluK4 knockout mice (n = 15) showed a decreased reaction 
relative to wild-type mice (n = 12) to acoustic pulses of varying intensity (p = 
0.0132). (B) %PPI was decreased in GluK4 knockout mice (p = 0.0073), 
suggesting impaired sensorimotor gating. (C) Varying the ISI did not result in 
significant differences in %PPI between wild-type and GluK4 knockout mice (p = 
0.1387). Bars represent mean ± SEM. ** p < 0.01, *** p < 0.001 
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Taken together, these results indicate that GluK4 knockout mice show deficits in 
PPI, as well as the acoustic startle response to a single pulse. The deficit in PPI 
indicates that GluK4 plays an essential role in sensorimotor gating, and 
reinforces the hypothesis that impaired GluK4 function or expression contributes 
to the pathogenesis of schizophrenia. Furthermore, the deficit in the acoustic 
startle response observed in GluK4 knockout mice suggests a more general 
difference in emotionality and arousal between wild-type and knockout mice, as 
the acoustic startle response is modulated by corticotropin releasing factor, a 
hormone that has been implicated in anxiety disorder and major depression 
(Risbrough et al., 2003).  Thus, the deficit in the acoustic startle response 
dovetails with the decreased anxiety- and depressive-like behaviors in GluK4 
knockout mice that I observed in the open field test and forced swim test, 
respectively.      
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CHAPTER 6: GLUK4 IN EXCITOTOXIC NEURODEGENERATION 
GluK4 Mediates Kainate-induced Neurodegeneration in the CA3 Region of the 
Hippocampus 
The hippocampus as a whole, and the CA3 region in particular, is exceptionally 
vulnerable to excitotoxic neurodegeneration due to its high concentration of 
ionotropic glutamate receptors (Nadler, 1981; Ben-Ari, 1985). The CA3 also 
corresponds to the region of highest GluK4 expression within the brain (Darstein 
et al., 2003). To determine the effect of GluK4 deficiency on excitotoxicity, I 
performed IH stereotaxic kainate injections on wild-type and GluK4 knockout 
animals. 24 hours after surgery, animals were perfused with saline and PFA, and 
their brains were removed and sliced on a microtome. Staining the resulting 
sections with FJC, a marker of degenerating neurons (Schmued et al., 2005), 
revealed that kainate resulted in extensive cell death in the CA1, CA3, and hilar 
regions of the hippocampus in wild-type animals (Figure 6.1a, b). However, the 
CA3 region appeared to be largely spared in GluK4 knockout animals (Figure 
6.1e, f). Because it was possible that the lack of FJC staining in the CA3 region 
of GluK4 knockout sections was actually the result of cell death so severe that 
the cells in that region had already been degraded, I co-stained the sections with 
DAPI to assess the general morphology and integrity of the remaining cells. In 
GluK4 knockout tissue, cells within the CA3 region appeared to be intact and 
densely packed, while in wild-type tissue, they appeared to be pyknotic and 
sparsely distributed (Figure 6.1c, d, g, h). Thus, the CA3 region was indeed 
neuroprotected following kainate injection in GluK4 knockout animals.  
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I then used stereological methods to quantify the density of FJC staining, and 
thereby compare the relative extent of neurodegeneration in wild-type versus 
GluK4 knockout hippocampal tissue. As I had observed in my preliminary 
investigations, I found that GluK4 deficiency resulted in significantly reduced 
kainate-induced cell death in the CA3 region (Student’s T-test, p = 0.0271), but 
not in the CA1, CA2, or dentate gyrus (Figure 6.1i). These results indicate that 
GluK4 activation is primarily responsible for excitotoxic cell death within the CA3. 
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FIGURE 6.1. GluK4 ablation attenuates kainate-induced neurodegeneration 
in the CA3. FJC- (A, B) and DAPI- (C, D) stained tissue from of KA-treated wild-
type animals revealed neurodegeneration throughout the hippocampus. (B) and 
(D) correspond to enlargements of the indicated regions of (A) and (C), 
respectively, and demonstrate extensive neurodegeneration in the CA3 region of 
the hippocampus. FJC- (E, F) and DAPI- (G, H) stained tissue from KA-treated 
GluK4 knockout animals revealed decreased neurodegeneration relative to wild-
type animals, specifically in the CA3 region of the hippocampus (F, H) where 
GluK4 expression is most concentrated. (F) and (H) represent enlargements of 
indicated regions of (E) and (G), respectively. (I) Stereological quantification of 
neurodegeneration, corresponding to mean area of FJC staining, demonstrated 
specific neuroprotection of the CA3 region in GluK4 knockouts (p = 0.0271). Bars 
represent mean ± SEM.  
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FIGURE 6.2. GluK4 ablation attenuates ischemia-induced 
neurodegeneration throughout the hippocampus. HI resulted in extensive 
neurodegeneration throughout the hippocampus of wild-type animals as 
indicated by FJC (A) and DAPI (B) staining. FJC staining for neurodegeneration 
(C) was strongly reduced in GluK4 knockout animals, and DAPI staining (D) 
showed intact cells throughout all subregions of the hippocampus. (E) 
Stereological quantification of neurodegeneration reflects neuroprotection 
throughout the hippocampus in GluK4 knockout animals relative to wild-type 
animals after HI (p = 0.0405), particularly in the CA1 (p = 0.0371), CA2 (p = 
0.0187), and CA3 (p = 0.0189) subregions. Bars represent mean ± SEM. 
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GluK4 Orchestrates Widespread Hippocampal Neurodegeneration Following HI  
To further explore the role of GluK4 in neurodegeneration in a clinically relevant 
context, Anna Kruyer, a fellow student in my laboratory with whom I worked 
closely on many of the experiments described herein, compared 
neurodegeneration in wild-type and GluK4 knockout mice following transient-
global ischemia (HI), a murine model of stroke. Mice were subjected to unilateral 
transection of the left common carotid artery, followed by 45 minutes of hypoxia. 
Using the same stereological methods to assess cell death as in the stereotaxic 
kainate injections described above, Anna found that HI resulted in extensive cell 
death in all hippocampal subregions. However, GluK4-deficient animals showed 
dramatically reduced neurodegeneration throughout the hippocampus relative to 
wild-type animals (Student’s T-test, p = 0.0405), particularly in the CA1 
(Student’s T-test, p = 0.0371), CA2 (Student’s T-Test, p = 0.0187) and CA3 
subregions (Student’s T-Test, p = 0.0189) (Figure 6.2). The robust 
neuroprotection afforded by GluK4 ablation suggests that GluK4 plays a role in 
initiating the molecular cascades that lead to neurodegenerative cell death. 
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CHAPTER 7: MOLECULAR MECHANISMS OF GLUK4-MEDIATED 
NEURODEGENERATION 
The neuroprotection observed in GluK4 knockout mice following administration of 
kainate or HI suggested that GluK4 was critical to the activation of cell death 
pathways. To elucidate the role of GluK4 in the molecular cascades leading to 
neurodegeneration, I designed a microarray assay in which I compared mRNA 
expression levels from kainate- versus PBS-injected wild-type and knockout 
samples. Enriched genes were further analyzed to extrapolate enriched 
molecular pathways. I chose to employ the kainate-mediated model of 
neurodegeneration over the HI-mediated model because the nature of the insult 
– kainate – is specific to kainate receptors and the extent of damage is highly 
reproducible between animals.  
 
Microarray Design 
Using the same IH injection protocol as I had to perform the stereology 
experiments described above, I bilaterally injected wild-type and GluK4 knockout 
mice with kainate or PBS. 24 hours after injection, hippocampi from both 
hemispheres were isolated, and one from each animal was further 
microdissected to isolate the CA3, as the neuroprotective effect of GluK4 ablation 
is restricted to the CA3 in the kainate-mediated model of neurodegeneration. 
However, the CA3 region is difficult to isolate and yields far less mRNA than 
whole hippocampus samples. To preclude the possibility that the CA3 samples 
might under-represent the molecular changes induced by kainate injection by 
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yielding insufficient or poor-quality mRNA, I included both CA3 and whole 
hippocampus samples in the microarray design. In sum, I tested the effects of 
treatment (kainate versus PBS), genotype (wild-type versus GluK4 knockout), 
and tissue (whole hippocampus versus CA3). All conditions included in the 
microarray are outlined in Table 7.1.  
 
TABLE 7.1. Microarray conditions. 
Genotype Injection Tissue Type 
Wild-type PBS Whole hippocampus 
Wild-type PBS CA3 
GluK4 Knockout PBS Whole hippocampus 
GluK4 Knockout PBS CA3 
Wild-type Kainate Whole hippocampus 
Wild-type Kainate CA3 
GluK4 Knockout Kainate Whole hippocampus 
GluK4 Knockout Kainate CA3 
 
Microarray Sample Quality Control 
All RNA samples were purified after extraction, and bioanalyzed to assess the 
RNA integrity number (RIN) of each sample. Any samples where the RIN fell 
below 8 were re-purified. 
 
To ensure that CA3 samples were free, or as free as possible, of contamination 
from neighboring subregions, I performed one-step RT-PCR on CA3 mRNA 
samples using primers that were designed to amplify Nov and Dsp, genes 
specific to the CA1 and DG subregions, respectively. Reactions for each region-
specific primer set were optimized for cycle number and RNA concentration. 
PCR products were then analyzed semi-quantitatively for Nov and Dsp levels, 
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and samples that yielded the lowest expression of each – i.e., were least 
contaminated – were selected for further experiments (Figures 7.1 and 7.2).  
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FIGURE 7.1. Assessing contamination of microarray CA3 samples by DG 
tissue. (A) Representative gels of one-step RT-PCR assays for the DG marker 
Dsp show varying levels of DG contamination in CA3 samples. A DG sample was 
run as a positive control in the last lane. (B) Semiquantitative analysis of Dsp 
expression was used to select the least-contaminated CA3 samples from each 
condition. KA, kainate-injected samples; PBS, PBS-injected samples; + control, 
pure DG mRNA used as template instead of CA3 mRNA. 
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FIGURE 7.2. Assessing contamination of microarray CA3 samples by CA1 
tissue. (A) Representative gels of one-step RT-PCR assays for the CA1 marker 
Nov show varying levels of CA1 contamination in CA3 samples. A CA1 sample 
was run as a positive control in the last lane. (B) Semiquantitative analysis of 
Nov expression was used to select the least-contaminated CA3 samples from 
each condition. + control, pure CA1 mRNA used as template instead of CA3 
mRNA. 
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Additionally, all CA3 and whole hippocampus samples were analyzed to 
determine whether the samples that were supposed to receive kainate had 
actually received it. FJC staining of kainate-injected tissue will occasionally 
reveal that kainate has not been properly administered, perhaps as a result of air 
bubbles in the injection syringe or defects in the injection pump. Thus, expression 
levels of Hsp27, a heat shock protein that has been shown to be highly up-
regulated following IP kainate injection (Brecht et al., 2005), were assessed by 
one-step RT-PCR as a positive indicator of kainate injection. Hsp27 has the 
added advantage of being neuroprotective in excitotoxic conditions, as 
transgenic mice that overexpress Hsp27 are neuroprotected in the context of 
MCAO, indicating that it may still be up-regulated in GluK4 CA3 samples despite 
resistance of cells in that region to kainate-induced neurodegeneration. Hsp27 
was indeed observed in both kainate-injected wild-type and GluK4 knockout 
tissue, and expression levels were indistinguishable using semi-quantitative 
analysis (Figure 7.3). Ultimately, all kainate-injected samples had received 
kainate.    
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FIGURE 7.3. Assessing Hsp27 expression as a measure of successful 
kainate injection. (A) Levels of Hsp27, a neuroprotective gene that is highly up-
regulated in the context of excitotoxicity, were assessed in kainate- and PBS-
injected samples using one-step RT-PCR. Kainate- and PBS-injected samples 
were interspersed in these gels, with the exception of the last gel in which only 
kainate-injected samples were run. (B) Semiquantitative analysis revealed that 
all samples that were supposed to receive kainate had actually received it.  
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Three samples from each of the eight conditions outlined in Table 7.1 were 
pooled and submitted to the Genomics Core Facility at The Rockefeller 
University, where they were then labeled, hybridized to the individual wells of an 
Illumina Expression BeadChip, and scanned. Raw gene expression signals were 
thresholded as described in materials and methods.  
 
Gene Enrichment in CA3 Versus Whole Hippocampus Samples 
For all conditions examined, whole hippocampus samples yielded fewer enriched 
genes than CA3 samples. For instance, the list of genes up-regulated by 2-fold or 
greater in wild-type CA3 tissue following kainate injection included 559 genes, 
while the same list in whole hippocampus tissue included only 336 genes. One 
reason for this difference may be that CA3-specific changes in gene regulation 
were counterbalanced by a lack of change, or perhaps changes in the opposite 
direction, in the same genes in other regions of the hippocampus. Thus, whole 
hippocampus samples were excluded from further analysis, and all of the results 
reported here are from CA3 samples. 
 
Gene Enrichment Following Kainate Injection in Wild-type Versus GluK4 
Knockout Samples 
To determine the effects of kainate on gene expression, the fold-change in gene 
expression levels in the kainate condition relative to the PBS condition was 
calculated for each genotype. The resulting wild-type and GluK4 knockout gene 
lists were then compared to determine the effects of kainate on gene expression 
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between genotypes. Only genes with a fold-change greater than |2| in the kainate 
condition relative to the PBS condition for each genotype were included in this 
analysis. 3 gene lists emerged: genes that were exclusively up-regulated in wild-
type tissue, i.e., up-regulated by 2-fold or more in wild-type tissue but not GluK4 
knockout tissue following kainate injection, relative to PBS (320 genes 
altogether); genes that were exclusively up-regulated in GluK4 knockout tissue 
(74 genes); and genes that were up-regulated in both wild-type and GluK4 
knockout tissue (239 genes) (Figure 7.4). The top 30 genes in the wild-type-
exclusive and GluK4 knockout-exclusive lists are outlined in Tables 7.2 and 7.3. 
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FIGURE 7.4. Schematic Venn diagram of gene enrichment in wild-type 
versus GluK4 knockout samples after kainate injection. 320 genes were 
exclusively enriched by |2|-fold or more following kainate injection (relative to 
PBS injection) in wild-type samples (orange); 74 genes were exclusively enriched 
in GluK4 knockout samples (blue); and 239 genes were enriched in both.    
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TABLE 7.2. Genes enriched in wild-type samples following kainate. 
  
Gene Name Symbol 
Fold-change in wild-
type following 
kainate, relative to 
PBS 
Fold-change in 
knockout following 
kainate, relative to 
PBS 
β-actin Actb -50.522327 -1.2285179 
growth hormone Gh 17.440138 1.1244828 
prolactin Prl 7.5980372 -1.0499934 
purkinje cell protein 2 (L7) Pcp2 6.7068973 1.4683733 
solute carrier family 13 (sodium/sulfate 
symporters), member 4 Slc13a4 6.142569 -1.9992677 
sulfatase 1 Sulf1 5.927293 -1.0554414 
prolactin receptor Prlr 5.5717325 -1.3291636 
decorin Dcn 5.001785 1.7570093 
matrix Gla protein Mgp 4.4215 1.5079937 
retinol dehydrogenase 5 Rdh5 4.349441 -1.2431543 
insulin-like growth factor 2 Igf2 4.2631984 -1.9494125 
insulin-like growth factor binding protein 2 Igfbp2 4.242587 -1.1547633 
nuclear receptor co-repressor 1 Ncor1 -4.0182915 1.1821797 
solute carrier family 17 (sodium-dependent 
inorganic phosphate cotransporter), member 
6 
Slc17a6 4.0027905 1.4765645 
lectin, galactose binding, soluble 1 Lgals1 3.896389 1.9174436 
gap junction protein, β-2 Gjb2 3.4975474 1.3912534 
interferon-induced protein with 
tetratricopeptide repeats 3 Ifit3 3.49664 1.3959935 
interferon, α-inducible protein 27 Ifi27 3.4579968 1.1008872 
tubulin, α-1c Tuba6 3.4517848 1.6111073 
rap guanine nucleotide exchange factor 
(GEF)-like 1 Rapgefl1 -3.4238975 -1.9603293 
tubulin, β-2b Tubb2b 3.2463224 1.39096 
leucine rich repeat containing 4B; similar to 
Leucine rich repeat containing 4B LOC100045241 -3.2053182 -1.5128021 
lectin, galactoside-binding, soluble, 3 binding 
protein Lgals3bp 3.2032213 1.2697843 
ubiquitin specific peptidase 18; similar to 
ubiquitin specific protease UBP43 LOC100048346 3.1747127 1.701681 
chemokine (C-C motif) ligand 2 Ccl2 3.154905 1.9624745 
protein kinase C, γ Prkcc -3.1515055 -1.9287628 
predicted gene 12141; heat shock protein 1 
(chaperonin) Hspd1 3.1073248 1.2092633 
I830012O16Rik RIKEN cDNA I830012O16 
gene LOC667370 3.1015675 1.7340547 
vesicle amine transport protein 1 homolog-like 
(T. californica) Vat1l 3.0500953 -1.2528175 
predicted gene 5778; similar to 
heterogeneous nuclear ribonucleoprotein 
A2/B1; heterogeneous nuclear 
ribonucleoprotein A2/B1 
Hnrnpa2b1 3.043459 1.1359648 
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TABLE 7.3. Genes enriched in GluK4 knockout samples following kainate   
Gene Name Symbol 
Fold-change in 
knockout following 
kainate, relative to PBS 
Fold-change in wild-
type following kainate, 
relative to PBS 
similar to α-lactalbumin; lactalbumin, α Lalba 3.6236696 1.1536819 
sclerostin domain containing 1 Sostdc1 -3.3527162 1.4620374 
inositol 1,4,5-trisphosphate 3-kinase A Itpka -3.2814567 -1.9674851 
glycine dehydrogenase Gldc -3.1782527 -1.9073267 
acyl-CoA thioesterase 11 Acot11 -3.0526004 -1.673179 
tyrosinase-related protein 1 Tyrp1 3.0267994 1.3415347 
cysteine and glycine-rich protein 3 Csrp3 3.000433 1.3494827 
Ca2+-dependent activator protein for 
secretion 2 Cadps2 -2.7261322 -1.7462686 
fibrinogen C domain containing 1 Fibcd1 -2.6653936 -1.2815868 
pleckstrin and Sec7 domain containing 2 Psd2 -2.6561596 -1.3567331 
chromagranin A Chga 2.6017258 1.8398476 
B-cell linker Blnk 2.5908782 1.6979231 
glycine decarboxylase Gldc -2.5458357 -1.817069 
sulfotransferase family 1A, phenol-preferring, 
member 1 Sult1a1 -2.5454924 -1.2607372 
serine peptidase inhibitor, Kazal type 8 Spink8 -2.520413 -1.592723 
similar to calponin 3, acidic; predicted gene 
4815; calponin 3, acidic 
LOC1000478
56 2.508167 1.8010483 
strawberry notch homolog 2 (Drosophila) Sbno2 2.5037324 1.9636917 
solute carrier family 7 (cationic amino acid 
transporter, ψ+ system), member 10 Slc7a10 -2.4803817 -1.3164182 
polymerase (DNA-directed), δ 4 Pold4 2.44297 1.8516624 
multiple EGF-like-domains 11 Megf11 2.4371126 1.8443365 
glucosaminyl (N-acetyl) transferase 2, I-
branching enzyme Gcnt2 2.425731 1.7545487 
lin-7 homolog B (C. elegans) Lin7b -2.39229 -1.9965154 
activin A receptor, type IC Acvr1c 2.3459048 1.6499034 
phosphoatidic acid phosphatase type 2B Ppap2b -2.3409045 -1.7861793 
ST6 (α-N-acetyl-neuraminyl-2,3-β-galactosyl-
1,3)-N-acetylgalactosaminide a-2,6-
sialyltransferase 4 
St6galnac4 2.3217778 1.772647 
chromogranin A Chga 2.3211932 1.7686646 
solute carrier family 39 member 12 Slc39a12 -2.3190215 -1.4546387 
VGF nerve growth factor inducible Vgf 2.3179793 1.6363449 
B-cell leukemia/lymphoma 3 Bcl3 2.3033428 1.9761575 
interferon γ induced GTPase Igtp 2.2822418 1.8902932 
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DAVID Analysis of Enriched Molecular Pathways Indicates Enrichment of the 
JNK Pathway in Kainate-treated Wild-type Samples 
The list of genes exclusively up-regulated following kainate treatment in wild-
type, but not GluK4 knockout tissue, represents the genes that are enriched in a 
GluK4-dependent manner. To gain insight into the molecular pathways in which 
GluK4 might participate to mediate neurodegeneration, this list was analyzed 
using the Database for Annotation, Visualization and Integrated Discovery 
(DAVID), a program that compares gene lists against various pathway databases 
and extracts statistically over-represented (i.e., enriched) pathways (Huang et al., 
2007).   
 
Using the DAVID program, the list of genes exclusively enriched in wild-type 
tissue was compared against the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database. Significantly enriched pathways (p < 0.05) are outlined in 
Table 7.4. The biological relevance of some of these pathways, such as the type 
II diabetes mellitus pathway, to GluK4-mediated excitotoxicity is not immediately 
clear. However, among the significantly enriched pathways, the Mitogen 
Activated Protein Kinase (MAPK) signaling pathway is of particular interest: while 
it includes many auxiliary pathways and governs diverse physiological 
processes, including proliferation, differentiation, and inflammation, it also 
mediates apoptosis through the subset of MAPK proteins that comprise the JNK 
pathway (Schaeffer and Weber, 1999).  
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TABLE 7.4. KEGG pathways exclusively enriched in wild-type samples following 
kainate  
 
 
There is strong evidence to suggest that the JNK pathway mediates excitotoxic 
neurodegeneration, as outlined in Chapter 1: mice deficient in JNK3, the 
neuronal isoform of JNK, are resistant to neurodegeneration following MCAO and 
IP kainate injection (Brecht et al., 2005), and JNK pathway-inhibiting compounds 
are neuroprotective (Bogoyevitch et al., 2004).  There is also evidence linking 
JNK pathway activation and kainate receptors: MLK3, an earlier initiator of the 
JNK pathway kinase cascade, can form a complex with GluK2 and PSD95 that 
results in MLK3-autophosphorylation and, subsequently, JNK pathway activation 
KEGG Pathway p Value Genes 
Homeostasis/Energy Metabolism     
Type II diabetes mellitus 0.0011 MAPK1, HK1, MAPK10, PRKCE, ABCC8, PRKCD 
GnRH signaling pathway 0.0047 MAPK1, ADCY9, PTK2B, JUN, MAPK10, CAMK2A, PRKCD 
Glycerolipid metabolism 0.0400 LPL, DGKB, DGKZ, MGLL 
Neurotransmission     
Neuroactive ligand-receptor 
interaction 0.0030 
TSPO, THRA, GRIA2, PRLR, NPY2R, GRIK5, GRIA3, 
NPY1R, GRM1, PRL, GH, F2R 
Long-term potentiation 0.0053 MAPK1, GRIA2, PPP3R1, GRM1, CAMK2A, PRKCC 
Long-term depression 0.0060 MAPK1, GNAO1, GRIA2, GRIA3, GRM1, PRKCC 
Gap junction 0.0125 MAPK1, TUBB2B, ADCY9, GRM1, PRKCC, TUBB4 
Calcium signaling pathway 0.0346 ADCY9, PTK2B, RYR3, PPP3R1, GRM1, CAMK2A, PRKCC, F2R 
Hemovascular function     
Vascular smooth muscle contraction 0.0128 KCNMA1, MAPK1, ADCY9, ACTA2, PRKCE, PRKCD, PRKCC 
Cell death     
MAPK signaling pathway 0.0270 MAPK1, DUSP1, JUN, PPP3R1, FGF10, HSPA1A, FGF13, MAPK10, PRKCC, HSPA8 
Immunity     
Natural killer cell mediated 
cytotoxicity 0.0473 ICAM1, MAPK1, PTK2B, PPP3R1, FCGR4, PRKCC 
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(Tian et al., 2005; Jiang et al., 2007). These findings, in conjunction with the 
enrichment of the MAPK pathway in wild-type but not GluK4 knockout tissue, 
suggested that GluK4 might mediate excitotoxic neurodegeneration through the 
JNK pathway.  
 
Performing the same DAVID analysis with the list of genes exclusively enriched 
in GluK4 knockout tissue after kainate – genes that might play a neuroprotective 
role in the context of excitotoxicity – yielded no significantly enriched pathways.  
 
 
GSEA Analysis Reveals Selective Enrichment of Cell Death Pathways in 
Kainate-treated Wild-type Samples 
The DAVID program does not take into account the relative enrichment (i.e., fold-
change values) of the genes within a given list, merely the gene names, when 
extrapolating enriched pathways. While this low stringency can be considered an 
advantage in the sense that it facilitates pathway discovery, it is also a 
disadvantage in the sense that it may over- or underestimate the importance of a 
given pathway by giving weight to the number – rather than the magnitude of 
regulation – of genes within a given list that coincide with a given pathway. 
Furthermore, DAVID cannot distinguish between significantly up-regulated 
versus significantly down-regulated pathways, thereby clouding downstream 
interpretations of biological relevance. 
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To address these issues, I performed a second round of analysis using GSEA 
software. GSEA can incorporate the magnitude – and, to some extent, the 
direction – of regulation of the genes within the list to generate a set of proposed 
pathways in which those genes might participate (Subramanian et al., 2005). 
GSEA was run from two distinct gene lists: all genes probed in the microarray 
from 1. wild-type, and 2. GluK4 knockout tissue, ranked by fold-change after 
kainate administration relative to their respective PBS baseline. These lists were 
then compared against the Biocarta pathway database to assess positively 
enriched (up-regulated) and negatively enriched (down-regulated) pathways. 
 
As with DAVID analysis, the set of positively enriched pathways that is exclusive 
to the wild-type condition (Table 7.5) gives insight into the molecular actions of 
GluK4 downstream of kainate administration. While the relevance of some of the 
enriched pathways to GluK4-mediated neurodegeneration is not immediately 
apparent (for instance, the erythrocyte pathway), there is a clear enrichment of 
cell-death-mediating pathways. These include, in order from most to least 
statistically significant, the p53 hypoxia pathway, which involves the induction of 
apoptosis through p53; the caspase pathway, which involves the induction of 
apoptosis through the caspase proteolytic cascade; the death receptor pathway, 
which involves the induction of apoptosis through DR3 and DR4/5 receptors; the 
D4-GDI pathway, which involves the induction of apoptosis through D4-GDI, a 
molecule that regulates the cytoskeletal changes associated with apoptosis 
through the Rho family of GTPases; the Fas pathway, which involves the 
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induction of apoptosis through the cell-surface expressed Fas receptor; and the 
ceramide pathway, which involves the induction of apoptosis through ceramide, a 
lipid signaling molecule.  
 
TABLE 7.5. Biocarta pathways exclusively enriched in wild-type samples 
following kainate 
Biocarta Pathway P Value Genes (with Core Enrichment) 
Cell Death     
p53 hypoxia Pathway 0.019 CDKN1A, HSP1A1, GADD45A, IGFBP3, CSNK1D 
Caspase Pathway 0.019 
ARHGDIB, LMNA, LMNB1, CASP8, CASP1, CASP4, 
CASP9, LMNB2, BIRC, CASP3, CASP7, CASP2, CASP6, 
APAF1, BIRC3, PRF1 
Death Receptor Pathway 0.018 
LMNA, FADD, CASP8, RELA, MAP3K14, NFKB1, 
TNFRSF10B, RIPK1, NFKBIA, TRAF2, CASP9, BIRC4, 
CASP3, CASP7, CASP6, APAF1, BIRC3 
D4-GDI Pathway 0.020 not reported by GSEA 
Fas Pathway 0.058 not reported by GSEA 
Ceramide Pathway 0.050 not reported by GSEA 
Cell Survival and Proliferation     
IGF-1 Pathway 0.041 FOS, JUN, SHC1 
Nerve Growth Factor Pathway 1.627 not reported by GSEA 
Immunity     
Toll-like Receptor Pathway 0.017 
FOS, CD14, TLR2, JUN, MAP2K3, MYD88, RELA, TLR7, 
TIRAP, MAP3K14, NFKB1, LY96, NFKBIA, TLR4, IRAK1, 
TLR6, TRAF6 
Natural Killer T-Cell Polarization 
Pathway 0.000 CCL4, CCL3, CCR5 
IL6 Cytokine Pathway 0.020 FOS, STAT, JUN, CEBPB, SHC1 
B Lymphocyte Pathway 0.051 not reported by GSEA 
Homeostasis/Energy 
Metabolism     
Insulin Pathway 0.034 FOS, JUN, SHC1 
Hemovascular Function     
Intrinsic Prothrombin Activation 
Pathway 0.017 
F2R, PROS1, SERPING1, COL4A4, COL4A5, COL4A1, 
F5, COL4A2, COL4A6, FGA, FGG, SERPINC1, KLKB1 
Erythrocyte Differentiation 
Pathway 0.034 not reported by GSEA 
 
Amongst the pathways that were positively enriched in the GluK4 knockout 
samples (Table 7.6), the EPO NFkB pathway stands out a potential modulator of 
cell survival in the CA3. Aside from its role in the production of erythrocytes, 
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erythropoietin (EPO) promotes neuroprotection in murine models of stroke by 
activating a variety of downstream signaling pathways, including the NFkB 
pathway (van der Kooij et al., 2008). This finding suggests that GluK4 may 
directly suppress the neuroprotective functions of EPO in the context of kainate-
induced excitotoxicity, or, perhaps more plausibly, that pathways downstream of 
GluK4 activation modulate EPO production. Establishing the molecular 
pathway(s) that lead(s) to the up-regulation of the EPO NFκB following kainate 
administration in the absence of GluK4 was outside the scope of this thesis, but 
may warrant future investigation. 
 
Very few pathways were negatively enriched either the wild-type or GluK4 
knockout samples. Two pathways mediating immunity – the MEF2D pathway, 
and the NK Cells pathway – were down-regulated in wild-type samples. In GluK4 
samples, down-regulated pathways included the Bad cell death pathway, the 
CK1 cell signaling pathway that is involved in dopamine signaling, and the 
Glycolysis and Kreb pathways, both of which regulate homeostasis and energy 
metabolism. The down-regulation of these pathways leads to many hypothesis 
as to their role in GluK4-mediated neurodegeneration. Down-regulation of the 
Bad cell death pathway in GluK4 knockout tissue may be of particular interest, as 
it parallels the up-regulation of pro-apoptotic pathways in wild-type tissue.  
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TABLE 7.6. Biocarta pathways exclusively enriched in GluK4 knockout samples 
following kainate 
Biocarta Pathway P Value Genes (with Core Enrichment) 
IMMUNITY     
Tcr Pathway 0.051 Not reported by GSEA 
Il2 Pathway 0.048 Not reported by GSEA 
Tid Pathway 0.053 Not reported by GSEA 
Cd40 Pathway 0.037 DUSP 1, NFKBIA, RELA, NFKB1, TRAF6, CHUK, IKBKG, MAP3K14 
41bb Pathway 0.019 JUN, NFKBIA, RELA, MAP4K5, NFKB1, IFNG, TNFSF9, CHUK, ATF2 
CELL SURVIVAL     
Rela Pathway 0.000 TNFRSF1A, NFKBIA, RELA, RIPK1, NFKB1, FADD, TRAF6, TNF, CHUK, IKBKG 
EPO NFkB Pathway 0.036 CDKN1A, NFKBIA, RELA, NFKB1, ARNT, JAK2, GRIN1, EPOR 
HEMOVASCULAR FUNCTION     
Vegf Pathway 0.000 NOS3, ELAVL1, EIF1A, FLT1, PXN, EIF2B4, PTK2, SHC1, ARNT, EIF2B2, PRKCA, EIF2S2, PIK3CA 
No1 Pathway 0.000 CHRNA1, CAV1, PRKG2, NOS3, TNNI1, ACTA1, FLT1 
CELL DEATH     
Tnf Stress Pathway 0.000 MAP2K3, JUN, TNFRSF1A, NFKBIA, RELA, RIPK1, NFKB1, TNF, CRADD, CHUK, IKBKG, MAP3K14 
SIGNAL TRANSDUCTION     
Ps1 Pathway 0.000 NOTCH1, ADAM17, BRTC, TCF1, CTNNB1, APC, DVL1, PSEN1, FDZ1 
 
 
Surprisingly, the MAPK pathway was positively enriched in both the wild-type and 
GluK4 knockout conditions, though more so in the wild-type than in the knockout 
condition (wild-type, p = 0.000; GluK4 knockout, p = 0.036; see Appendix 1). This 
finding suggests several interpretations. One possibility is that the up-regulation 
of the MAPK pathway in GluK4 knockout tissue is more limited than in wild-type 
tissue, and that it may be statistically, but not biologically significant. Another 
possibility is that that MAPK pathway activation serves different functions in wild-
type versus GluK4 knockout conditions – that it may promote neurodegeneration 
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in the wild-type condition and neuroprotection in the GluK4 knockout condition. 
As discussed above, the MAPK pathway is comprised of several auxiliary 
pathways, each with multiple, wide-ranging functions including cell proliferation in 
addition to apoptosis. While GSEA does identify the specific genes within each 
pathway that are enriched for a given condition (wild-type versus GluK4 
knockout), the overlap in genes between the various auxiliary pathways makes it 
difficult to assess which pathways are enriched. Thus, it is difficult to determine 
from these data whether the JNK pathway is involved in either condition. 
 
Biochemical Analysis of JNK Pathway Activation Suggests Biphasic Role of 
GluK4 
To better understand the interaction between GluK4 and the JNK pathway, I 
investigated the phosphorylation states of JNK pathway components by Western 
blot in kainate-injected wild-type and GluK4 knockout CA3 tissue. I hypothesized 
that analysis of the JNK pathway at the protein level would yield a more accurate 
– and more physiologically relevant – representation of JNK pathway activation 
than analysis at the mRNA level, as JNK pathway activation is dependent upon 
kinase-mediated phosphorylation of proteins.  
 
The JNK pathway is activated by the phosphorylation of a MAPK kinase kinase, 
such as MLK3, which in turn phosphorylates MAPK kinase 4 or 7 (Hirai et al., 
1997; Nagata et al., 1998). I found that phosphorylated MAPK kinase 4 (MKK4) 
was significantly up-regulated in wild-type CA3 samples following kainate 
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treatment as compared to PBS treatment, but remained unchanged in CA3 
samples from GluK4 knockout mice (Student’s T-test, p = 0.003; Figure 7.5a) 
 
MAPK kinases perpetuate the kinase cascade by phosphorylating one of three 
JNK isoforms: JNK 1, 2, or 3. While JNK 1 and JNK 2 are expressed 
systemically, JNK 3 is primarily expressed in neurons (Gupta et al., 1996; Martin 
et al., 1996). Though native JNK1 and JNK 2/3 expression remained unchanged 
after kainate administration (Figure 7.5b), I observed an increase, though not 
statistically significant, in wild-type levels of phosphorylated JNK 2/3 after kainate 
treatment (Student’s T-test, p = 0.087; Figure 7.5c). However, the increase in 
phosphorylated JNK 2/3 levels in kainate-treated wild-type samples relative to 
kainate-treated GluK4 knockout samples was statistically significant (Student’s T-
test, p=0.007; Figure 7.5c). Phosphorylated JNK 1 expression remained 
unchanged in all conditions (Figure 7.5c). 
 
Phosphorylated JNK isoforms regulate the activity of activator protein 1 (AP-1), a 
transcription factor that modulates various cellular processes including apoptosis 
(Whitmarsh and Davis, 1996). AP-1 assembles as a homo- or heterodimer from a 
number of DNA-binding bZip proteins, including c-Jun, activating transcription 
factor 2 (ATF2), and c-Fos. Native cJun, phosphorylated cJun, and 
phosphorylated ATF-2 were all up-regulated in kainate-treated wild-type samples 
relative to PBS-treated samples (Student’s T-test, p = 0.002, p = 0.011, and p = 
0.004, respectively), but remained unchanged between kainate- and PBS-treated 
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GluK4 knockout samples (Figure 7.5d - f). Though c-Fos expression was not 
significantly different between kainate- and PBS-treated wild-type samples, it was 
down-regulated in kainate-treated GluK4 knockout samples relative to PBS-
treated GluK4 knockout samples and kainate-treated wild-type samples 
(Student’s T-test, p = 0.001 and p = 0.053, respectively; Figure 7.5g). 
Surprisingly, phosphorylated ATF-2, c-Jun, phosphorylated c-Jun, and c-Fos 
levels were all constitutively higher in PBS-treated GluK4 knockout samples than 
in PBS-treated wild-type samples (Student’s T-test, p = 0.044, p = 0.048, p = 
0.038, and p = 0.053, respectively; Figure 7.5d - g).  
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Figure 7.5. GluK4 ablation results in decreased JNK pathway activation 
following kainate, but increased JNK pathway activation at baseline. (A) 
The active form of one of the earliest kinases in the JNK pathway, MKK4, was 
up-regulated in wild-type CA3 tissue after KA treatment relative to PBS 
treatment, but not in GluK4 CA3 tissue. (B) The native neuronal isoform of JNK 
(JNK 2/3, 54 kDa, top band) remained unchanged between genotypes after PBS 
or KA treatment. The bottom band represents the JNK 1 isoform (46 kDa), which 
is expressed globally. (C) Despite the fact that the native form of JNK 2/3 
remained unchanged in all conditions, the phosphorylated (activated) form of 
JNK 2/3 is up-regulated in KA-treated wild-type tissue relative to KA-treated 
GluK4 knockout tissue. (D) The native form of cJun, a member of the AP-1 
transcription factor complex that is activated downstream of JNK, was up-
regulated in wild-type tissue following KA treatment relative to PBS treatment. 
The increase in cJun expression between PBS- and KA treated GluK4 knockout 
tissue was not significant, due to variability between samples. Basal c-Jun 
expression was higher in PBS-treated GluK4 knockout tissue than in PBS-treated 
wild-type tissue.  
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Figure 7.5, continued. (E) The phosphorylated (activated) form of cJun was up-
regulated in KA- versus PBS- treated wild-type tissue but not GluK4 knockout 
tissue. However, phosphorylated c-Jun expression was higher after PBS 
treatment in GluK4 knockout tissue than in wild-type tissue. (F) Phorphorylated 
ATF-2, another member of the AP-1 complex, followed a similar expression 
pattern to phosphorylated cJun. Phosphorylated ATF-2 was up-regulated in up-
regulated in KA- versus PBS- treated wild-type tissue but not GluK4 knockout 
tissue, though its expression was higher after PBS treatment in GluK4 knockout 
tissue than in wild-type tissue. (G) cFos is also a member of the AP-1 
transcription complex. Its expression was strongly down-regulated between KA-
treated wild-type and GluK4 knockout tissue, and between PBS- and KA-treated 
GluK4 knockout tissue. As with the other members of the AP-1 complex, c-Fos 
expression was increased at baseline in PBS-treated GluK4 knockout versus 
wild-type tissue. Bars represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.  
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Collectively, these data suggest that GluK4 can regulate JNK pathway activity in 
a biphasic, context-dependent manner. In the context of excitotoxicity, GluK4 
appears to be essential to the activation of the JNK pathway throughout its 
various kinase tiers, which further suggests that GluK4 acts on one or more of 
the early components of the pathway to initiate neurodegeneration. In non-
pathological contexts, GluK4 seems to play a role in suppressing JNK pathway 
activation.  
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CHAPTER 8: GLUK4 IN KAINATE-INDUCED SEIZURES 
Mesial temporal lobe epilepsy (mTLE) is one of the most common forms of 
epilepsy, and is characterized by recurrent focal seizures that originate in 
populations of hyperexcitable, hypersynchronous cells in the hippocampus 
(Falconer et al., 1964). In most affected patients, mTLE arises in tandem with 
lesions or alterations in neuronal connectivity that are the result of previous 
neuronal insults, including trauma, encephalitis, and ischemia (Engel, 1993; 
Camilo and Goldstein, 2004). Approximately 70% of patients with mTLE also 
develop hippocampal sclerosis, which is characterized by neurodegeneration, 
astrogliosis, and a form of synaptic reorganization in the dentate gyrus known as 
mossy fiber sprouting (Babb and Brown, 1986).  
 
Kainate, in addition to being a potent excitotoxin, is also an epileptogenic 
compound that reproduces many of the hallmarks of mTLE in animals: recurring 
motor seizures, hippocampal neurodegeneration, and mossy fiber sprouting 
(Vincent and Mulle, 2009). In this model, animals are typically injected IP with 
kainate and monitored for seizure activity for 2 – 4 hours thereafter. Seizure 
severity is normally scored by hand and ranked using a metric developed by 
Racine (Racine, 1972).  
 
I hypothesized that GluK4 might play a role in the kainate model of mTLE based 
on several lines of evidence. Mice deficient in GluK2, the kainate receptor 
subunit with which GluK4 co-precipitates in the CA3, are resistant to kainate-
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induced seizures (Mulle et al., 1998). Meanwhile, rats that were injected IH with a 
viral vector that transduced GluK2 experienced seizures 4 hours after injection 
(Telfeian et al., 2000). Furthermore, GluK4 expression is highest in the CA3, and 
this region has been shown to be an epicenter of seizurogenic activity (Avoli and 
Barbarosie, 1999). Synchronized discharges that originate within the network of 
glutamatergic collaterals of the CA3, and subsequently spread throughout the 
hippocampal subfields, are thought to underlie interictal spiking, a pathological 
EEG pattern that may predict or precipitate epileptic seizures (Avoli et al., 2006). 
While the anesthetics administered during the IH kainate injections prevented 
motor seizures in the experiments described above (see Chapter 6), the 
neuroprotection afforded by GluK4 ablation in this paradigm suggested that 
GluK4 knockout mice might also have altered susceptibility to kainate-induced 
seizures.  
 
Additionally, GluK4-mediated seizures could explain the robust difference in 
neurodegeneration following HI between wild-type and knockout animals. HI has 
been shown to result in spontaneous motor seizures within 72 hours of surgery in 
unanesthetized adult animals, and the occurrence of HI-induced seizures 
correlated with the severity of HI-induced neurodegeneration (El-Hayek et al., 
2011). Though seizures were not specifically evaluated in Anna’s HI experiments 
described above (see Chapter 6) they were often observed in passing. Thus, HI 
could induce seizures that originate in GluK4-expressing cell populations of the 
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CA3, then propagate throughout brain and produce widespread neuronal cell 
death in wild-type, but not GluK4 knockout animals.  
 
High, Incremental Doses of Kainate Suggest Decreased Seizure Susceptibility In 
GluK4 Knockout Mice 
To explore the role of GluK4 in seizure generation, wild-type and GluK4 knockout 
animals were injected IP with an initial dose of 30 mg/kg kainate, followed by two 
15 mg/kg doses at 45 minute intervals. Seizures were scored using a modified 
version of Racine’s scale (see Chapter 2, p. 39). This dosing scheme resulted in 
high mortality: 3 of 9 animals (33.33%) died. Nevertheless, seizure scores from 
the remaining animals (wild-type, n = 3; GluK4 knockout, n = 3) suggested that 
GluK4 knockout mice might be more resistant to kainate-induced seizures than 
wild-type mice. Though the high variability and low n in the seizure score data 
precluded any significant results by two-way ANOVA (effect of genotype, F = 
2.67, p = 0.1776; Figure 8.1a), GluK4 knockout mice were almost entirely 
unaffected by the initial 30 mg/kg dose of kainate (time (t) = 0 minutes), while 
wild-type mice showed low-grade seizures. Following the next injection (15 
mg/kg; t = 45 minutes), both wild-type and GluK4 knockout animal scores 
escalated, and animals of both genotypes showed intermittent high-grade 
seizures (level 4 - 5). Following the last injection (15 mg/kg; t = 90 minutes), wild-
type animals showed sustained high-grade seizures, plateauing at level 5, while 
GluK4 knockout animals showed sustained mid-grade seizures, plateauing at 
level 3.   
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Increased Seizure Activity in GluK4 Knockout Mice at Low Doses of Kainate 
Because the above dosing scheme resulted in high mortality, and because the 
difference in seizure scores between wild-type and GluK4 knockout mice 
appeared to be most pronounced after the first injection, I lowered the dose of 
kainate administered using several dosing schemes. An initial dose of 15 mg/kg 
kainate followed by two doses of 5 mg/kg at 10 minute intervals yielded no 
significant difference in seizure sensitivity by two-way ANOVA (wild-type n = 2, 
GluK4 knockout n = 3; effect of genotype, F = 0.02, p = 0.9018; Figure 8.1b) or 
appreciable trend to suggest that a difference might exist: both wild-type and 
Glu4 knockout mice plateaued at level 4 seizures. Similar results were observed 
with an initial dose of 15 mg/kg, followed by a single dose of 5 mg/kg after 20 
minutes (wild-type n = 3, GluK4 knockout, n = 3; two-way ANOVA, effect of 
genotype, F = 1.25, p = 0.3262; Figure 8.1c), though seizure scores in GluK4 
knockout animals did not seem to increase as steadily as in wild-type animals. 
Finally, a single injection of 15 mg/kg without subsequent injections did not yield 
significant results by two-way ANOVA (wild-type n = 4; GluK4 knockout n = 2; 
effect of genotype, F = 3.69, p = 0.1270; Figure 8.1d). At this dose, GluK4 
knockout mice appeared more sensitive to the effects of kainate, though the low 
n and high variability again made results difficult to interpret.  
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FIGURE 8.1. GluK4 knockout mice trend towards altered seizure 
susceptibility. (A) GluK4 knockout mice showed a decrease, though not 
significant, in susceptibility to high incremental doses of IP kainate relative to 
wild-type mice (p = 0.1776). (B) A low-dose incremental injection scheme did not 
reveal differences in seizure activity between wild-type and GluK4 knockout mice 
(p = 0.9081).  (C) A second low-dose incremental injection scheme failed to 
reveal a difference between genotypes (p = 0.3262). (D) Surprisingly, single 
injections of a low dose of kainate reveal a trend towards increased seizure 
susceptibility in GluK4 knockout animals. Arrows indicate injection time points. *** 
= 30 mg/kg kainate; ** = 15 mg/kg kainate; * = 5 mg/kg kainate. 
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Though none of the results obtained were significant, there appeared to be two 
trends in the data: at very high doses of kainate (initial injection of 30 mg/kg, 
followed by 2 injections of 15 mg/kg), GluK4 knockout mice appear to be less 
sensitive to kainate-induced seizures that wild-type mice; at very low doses of 
kainate (single injection of 15 mg/kg), GluK4 knockout mice may be more 
sensitive to kainate-induced seizures than wild-type mice. Further experiments 
would be needed to confirm these findings, but they suggest nevertheless that 
the role of GluK4 in kainate-induced seizures may be dose-dependent.  
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CHAPTER 9: DISCUSSION  
Like the other ionotropic glutamate receptors, NMDA and AMPA receptors, post-
synaptic kainate receptors initiate EPSCs upon ligand binding. However, kainate 
receptors are unique in that they also modulate neurotransmitter release in a bi-
directional manner when expressed pre-synaptically. Furthermore, kainate 
receptors have been found to alter inhibitory transmission at GABAergic 
terminals, as well as to serve non-canonical, metabotropic functions (Rodríguez-
Moreno and Sihra, 2011). Ultimately, through their complex and diverse 
functions, kainate receptors are responsible for fine-tuning the excitability of 
neuronal networks within the CNS, and for preventing aberrant excitatory 
transmission. Here, I have presented evidence that loss of a single kainate 
receptor subunit, GluK4, disrupts this tenuous balance, and uncovers a crucial 
role for GluK4 in diverse neurological processes.   
 
Persistent GRIK4 mRNA Expression in GluK4 Knockout Animals 
To study the function of GluK4 in the CNS, I generated a global GluK4 knockout 
mouse line by crossing mice in which exon 16 of GRIK4 was floxed, with 
transgenic mice in which cre was expressed in the germline. I found through an 
exhaustive investigation of GluK4 expression in the GluK4 knockout line that 
GluK4 was effectively ablated at the protein level, rendering these mice 
functional knockouts. However, GRIK4 mRNA was missing the region 
corresponding to exon 16 but was otherwise intact in GluK4 knockout animals, 
and expressed at normal levels.  
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There are several potential explanations for the observation that GRIK4 mRNA 
persists in GluK4 knockout animals, but GluK4 protein does not. One possibility 
is that the absence of exon 16 renders GRIK4 mRNA unstable in a way that 
discourages translation, or decreases translational efficiency to a point where 
GluK4 protein is undetectable by western blot. Another possibility is that GluK4 
protein is indeed generated from the altered GRIK4 mRNA present in GluK4 
knockout mice, but that the protein is inherently unstable without the p-loop 
region corresponding to exon 16 and therefore gets ubiquitinated or otherwise 
flagged for degradation. Because no GluK4 protein was detected by western blot, 
GluK4 degradation in this scenario would need to occur fairly quickly after 
translation, or else turnover of GluK4 is so slow that it doesn’t accumulate quickly 
– it can persist at levels below the threshold for western blot detection before it 
gets degraded. One means of testing this hypothesis would be to generate a 
mouse where floxed GRIK4 is fused to a reporter gene, with the caveat that the 
reporter could further destabilize or interfere with the structure of the cre-excised 
(referred to hereafter as “mutant”) form of GluK4 protein. The presence of the 
reporter could then be assessed in a quantitative, GluK4-independent assay that 
is more sensitive than western blotting.   
 
Alternatively, mutant GluK4 may be stable, but it may somehow fail a cellular 
checkpoint in the process of kainate receptor assembly, and therefore get 
targeted for destruction. There have been several previous reports of critical 
checkpoints during kainate receptor assembly. Within the endoplasmic reticulum 
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(ER), high affinity GluK5 subunits are probed for their ability to properly bind 
glutamate before they, and any receptor complex in which they participate, can 
be trafficked to the plasma membrane (Valluru et al., 2005). Coatomer protein 
complex I (COPI) and 14.3.3ζ proteins also interact with GluK5 to regulate GluK5 
trafficking. COPI interacts with the ER retention motif in GluK5 to promote 
sequestration of GluK5 within the ER, and this association is reduced upon the 
assembly of GluK5 with GluK2 (Vivithanaporn et al., 2006). As the association 
between GluK5 and COPI is reduced, the association between GluK5 and 
14.3.3ζ is increased, and 14.3.3ζ promotes the forward trafficking of heteromeric 
kainate receptors containing GluK5 to the plasma membrane (Vivithanaporn et 
al., 2006). These findings in GluK5 suggest that similar mechanisms may exist to 
regulate the inclusion of GluK4 in functional kainate receptor subunits, and that 
misfolding of GluK4 or the absence of the p-loop may compromise the ability of 
mutant GluK4 to pass critical checkpoints.   
 
Finally, it is possible that mutant GluK4 protein is stable and does not get 
degraded at all, but is truncated or folded in such a way that it cannot be 
detected by either of the antibodies used in my western blotting assays. One 
means of addressing this issue would be to generate a range of custom 
antibodies directed against all regions of GluK4 and to run western blots using 
denaturing conditions to ensure that the altered secondary structure of mutant 
GluK4 did not obscure the antibody binding regions.     
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Memory Deficits in GluK4 Knockout Animals 
Because GluK4 ablation results in aberrant mossy fiber LTP (Catches et al., 
2012), I hypothesized that GluK4 may play a role in learning and memory, both of 
which are LTP-dependent processes. I compared the performance of wild-type 
and GluK4 knockout mice in various hippocampus-dependent learning tasks to 
assess the nature and extent of the memory deficits induced by GluK4 ablation, 
and found that working memory was intact in GluK4 knockout mice, but that fear 
memory and spatial memory were impaired. These findings are consistent with 
previous studies which have highlighted the importance of the CA3 – the 
hippocampal region where GluK4 expression is most concentrated – to 
associative learning processes such as fear conditioning (Daumas et al., 2004) 
and the MWM (Steffenach et al., 2002; Stupien et al., 2003; Florian and Roullet, 
2004).  
 
One caveat to my findings could be that, while GluK4 knockout mice showed 
decreased freezing behavior relative to wild-type mice during successive tone-
shock pairings on the first day of fear conditioning, and I have interpreted this 
deficit to be an indication of impaired fear memory acquisition, it is possible to 
attribute this deficit to other sources. The decreased freezing behavior observed 
in GluK4 knockout mice in response to the foot shock may be akin to their 
decreased response to the acoustic startle – that is, a reflection of decreased 
arousal or attention rather than learning. Thus, wild-type and GluK4 knockout 
mice may have sensed the footshock with equal intensity, as the incremental 
 130 
hotplate test indicated that both genotypes have equivalent pain thresholds, but 
GluK4 knockout mice may have attached less emotional valence to the 
experience.  
 
Another possibility is that the decrease in freezing behavior is a reflection of the 
basal hyperactivity observed in GluK4 animals during the open field tasks. This 
seems unlikely, however, as basal freezing behavior within the fear conditioning 
chamber was not significantly different between wild-type and GluK4 mice during 
the acclimatization period preceding the tone-shock pairings on day 1. 
Furthermore, freezing behavior did not differ between wild-type and GluK4 
knockout animals in the contextual or cued paradigms on day 2, although the 
argument could be made that hyperactivity in the GluK4 knockout animals may 
have masked a true deficit in freezing behavior and, thus, in learning and 
memory. Nevertheless, one means of addressing this issue would be to measure 
behavioral outputs of fear that were not dependent on movement, such as 
ultrasonic vocalizations or hypertension. 
 
Basal hyperactivity in the GluK4 knockout line may have also been a 
confounding factor in the MWM results, and could explain why knockout mice 
took longer trajectories to reach the hidden platform during the hidden platform 
trials. However, the increase in distance traveled during these trials was not 
accompanied by an increase in swimming velocity relative to wild-type animals, 
while the increase in distance traveled during the open field test was, suggesting 
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that increased velocity is a feature of hyperactivity in GluK4 knockout animals. 
Furthermore, visual platform performance did not differ between GluK4 knockout 
and wild-type animals. The increase in the distance traveled by the GluK4 
knockout cohort during the hidden platform trials is therefore more likely to be a 
product of impaired cognitive processes rather than hyperactivity. 
 
The learning and memory deficits in GluK4 knockout mice may provide further 
evidence for a role of GluK4 in human neuropsychiatric disorders: cognitive 
function, and particularly declarative and working memory, are consistently 
impaired in individuals with schizophrenia (Stone et al., 1998). Additionally, the 
number of synapses between mossy fibers and CA3 pyramidal neuronal spines 
is reduced in schizophrenic patients (Kolomeets et al., 2007), which may result in 
reduced excitatory transmission in this region and thereby parallel the effects of 
GluK4 ablation.  
 
Ultimately, further research into the role of GluK4 in memory is warranted in 
humans. A previous study on the relationship between GluK4 and hippocampal 
activation has shown that patients who carry a deletion variant of GRIK4 that 
increases GRIK4 mRNA expression demonstrate greater hippocampal activation 
during a facial processing task than patients who carry the normal GRIK4 allele 
(Whalley et al., 2009b; 2009a). To elucidate the effects of GluK4 on memory in 
humans, this experimental paradigm could be modified so that the test subjects 
were performing a hippocampus-dependent memory task.    
 132 
Another future line of research could be to investigate the effects of GluK4 
ablation in CA3 networks outside of the mossy fiber pathway. The majority of 
excitatory synapses within the CA3 originate from pyramidal cells that form 
recurrent collaterals onto neighboring pyramidal cells to form a self-contained 
network of excitatory input within the CA3 (Ishizuka et al., 1990). It has been 
proposed that modification of synaptic strength within this autoassociative 
network contributes to hippocampus-dependent memory (Gardner-Medwin, 
1976). Recurrent collaterals within the CA3 project to the stratum oriens and 
stratum radiatum of the CA3 (Ishizuka et al., 1990), and GluK4 is expressed 
(albeit weakly) in the stratum radiatum (Darstein et al., 2003), suggesting that 
GluK4 may contribute to memory forming process through its actions at mossy 
fiber synapses as well as at recurrent CA3 synapses. GluK4-mediated activity at 
both types of synapses may in fact be interdependent, as the mnemonic 
functions of the autoassociative CA3 network rely in part on mossy fiber input 
(McNaughton and Morris, 2002). Assessing the electrophysiological properties of 
this autoassociative network in GluK4 knockout mice might further elucidate the 
role of GluK4 in memory. 
 
Altered Behavior and Mood in GluK4 Knockout Animals, and Implications for 
Human Neuropsychiatric Disorders 
The behavioral phenotype of GluK4 knockout mice strongly suggests that GluK4 
regulates mood. I observed decreased anxiety- and depressive-type behavior in 
GluK4 knockout mice in the open field and forced swim tests, respectively. 
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Furthermore, the fact that GluK4 mice exhibit a decreased acoustic startle 
response compared to wild-type mice is an indication that basal levels of arousal 
and emotionality differ between the genotypes. The acoustic startle response is 
regulated by corticotropin releasing factor, which activates the hypothalamic-
pituitary-adrenal axis in response to stress, and contributes to anxiety and 
depression disorders (Risbrough et al., 2003). These findings are consistent with 
a previous study in which GRIK4 mRNA expression was significantly up-
regulated following chronic restraint stress, and was shown to be regulated by 
the adrenal steroid corticosterone (Hunter et al., 2009). Furthermore, an allelic 
variant of GRIK4 is associated with the outcome of selective serotonin reuptake 
inhibitor treatment in patients with major depressive disorder (Paddock et al., 
2007). Thus, the anxiolytic, antidepressant effects of GluK4 ablation suggest that 
GluK4 may be involved in regulating baseline affect and mood, and that aberrant 
GluK4 expression may contribute to anxiety and depression in humans.  
 
As with the memory assays described above, hyperlocomotion in GluK4 
knockout animals may be a confounding factor in the interpretation of the open 
field and forced swim results because the scored behaviors in these experiments 
are dependent upon mobility. However, there are several lines of evidence to 
suggest that the differences in anxiety and depressive-type behaviors between 
wild-type and GluK4 knockout mice are valid. In both open field paradigms (short 
/ lit, and long / dark), GluK4 mice showed an overall preference for the periphery 
of the open field over the center, much as wild-type mice did. This observation 
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indicates that, despite being hyperlocomotive, GluK4 mice nevertheless exhibited 
directed motor behaviors – they were not randomly moving through the open 
field. The difference between wild-type and GluK4 knockout mice in their 
preference for the center of the field can therefore be attributed to the fact that 
the GluK4 knockout mice perceived the center zone to be less aversive than the 
wild-type mice do.  
 
Furthermore, a concurrent study of GluK4 knockout mouse behavior that 
supports many of our findings has recently been published (Catches et al., 2012). 
The authors employed several non-locomotor tests that bypass the issue of 
hyperlocomotion in GluK4 knockout mice. They demonstrated, using a novelty-
induced suppression of feeding test, that GluK4 knockout mice are less anxious 
than wild-type mice: GluK4 knockout mice exhibit a shorter latency to consume 
food placed in a novel, anxiogenic environment than wild-type mice do. The 
authors also demonstrated, using a sucrose preference test, that GluK4 knockout 
mice are less prone to depressive type behaviors: GluK4 knockout mice exhibit a 
greater preference for a 1% sucrose solution than wild-type mice do, presumably 
because they derive greater pleasure from this stimulus than wild-type mice do, 
and, by extension, are less depressive.  
 
Finally, hyperlocomotion is often considered in animal models of psychological 
disorders to be a reflection or behavioral correlate of psychomotor agitation, an 
endophenotype of both bipolar disorder and schizophrenia (van den Buuse, 
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2010). According to the dopamine hypothesis of schizophrenia, psychomotor 
agitation and other positive symptoms of schizophrenia can be attributed to 
excess dopaminergic activity, and, indeed, drugs that enhance dopamine 
neurotransmission such as amphetamine induce hyperactivity in rodents (van 
den Buuse, 2010). Meanwhile, the glutamate hypothesis of schizophrenia 
postulates that the positive symptoms of schizophrenia are related to insufficient 
glutamatergic activity, and NMDA receptor antagonists such as MK-801 and 
phencyclidine also induce hyperactivity in rodents, as does GluK2 ablation 
(Shaltiel et al., 2008; Gunduz-Bruce, 2009). Thus, hyperlocomotion in GluK4 
knockout mice may be a relevant phenotype to the understanding of the role of 
GluK4 in neuroaffective disorders. 
 
The involvement of GluK4 in schizophrenia and bipolar disorder is further 
supported by data from the PPI assays. Compared to wild-type mice, GluK4 
knockout mice showed decreased inhibition of the acoustic startle response 
when the startle-inducing tone was preceded by a weaker tone. Deficits in PPI 
are common in patients with schizophrenia, and have also been observed in 
patients with bipolar disorder during periods of acute psychotic mania (Perry et 
al., 2001). The relationship between PPI and psychosis is not fully understood. 
However, PPI deficits may be a reflection of the fact that psychotic patients are 
unable to discriminate between trivial and salient stimuli within their environment, 
and are therefore subjected to constant cognitive overload as they respond to 
each with equal measure (Perry and Braff, 1994; Geyer et al., 2002). While 
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psychosis and cognitive overload are difficult to model definitively in animals, 
GluK4 ablation at the very least phenocopies a human correlate of these 
dysfunctions by inducing PPI impairments in GluK4 knockout mice.  
 
The results obtained in the open field and forced swim trials may be relevant to 
psychological disorders, as the basal decreases in anxiety and despair in GluK4 
knockout animals may parallel the dramatic mood elevation and increased risk-
taking behavior that are characteristic of bipolar disorder (Belmaker, 2004). 
Taken together with the cognitive and sensorimotor gating impairments observed 
in GluK4 knockout animals, and the ample evidence from human studies 
implicating GluK4 in bipolar disorder and schizophrenia, my findings suggest that 
aberrant GluK4 expression may explain certain facets of these diseases.  
 
My findings in GluK4 knockout animals are also largely congruent with those 
observed by other groups in GluK2 knockout animals (Ko et al., 2005; Shaltiel et 
al., 2008). Like GluK4 knockout mice, GluK2 knockout mice are less anxious, 
more risk-taking, and show fewer manifestations of despair than wild-type mice. 
However, GluK2 knockout mice display hyperaggression in resident-intruder 
assays, while I was unable to observe any behavioral markers of aggression in 
GluK4 knockout mice in a pilot study of the same test (data not shown). GluK2 
knockout mice also show significant reduction in fear memory recall, as indicated 
by decreased freezing times relative to wild-type mice in both contextual and 
cued fear conditioning paradigms (Ko et al., 2005), while I found only impaired 
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acquisition of fear memory in GluK4 knockout mice. The discrepancies observed 
between GluK2 and GluK4 knockout behavior suggest the possibility that GluK2 
and GluK4 may co-assemble to regulate anxiety, risk-taking, and despair, but 
that GluK2 and GluK4 may assemble with other kainate receptor subunits to 
regulate aggression and fear memory retrieval in the case of GluK2, and fear 
memory acquisition in the case of GluK4. 
 
GluK4-mediated Excitotoxic Neurodegeneration, and Regulation of the JNK 
Pathway 
Excitoxicity is responsible for the widespread cell death that underlies many of 
the debilitating aspects of neurodegenerative diseases such as ischemic stroke. 
It is triggered by the excessive stimulation of glutamate receptors, whereupon 
large influxes of calcium into neurons instigate a host of cytotoxic events, 
including mitochondrial dysfunction, nitric oxide and free radical production, and 
activation of cell death pathways (reviewed in (Lau and Tymianski, 2010)). 
Depending on the nature and the magnitude of the insult, affected neurons 
ultimately undergo apoptotic, necrotic, or programmed cell death (Wang et al., 
2005; 2005; Tokuhara et al., 2007). 
 
I observed that the CA3 region of the hippocampus in GluK4 knockout animals is 
protected against neurodegeneration following kainate-induced excitotoxicity. To 
elucidate the pathways downstream of GluK4 activation that lead to 
neurodegeneration, I compared the transcriptomes of wild-type and GluK4 
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knockout CA3 tissue after kainate or vehicle injection. I found that the MAP 
kinase pathway, as well as other apoptotic cell death pathways, were up-
regulated in wild-type, but not GluK4 knockout tissues following kainate injection, 
suggesting that these pathways may interact with GluK4 to mediate cell death. 
Biochemical analysis of the JNK pathway, a subset of the MAP kinase pathway 
that is known to mediate excitotoxic cell death (Bogoyevitch et al., 2004), 
revealed that the JNK pathway was activated in wild-type tissue, but not GluK4 
tissue, following kainate administration. Furthermore, basal JNK pathway 
activation was higher in GluK4 knockout tissue than in wild-type tissue. Together, 
these results suggest a biphasic role for GluK4 in the modulation of the JNK 
pathway: under basal conditions, GluK4 serves to suppress JNK pathway 
activations, while under excitotoxic conditions, GluK4 serves to activate the JNK 
pathway. 
 
Several scenarios present themselves as to how GluK4 and the JNK pathway 
interact. One possibility is that GluK4 interacts with the JNK pathway directly by 
participating in heteromeric receptor complexes with GluK2, and, by extension, 
the GluK2 / PSD-95 / MLK3 signaling complex that activates the JNK pathway 
(Tian et al., 2005). GluK4 may also participate in other non-canonical, 
metabotropic actions that indirectly induce the JNK pathway. The JNK pathway 
has many upstream effectors, including G-proteins (Yang et al., 2006), and 
kainate receptors are known to couple with G-proteins to mediate various cellular 
signaling events, such as pre-synaptic glutamate and GABA release (Rodríguez-
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Moreno and Sihra, 2011; Sihra and Rodríguez-Moreno, 2011). It is also possible 
that GluK4 subserves a purely ionotropic function in the initiation of excitotoxic 
cell death by either fluxing calcium directly into post-synaptic cells, or by 
triggering excess glutamate release from presynaptic cells and thereby activating 
any or all forms of post-synaptic ionotropic glutamate receptors, which then flux 
calcium into post-synaptic cells. Calcium ions can initiate a large number of 
signal transduction pathways, and elevated intracellular calcium levels have been 
shown to induce JNK pathway activation in macrophages (Kim and Sharma, 
2004).  
 
The means by which JNK pathway activation results in cell death remains 
controversial (Lin, 2003). JNK may indirectly activate caspase-dependent cell 
death pathways, either through the intermediary of mitochondrial cytochrome c-
dependent pathways (Tournier et al., 2000) or TNFa-dependent pathways 
(Chang et al., 2006). Nevertheless, GSEA analysis of my microarray results 
indicated that several cell death pathways were up-regulated in wild-type but not 
GluK4 knockout tissue following kainate administration. One can speculate that 
these pathways are downstream of JNK activation, although proving this 
hypothesis would be challenging. Repeating the microarray experiment with an 
extra condition, where mice were treated with a JNK pathway inhibitor such as D-
JNKI1 or sp600125 in addition to kainate or vehicle to determine whether the 
same cell death pathways were differentially regulated between wild-type and 
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GluK4 knockout mice in the absence of JNK activity, would be a first step in 
establishing a link between JNK and downstream cell death pathways. 
 
In contrast to the regionalized neuroprotection that I observed in GluK4 knockout 
mice following kainate-induced excitotoxicity, the neuroprotection observed 
following HI extended throughout the hippocampus. One explanation for this 
phenomenon could be that, in the context of HI, GluK4 activates cell death 
pathways other than, or in addition to, the JNK pathway. These pathways may be 
more pervasive than the JNK pathway, or they may incite alternative forms of cell 
death. Another possibility is that the neurodegeneration resulting from HI may 
stem from GluK4-mediated seizures. While avertin, the long-acting anesthetic 
used during the IH kainate injection procedure, may have precluded seizure 
activity in the IH kainate paradigm, the short-acting isofluorane anesthetic used in 
the HI procedure would have permitted it. Indeed, Anna observed sporadic 
seizures in HI-treated animals, though she was blind to the genotype of the 
affected animals at the time. The potential role of GluK4 in seizures is further 
discussed below.  
 
Finally, the microarray experiment generated a vast collection of data, and 
following up on each potentially relevant lead was outside the scope of my thesis. 
However, there are several microarray results that may warrant further 
investigation. For instance, biochemical analysis of the cell death pathways that 
emerged from GSEA analysis as being differentially regulated in wild-type and 
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GluK4 knockout tissue following kainate administration may provide insight into 
the relationship between GluK4, JNK pathway activation, and cell death 
pathways. Furthermore, there were a handful of genes that were differentially 
regulated between wild-type and GluK4 knockout tissue at baseline (i.e., after 
vehicle injection). One such gene, transmembrane protein 25 (Tmem25), was 
down-regulated 45.03-fold in GluK4 knockout samples relative to wild-type 
samples. Very little is known about the function of Tmem25, other than the fact 
that it is a member of the immunoglobulin superfamily (Katoh and Katoh, 2004), 
and that it may be a biomarker for breast cancer (Doolan et al., 2009). However, 
a preliminary search of the online Allan Mouse Brain Atlas (Allan Institute for 
Brain Science)  indicates that Tmem25 expression is highly concentrated within 
the CA3 region of the hippocampus, which, again, is an area of highly 
concentrated GluK4 expression. Furthermore, the fact that Tmem25 is a 
transmembrane protein (Katoh and Katoh, 2004) whose expression is heavily 
influenced by the presence or absence of GluK4 suggests that it may serve as an 
auxiliary protein for GluK4, perhaps aiding in GluK4 trafficking.  
 
The microarray experiment may ultimately be worth repeating, with the following 
modifications: 1. using individual, rather than pooled, biological replicates to 
facilitate downstream analysis; 2. excluding whole hippocampus samples; 3. 
including samples injected with both kainate or vehicle plus a JNK inhibitor; 4. 
including un-injected samples from each genotype to better understand basal 
differences between wild-type and GluK4 knockout transcriptomes; and 5. 
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including samples from mice that had been sacrificed at a series of time points 
following kainate or vehicle injection to assess the time-course of GluK4-
mediated pathway activation.  
 
Parsing the Role of GluK4 in Kainate-Induced Seizures 
To investigate the role of GluK4 in mTLE and seizures, I injected wild-type and 
GluK4 knockout mice IP with kainate using several dosing schemes. While none 
of the dosing schemes yielded significant results, there appeared to be two 
trends in the data: at very high doses of kainate GluK4 knockout mice appeared 
to be less sensitive to kainate-induced seizures than wild-type mice, while at very 
low doses of kainate GluK4 knockout mice appeared to be more sensitive. These 
results again suggest a biphasic role for GluK4 in the regulation of synaptic 
activity. 
 
One reason for the dose-dependent effects of kainate on seizure activity in 
GluK4 knockout mice could be that lower doses of kainate preferentially activate 
GluK4-containing presynaptic autoreceptors, which are somewhat more 
abundant than postsynaptic receptors (Darstein et al., 2003), and that these 
receptors may serve to prevent neurotransmitter release and curb excitatory 
transmission (Frerking et al., 2001). Meanwhile, higher doses of kainate may 
activate facilitatory post-synaptic receptors to a greater extent than lower doses 
do, and the excitatory post-synaptic receptor response may outweigh the 
inhibitory presynaptic receptor response.  
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Though results were not significant for any of the dosing schemes evaluated, 
there are several variables which may have obfuscated a true difference in 
kainate sensitivity between wild-type and GluK4 knockout animals. One of the 
major drawbacks of this experiment is the scoring method: seizure scores must 
be evaluated by hand, as there is no suitable video tracking software (to my 
knowledge) to automate scoring, and the scores are therefore subjective. To 
address this issue, all experiments were live-scored by two independent 
observers, and the scores from both observers were then averaged. 
Nevertheless, the Racine scale used for scoring leaves room for ambiguity, 
particularly because seizure severity does not always increase in a linear manner 
from levels 0 – 6. In some cases, it was difficult to score seizure events 
definitively. 
 
A second drawback of this paradigm is that it is relatively low-throughput. I found 
that the maximum number of mice that could be tested at once was 6; beyond 
that, it was difficult to keep track of the behavior of individual mice, and to inject 
them swiftly. Coupled with the fact that there was high inter-animal variability in 
kainate sensitivity within genotypes, perhaps due to differences in kainate 
metabolism and bioavailability, the low n may have contributed to the lack of 
significant results. While in some instances I did try repeating experiments and 
combining the results, I found that there was high variability within genotypes 
between experimental days. This may have been due to differences in the time of 
day at which experiments were initiated, as circadian rhythms could, in theory, 
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affect kainate metabolism. Another possibility is that the kainate solutions 
injected on different experimental days were inconsistent: kainate was mixed 
fresh daily from powder, and the powder often originated from separate lots 
(though it was always produced by the same manufacturer, Tocris). Finally, the 
within-genotype differences across experimental days may have been, once 
again, an artifact of inter-animal differences in kainate metabolism and 
bioavailability.  
 
Were these experiments to be continued, they would require much larger 
cohorts, and either a means of scoring all the animals simultaneously, e.g. by 
video-recording the trials and scoring 6 animals at a time from the recordings, or 
a means of spreading the experiment across several days such that the time of 
day that the animals were tested was consistent, and the kainate used was 
always from the same batch. It might also be beneficial to evaluate other, more 
objective measures of seizure severity, such as electroencephalographic 
recordings (Hatazaki et al., 2007). Finally, another potential avenue of 
investigation could be to compare seizure severity in wild-type versus GluK4 
knockout mice following HI. 
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Coda 
The GluK4 kainate receptor subunit has, arguably, been overlooked in previous 
studies of kainate receptor function. Because of its restricted expression pattern 
relative to other subunits, its contribution to overall network activity was assumed 
to be less influential than that of the other subunits, and its signaling properties 
were largely extrapolated from those of GluK5 (Huettner, 2003). However, from 
the work described in this thesis, the wide-ranging impact of GluK4 – and of its 
absence – on mood, memory, and excitotoxicity, has come into focus. 
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APPENDIX 1. Biocarta pathways enriched in both wild-type and GluK4 knockout 
samples following kainate administration 
Biocarta Pathway WT P Value 
WT Genes (with Core 
Enrichment) 
KO P 
Value 
KO Genes (with Core 
Enrichment) 
OXITATIVE STRESS         
VITCB PATHWAY 0.000 
SLC23A2, P4HB, COL4A4, 
COL4A5, COL4A1, 
COL4A2, SCL2A1, 
COL4A6, COL4A3, 
SLC23A1, SLC2A3 
0.020 
COL4A2, COL4A1, P4HB, 
SLC2A1, SLC23A1, 
SLC23A2 
ARENRF2 PATHWAY 0.000 FOS, JUN, MAFF, NFE2L2, MAFG 0.000 
FOS, JUN, MAFF, MAFK, 
CREB1, FXYD2, PRKCA 
FREE PATHWAY 0.056 Not reported by GSEA 0.043 Not reported by GSEA 
IMMUNITY         
CCR5 PATHWAY 0.000 CCL4, FOS, CCL2, JUN, CCR5 0.000 
CCL4, FOS, CCL2, JUN, 
CC45 
MONOCYTE PATHWAY 0.000 CD44, ICAM1, PECAM1, ITGB1, SELP 0.000 
CD44, ICAM1, PECAM1, 
SELP, ITGB1 
IL22BP PATHWAY 0.000 SOCS3, STAT3, STAT1, STAT5A 0.020 
SOCS3, STAT3, JAK3, 
JAK1, IL22RA1, STAT1, 
STAT5A 
CLASSIC PATHWAY 0.000 C4B, C3, C1QA, C1QB, C2 0.019 Not reported by GSEA 
IL1R PATHWAY 0.038 
JUN, MAP2K3, MYD88, 
IL1RAP, RELA, IL1A, IL1B, 
MAP3K14, NFKB1, IL1RN, 
NFKBIA, IRAK3, TGFB3, 
IRAK1, TRAF6, IL1R1, 
MAP3K7IP1, TNF, TOLLIP, 
MAP3K7, MAP3K1 
0.000 
MAP2K3, JUN, MYD99, 
NFKBIA, IL1B, IL1RAP, 
RELA, TGFB3, TOLLIP, 
NFKB1, IRAK3, MAP3K7, 
TRAF6, IL1A, TNF, CHUK 
IL2RB PATHWAY 0.000 SOCS3, FOS 0.000 
SOCS3, FOS, JAK3, 
JAK1, NMI, PTPN6, 
STAT5A, BCL2L1, 
RPS6KB1, BCL2, SHC1, 
IL2RG, MYC 
IL10 PATHWAY 0.019 
STAT3, HMOX1, BLVRB, 
STAT1, STAT5A, IL1A, 
BLVRA 
0.000 
STAT3, HMOX1, JAK1, 
STAT1, STAT5A, BLVRA, 
BVLRB, IL1A, TNF 
COMP PATHWAY 0.018 C4B, C3, C1QA, C1QB, MASP2 0.037 Not reported by GSEA 
ETS PATHWAY 0.035 FOS, CSF1, JUN, ETS2 0.019 FOS, JUN, CSF1, ETS1, ETS2, E2F4 
CDMAC PATHWAY 0.016 FOS, JUN, RELA, NFKB1, NFKBIA 0.037 
FOS, JUN, NFKBIA, 
RELA, NFKB1, CUZD1, 
TNF, MYC, PRKCA 
LAIR PATHWAY 0.000 ICAM1, C3, VCAM1, IL1A, ITGB1, SELP 0.000 
C3, ICAM1, SELP, ITGB1, 
IL1A, TNF 
BCR PATHWAY 0.036 FOS, JUN, BLNK, SHC1, VAV1, NFATC4 0.052 Not reported by GSEA 
TNFR2 PATHWAY 0.020 Not reported by GSEA 0.039 Not reported by GSEA 
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APPENDIX 1, Continued 
 
Biocarta Pathway WT P Value 
WT Genes (with Core 
Enrichment) 
KO P 
Value 
KO Genes (with Core 
Enrichment) 
CELL SIGNALING         
CELL2CELL PATHWAY 0.055 
PECAM1, CTNNA1, 
ACTN1, CTNNB1, BCAR1, 
ACTN3, PXN, CSK, VCL, 
PTK2 
0.000 
PECAM1, PXN, ACTN1, 
CTNNA1, PTK2, CTNNB1, 
CTNNA2, CSK, BCAR1, 
VCL 
PAIN         
DREAM PATHWAY 0.000 FOS, JUN, CREM 0.019 FOS, JUN, PRKAR2A, CREM, CREB1 
CELL PROLIFERATION 
AND DIFFERENTIATION         
Promoting     
TPO PATHWAY 0.000 FOS, STAT3, JUN, SHC1, STAT1, STAT5A 0.053 
FOS, STAT3, JUN, 
STAT1, STAT5A, SHC1, 
PRKCA, JAK2, PIK3CA 
PDGF PATHWAY 0.000 FOS, STAT3, JUN, SHC1, STAT1, STAT5A 0.019 
FOS, STAT3, JUN, JAK1, 
STAT1, STAT5A, SHC1, 
SRF, PRKCA, PIK3CA 
EGF PATHWAY 0.020 FOS, STAT3, JUN, SHC1, STAT1, STAT5A 0.020 
FOS, STAT3, JUN, JAK1, 
STAT1, STAT5A, SHC1, 
SRF, PRKCA, PIK3CA 
MET PATHWAY 0.019 FOS, STAT3, JUN, DOCK1, ACTA1, ITGB1, RAP1B 0.000 
FOS, STAT3, JUN, 
DOCK1, ACTA1, PXN, 
GAB1, ITGB1 
IL3 PATHWAY 0.000 FOS, SHC1, STAT5A, PTPN6 0.034 Not reported by GSEA 
KERATINOCYTE 
PATHWAY 0.036 Not reported by GSEA 0.019 
FOS, MAP2K3, JUN, 
TNFRSF1A, ETS1, 
PRKCD, NFKBIA, ETS2, 
RELA, RIPK1, PRKCH, 
NFKB1, MAP2K7, SP1, 
TNF, BCL2, CHUK, 
PRKCA 
Inhibiting     
P53 PATHWAY 0.000 
CDKN1A, GADD45A, 
CDK2, TIMP3, CCND1, 
PCNA, BAX 
0.019 
CKDN1A, GADD45A, 
CDK2, MDM2, PCNA, 
CCND1, TIMP3, BCL2 
HEMOVASCULAR 
FUNCTION         
TPO PATHWAY 0.000 FOS, STAT3, JUN, SHC1, STAT1, STAT5A 0.053 
FOS, STA3, JUN, STAT1, 
STAT5A, SHC1, PRKCA, 
JAK2, PIK3CA 
CARDIAC EGF 
PATHWAY 0.000 
FOS, JUN, RELA, EDN1, 
NFKB1, EDNRB, ADAM12, 
EGFR 
0.019 
FOS, JUN, RELA, NFKB1, 
ADAM12, EDN1, MYC, 
PRKCA 
EPO PATHWAY 0.032 FOS, JUN, SHC1, STAT5A, PTPN6 0.047 Not reported by GSEA 
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APPENDIX 1, Continued 
 
Biocarta Pathway WT P Value 
WT Genes (with Core 
Enrichment) 
KO P 
Value 
KO Genes (with Core 
Enrichment) 
CELL DEATH         
MAPK PATHWAY 0.000 
FOS, JUN, MAP2K3, 
MAPKAPK2, MAPKAPK3, 
SHC1, PRS6KA1, STAT1, 
MAP3K8, RELA, MAPK6, 
MAPK9, MAX, MAP3K6, 
MAP3K14, NFKB1, RIPK1, 
NFKBIA, TRAF2, MAPK4, 
MAPK12, MAPK7 
0.036 
FOS, MAPK23, JUN, 
MAPKAPK2, MAP3KA, 
MAPK6, MAP3K6, 
NFKBIA, RPS6KA1, 
MAPKAPK3, MAPK11, 
RELA, MAP4K5, MAP4K4, 
TGFB3, RIPK1, NFKB1, 
STAT1, MAP2K7, SP1, 
MAPK12, RPS6KB1, 
MEF2C, MAP3K7, 
RPS6KA3, TGFBR1, 
RPS6KB2, SHC1, CHUK, 
CREB1, MYC 
FREE PATHWAY 0.056 Not reported by GSEA 0.043 Not reported by GSEA 
TNFR1 PATHWAY 0.036 Not reported by GSEA 0.000 
JUN, TNFRSF1A, LMNA, 
ARHGDIB, LMNB1, 
CASP8, RIPK1, FADD, 
MAP3K7, TNF, CRADD, 
BAG4, LMNB2 
CELL SURVIVAL         
NFKB PATHWAY  0.000 
MYD88, TNFRSF1A, 
FADD, RELA, IL1A, 
MAP3K14, NFKB1, RIPK1, 
TLR4, IRAK1, TRAF6, 
IL1R1, MAP3K7IP1, TNF, 
MAP3K7, MAP3K1 
0.000 
MYD99, TNFRSF1A, 
NFKBIA, RELA, RIPK1, 
TLR4, NFKB1, FADD, 
MAP3K7, TRAF6, IL1A, 
TNF, CHUK, IKBKG, 
MAP3K14 
HSP27 PATHWAY 0.000 HSPB1, MAPKAPK2, FAS, MAPKAPK3, ACTA1, IL1A 0.000 
HSPB1, FAS, MAPKAPK2, 
MAPKAPK3, ACTA1, IL1A, 
TNF, BCL2 
MAPK PATHWAY 0.000 
FOS, JUN, MAP2K3, 
MAPKAPK2, MAPKAPK3, 
SHC1, PRS6KA1, STAT1, 
MAP3K8, RELA, MAPK6, 
MAPK9, MAX, MAP3K6, 
MAP3K14, NFKB1, RIPK1, 
NFKBIA, TRAF2, MAPK4, 
MAPK12, MAPK7 
0.036 
FOS, MAPK23, JUN, 
MAPKAPK2, MAP3KA, 
MAPK6, MAP3K6, 
NFKBIA, RPS6KA1, 
MAPKAPK3, MAPK11, 
RELA, MAP4K5, MAP4K4, 
TGFB3, RIPK1, NFKB1, 
STAT1, MAP2K7, SP1, 
MAPK12, RPS6KB1, 
MEF2C, MAP3K7, 
RPS6KA3, TGFBR1, 
RPS6KB2, SHC1, CHUK, 
CREB1, MYC 
P38 MAPK PATHWAY 0.031 
CDKN1A, GADD45A, 
CDK2, IMP3, CCND1, 
PCNA, BAX 
0.000 
HSPB1, MAPKAPK2, 
DDIT3, HMGN1, TGFB3, 
RIPK1, CDC42, STAT1, 
MEF2C, MAP3K7, 
TGFBR1, SHC1, CREB1, 
MYC, ATF2, HSPB2 
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Biocarta Pathway WT P Value 
WT Genes (with Core 
Enrichment) 
KO P 
Value 
KO Genes (with Core 
Enrichment) 
GSK3 PATHWAY 0.000 
CD14, LBP, MYD88, 
CCND1, RELA, FZD1, 
TIRAP, NFKB1, LY96, 
CTNNB1, TLR4 
0.000 
CD14, MYD88, TIRAP, 
RELA, TLR4, TOLLIP, 
NFKB1, LEF1, CCND1, 
CTNNB1, APC, PIK3CA, 
LY96, DVL1 
SODD PATHWAY 0.000 TNFRSF1A, FADD, CASP9, RIPK1, TRAF2 0.038 
TNFRSF1A, CASP8, 
RIPK1, FADD, TNF, BAG4 
TNFR1 PATHWAY 0.036 Not reported by GSEA 0.000 
JUN, TNFRSF1A, LMNA, 
ARHGDIB, LMNB1, 
CASP8, RIPK1, FADD, 
MAP3K7, TNF, CRADD, 
BAG4, LMNB2 
OTHER         
MTA3 PATHWAY 0.000 HSPB1, TUBA6, GREB1 0.000 HSPB1, GREB1, TUBA6 
NTHI PATHWAY 0.017 
TLR2, DUSP1, MAP2K3, 
MYD88, TGFBR2, RELA, 
IL1B, MAP3K14, NFKB1, 
NFKBIA 
0.019 
TLR2, MAP2K3, MYD88, 
DUSP1, NFKBIA, 
TGFBR2, IL1B, MAPK11, 
RELA, NFKB1, MAP3K7, 
TNF, TGFBR1, CHUK 
RNA PATHWAY 0.017 DNAJC3, RELA, EIF2S2, MAP3K14, NFKB1, NFKBIA 0.000 
NFKBIA, RELA, NFKB1, 
DNAJC3, CHUK, IF2S2, 
MAP3K14, EIF2S1 
RANKL PATHWAY 0.019 
FOS, RELA, NFKB1, 
IFNAR2, TRAF6, TNFSF11, 
TNFRSF11A 
0.000 FOS, RELA, NFKB1, TRAF6, TNFRSF11A 
HIVNEF PATHWAY 0.036 
ARHGDIB, LMNA, 
TNFRSF1A, FADD, 
LMNB1, CDC2L1, CASP8, 
RELA, MAP3K14, NFKB1, 
RIPK1, NFKBIA, GSN, 
TRAF2, CASP9, MAP2K7, 
LMNB2, BIRC4, CASP3, 
TNF, MDM2, MAP3K1, 
CASP7, CASP2, PTK2, 
CASP6, APAF1, BIRC3 
0.000 
TNFRSF1A, LMNA, 
ARHGDIB, LMNB1, 
PRKCD, NFKBIA, 
CDC2L1, RELA, CASP8, 
RIPK1, NFKB1, MAP2K7, 
MDM2, FADD, PTK2, TNF, 
CRADD, BCL2, CHUK, 
BAG4, LMNB2, MAP3K14, 
GSN 
GLEEVEC PATHWAY 0.019 FOS, JUN, STAT1, STAT5A 0.000 Not reported by GSEA 
 
 150 
REFERENCES 
Allan Institute for Brain Science Allan Mouse Brain Atlas. Http://Mouse.Brain-
Map.org. 
 
Amaral, D.G., and Witter, M.P. (1989). The three-dimensional organization of the 
hippocampal formation: a review of anatomical data. Neuroscience 31, 571–591. 
 
Avoli, M., and Barbarosie, M. (1999). Interictal-ictal interactions and limbic 
seizure generation. Rev. Neurol. (Paris) 155, 468–471. 
 
Avoli, M., Biagini, G., and de Curtis, M. (2006). Do interictal spikes sustain 
seizures and epileptogenesis? Epilepsy Curr 6, 203–207. 
 
Babb, T.L., and Brown, W.J. (1986). Neuronal, dendritic, and vascular profiles of 
human temporal lobe epilepsy correlated with cellular physiology in vivo. Adv 
Neurol 44, 949–966. 
 
Belmaker, R.H. (2004). Bipolar disorder. N. Engl. J. Med. 351, 476–486. 
 
Ben-Ari, Y. (1985). Limbic seizure and brain damage produced by kainic acid: 
mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 14, 
375–403. 
 
Bettler, B., Boulter, J., Hermans-Borgmeyer, I., O'Shea-Greenfield, A., Deneris, 
E.S., Moll, C., Borgmeyer, U., Hollmann, M., and Heinemann, S. (1990). Cloning 
of a novel glutamate receptor subunit, GluR5: expression in the nervous system 
during development. Neuron 5, 583–595. 
 
Bliss, T.V., and Collingridge, G.L. (1993). A synaptic model of memory: long-term 
potentiation in the hippocampus. Nature 361, 31–39. 
 
 151 
Bogoyevitch, M.A., Boehm, I., Oakley, A., Ketterman, A.J., and Barr, R.K. (2004). 
Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic 
potential. Biochim Biophys Acta 1697, 89–101. 
 
Bortolotto, Z.A., Lauri, S., Isaac, J.T.R., and Collingridge, G.L. (2003). Kainate 
receptors and the induction of mossy fibre long-term potentiation. Philosophical 
Transactions of the Royal Society B: Biological Sciences 358, 657–666. 
 
Brecht, S., Kirchhof, R., Chromik, A., Willesen, M., Nicolaus, T., Raivich, G., 
Wessig, J., Waetzig, V., Goetz, M., Claussen, M., et al. (2005). Specific 
pathophysiological functions of JNK isoforms in the brain. Eur J Neurosci 21, 
363–377. 
 
Brody, D.L., and Holtzman, D.M. (2006). Morris water maze search strategy 
analysis in PDAPP mice before and after experimental traumatic brain injury. Exp 
Neurol 197, 330–340. 
 
Brown, T.H., Kairiss, E.W., and Keenan, C.L. (1990). Hebbian synapses: 
biophysical mechanisms and algorithms. Annu Rev Neurosci 13, 475–511. 
 
Camilo, O., and Goldstein, L.B. (2004). Seizures and epilepsy after ischemic 
stroke. Stroke 35, 1769–1775. 
 
Castillo, P.E., Malenka, R.C., and Nicoll, R.A. (1997). Kainate receptors mediate 
a slow postsynaptic current in hippocampal CA3 neurons. Nature 388, 182–186. 
 
Catches, J.S., Xu, J., and Contractor, A. (2012). Genetic ablation of the GluK4 
kainate receptor subunit causes anxiolytic and antidepressant-like behavior in 
mice. Behav Brain Res 228, 406–414. 
 
Chang, L., Kamata, H., Solinas, G., Luo, J.-L., Maeda, S., Venuprasad, K., Liu, 
Y.-C., and Karin, M. (2006). The E3 ubiquitin ligase itch couples JNK activation to 
TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 124, 601–613. 
 152 
Contractor, A., Sailer, A.W., Darstein, M., Maron, C., Xu, J., Swanson, G.T., and 
Heinemann, S.F. (2003). Loss of kainate receptor-mediated heterosynaptic 
facilitation of mossy-fiber synapses in KA2-/- mice. J Neurosci 23, 422–429. 
 
Cossart, R., Tyzio, R., Dinocourt, C., Esclapez, M., Hirsch, J.C., Ben-Ari, Y., and 
Bernard, C. (2001). Presynaptic kainate receptors that enhance the release of 
GABA on CA1 hippocampal interneurons. Neuron 29, 497–508. 
 
Coussen, F., and Mulle, C. (2006). Kainate receptor-interacting proteins and 
membrane trafficking. Biochem Soc Trans 34, 927–930. 
 
Darstein, M., Petralia, R.S., Swanson, G.T., Wenthold, R.J., and Heinemann, 
S.F. (2003). Distribution of kainate receptor subunits at hippocampal mossy fiber 
synapses. J Neurosci 23, 8013–8019. 
 
Daumas, S., Halley, H., and Lassalle, J.-M. (2004). Disruption of hippocampal 
CA3 network: effects on episodic-like memory processing in C57BL/6J mice. Eur 
J Neurosci 20, 597–600. 
 
Doolan, P., Clynes, M., Kennedy, S., Mehta, J.P., Germano, S., Ehrhardt, C., 
Crown, J., and O'Driscoll, L. (2009). TMEM25, REPS2 and Meis 1: favourable 
prognostic and predictive biomarkers for breast cancer. Tumour Biol. 30, 200–
209. 
 
El-Hayek, Y.H., Wu, C., Chen, R., Al-Sharif, A.R., Huang, S., Patel, N., Du, C., 
Ruff, C.A., Fehlings, M.G., Carlen, P.L., et al. (2011). Acute postischemic 
seizures are associated with increased mortality and brain damage in adult mice. 
Cereb Cortex 21, 2863–2875. 
 
Engel, J. (1993). Update on surgical treatment of the epilepsies. Summary of the 
Second International Palm Desert Conference on the Surgical Treatment of the 
Epilepsies (1992). pp. 1612–1617. 
 
 153 
Falconer, M.A., Serafetinides, E.A., and Corsellis, J.A. (1964). Etiology and 
Pathogenesis of Temporal Lobe Epilepsy. Arch. Neurol. 10, 233–248. 
 
Fernandes, H.B., Catches, J.S., Petralia, R.S., Copits, B.A., Xu, J., Russell, T.A., 
Swanson, G.T., and Contractor, A. (2009). High-Affinity Kainate Receptor 
Subunits Are Necessary for Ionotropic but Not Metabotropic Signaling. Neuron 
63, 818–829. 
 
Florian, C., and Roullet, P. (2004). Hippocampal CA3-region is crucial for 
acquisition and memory consolidation in Morris water maze task in mice. Behav 
Brain Res 154, 365–374. 
 
Fogarty, D., Perez-Cerda, F., and Matute, C. (2000). KA1-like kainate receptor 
subunit immunoreactivity in neurons and glia using a novel anti-peptide antibody. 
Brain Res Mol Brain Res 81, 164–176. 
 
Frerking, M., and Ohliger-Frerking, P. (2002). AMPA receptors and kainate 
receptors encode different features of afferent activity. J Neurosci 22, 7434–
7443. 
 
Frerking, M., Schmitz, D., Zhou, Q., Johansen, J., and Nicoll, R.A. (2001). 
Kainate receptors depress excitatory synaptic transmission at CA3-->CA1 
synapses in the hippocampus via a direct presynaptic action. J Neurosci 21, 
2958–2966. 
 
Gardner-Medwin, A.R. (1976). The Recall of Events through the Learning of 
Associations between their Parts. Proceedings of the Royal Society B: Biological 
Sciences 194, 375–402. 
 
Geyer, M.A., McIlwain, K.L., and Paylor, R. (2002). Mouse genetic models for 
prepulse inhibition: an early review. Mol Psychiatry 7, 1039–1053. 
 
 
 154 
Geyer, M.A., Swerdlow, N.R., Mansbach, R.S., and Braff, D.L. (1990). Startle 
response models of sensorimotor gating and habituation deficits in 
schizophrenia. Brain Res Bull 25, 485–498. 
 
Gunduz-Bruce, H. (2009). The acute effects of NMDA antagonism: from the 
rodent to the human brain. Brain Res Rev 60, 279–286. 
 
Gupta, S., Barrett, T., Whitmarsh, A.J., Cavanagh, J., Sluss, H.K., Dérijard, B., 
and Davis, R.J. (1996). Selective interaction of JNK protein kinase isoforms with 
transcription factors. Embo J 15, 2760–2770. 
 
Hampson, D.R., Huie, D., and Wenthold, R.J. (1987). Solubilization of kainic acid 
binding sites from rat brain. J Neurochem 49, 1209–1215. 
 
Hatazaki, S., Bellver-Estelles, C., Jimenez-Mateos, E.M., Meller, R., Bonner, C., 
Murphy, N., Matsushima, S., Taki, W., Prehn, J.H.M., Simon, R.P., et al. (2007). 
Microarray profile of seizure damage-refractory hippocampal CA3 in a mouse 
model of epileptic preconditioning. Neuroscience 150, 467–477. 
 
Herb, A., Burnashev, N., Werner, P., Sakmann, B., Wisden, W., and Seeburg, 
P.H. (1992). The KA-2 subunit of excitatory amino acid receptors shows 
widespread expression in brain and forms ion channels with distantly related 
subunits. Neuron 8, 775–785. 
 
Hirai, S.I., Katoh, M., Terada, M., Kyriakis, J.M., Zon, L.I., Rana, A., Avruch, J., 
and Ohno, S. (1997). MST/MLK2, a member of the mixed lineage kinase family, 
directly phosphorylates and activates SEK1, an activator of c-Jun N-terminal 
kinase/stress-activated protein kinase. J Biol Chem 272, 15167–15173. 
 
Hollmann, M., Maron, C., and Heinemann, S. (1994). N-glycosylation site tagging 
suggests a three transmembrane domain topology for the glutamate receptor 
GluR1. Neuron 13, 1331–1343. 
 
 155 
Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2008). Systematic and 
integrative analysis of large gene lists using DAVID bioinformatics resources. Nat 
Protoc 4, 44–57. 
 
Huang, D.W., Sherman, B.T., Tan, Q., Collins, J.R., Alvord, W.G., Roayaei, J., 
Stephens, R., Baseler, M.W., Lane, H.C., and Lempicki, R.A. (2007). The DAVID 
Gene Functional Classification Tool: a novel biological module-centric algorithm 
to functionally analyze large gene lists. Genome Biol 8, R183. 
 
Huettner, J.E. (2003). Kainate receptors and synaptic transmission. Progress in 
Neurobiology 70, 387–407. 
 
Hughes, R.N. (2004). The value of spontaneous alternation behavior (SAB) as a 
test of retention in pharmacological investigations of memory. Neurosci Biobehav 
Rev 28, 497–505. 
 
Hughes, T.E. (1994). Transmembrane topology of the glutamate receptors. A tale 
of novel twists and turns. J Mol Neurosci 5, 211–217. 
 
Hunsaker, M.R., Tran, G.T., and Kesner, R.P. (2009). A behavioral analysis of 
the role of CA3 and CA1 subcortical efferents during classical fear conditioning. 
Behav Neurosci 123, 624–630. 
 
Hunsberger, J.G., Bennett, A.H., Selvanayagam, E., Duman, R.S., and Newton, 
S.S. (2005). Gene profiling the response to kainic acid induced seizures. Brain 
Res Mol Brain Res 141, 95–112. 
 
Hunter, R.G., Bellani, R., Bloss, E., Costa, A., McCarthy, K., and McEwen, B.S. 
(2009). Regulation of Kainate Receptor Subunit mRNA by Stress and 
Corticosteroids in the Rat Hippocampus. PLoS ONE 4, e4328. 
 
 
 156 
Ishizuka, N., Weber, J., and Amaral, D.G. (1990). Organization of 
intrahippocampal projections originating from CA3 pyramidal cells in the rat. J 
Comp Neurol 295, 580–623. 
 
Jacob, C.P., Koutsilieri, E., Bartl, J., Neuen-Jacob, E., Arzberger, T., Zander, N., 
Ravid, R., Roggendorf, W., Riederer, P., and Grünblatt, E. (2007). Alterations in 
expression of glutamatergic transporters and receptors in sporadic Alzheimer's 
disease. J. Alzheimers Dis. 11, 97–116. 
 
Jiang, H.-X., Guan, Q.-H., Pei, D.-S., and Zhang, G.-Y. (2007). Functional 
cooperation between KA2 and GluR6 subunits is involved in the ischemic brain 
injury. J Neurosci Res 85, 2960–2970. 
 
Katoh, M., and Katoh, M. (2004). Identification and characterization of human 
TMEM25 and mouse Tmem25 genes in silico. Oncol. Rep. 12, 429–433. 
 
Kesner, R.P. (2007). Behavioral functions of the CA3 subregion of the 
hippocampus. Learn Mem 14, 771–781. 
 
Kim, J., and Sharma, R.P. (2004). Calcium-mediated activation of c-Jun NH2-
terminal kinase (JNK) and apoptosis in response to cadmium in murine 
macrophages. Toxicol. Sci. 81, 518–527. 
 
Knight, H.M., Walker, R., James, R., Porteous, D.J., Muir, W.J., Blackwood, 
D.H.R., and Pickard, B.S. (2011). GRIK4/KA1 protein expression in human brain 
and correlation with bipolar disorder risk variant status. American Journal of 
Medical Genetics Part B, Neuropsychiatric Genetics : the Official Publication of 
the International Society of Psychiatric Genetics. 
 
Ko, S., Zhao, M.-G., Toyoda, H., Qiu, C.-S., and Zhuo, M. (2005). Altered 
behavioral responses to noxious stimuli and fear in glutamate receptor 5 
(GluR5)- or GluR6-deficient mice. J Neurosci 25, 977–984. 
 
 157 
Koch, M. (1996). The septohippocampal system is involved in prepulse inhibition 
of the acoustic startle response in rats. Behav Neurosci 110, 468–477. 
 
Kolomeets, N.S., Orlovskaya, D.D., and Uranova, N.A. (2007). Decreased 
numerical density of CA3 hippocampal mossy fiber synapses in schizophrenia. 
Synapse 61, 615–621. 
 
Köhler, M., Burnashev, N., Sakmann, B., and Seeburg, P.H. (1993). 
Determinants of Ca2+ permeability in both TM1 and TM2 of high affinity kainate 
receptor channels: diversity by RNA editing. Neuron 10, 491–500. 
 
Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, 
J.D., Heninger, G.R., Bowers, M.B., and Charney, D.S. (1994). Subanesthetic 
effects of the noncompetitive NMDA antagonist, ketamine, in humans. 
Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. 
Gen. Psychiatry 51, 199–214. 
 
Lau, A., and Tymianski, M. (2010). Glutamate receptors, neurotoxicity and 
neurodegeneration. Pflugers Arch 460, 525–542. 
 
Lein, E.S., Zhao, X., and Gage, F.H. (2004). Defining a molecular atlas of the 
hippocampus using DNA microarrays and high-throughput in situ hybridization. J 
Neurosci 24, 3879–3889. 
 
Leuschner, W.D., and Hoch, W. (1999). Subtype-specific assembly of alpha-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits is 
mediated by their n-terminal domains. J Biol Chem 274, 16907–16916. 
 
Lin, A. (2003). Activation of the JNK signaling pathway: breaking the brake on 
apoptosis. Bioessays 25, 17–24. 
 
 
 158 
Liu, X.-M., Pei, D.-S., Guan, Q.-H., Sun, Y.-F., Wang, X.-T., Zhang, Q.-X., and 
Zhang, G.-Y. (2006). Neuroprotection of Tat-GluR6-9c against neuronal death 
induced by kainate in rat hippocampus via nuclear and non-nuclear pathways. J 
Biol Chem 281, 17432–17445. 
 
Lodge, D. (2009). The history of the pharmacology and cloning of ionotropic 
glutamate receptors and the development of idiosyncratic nomenclature. 
Neuropharmacology 56, 6–21. 
 
London, E.D., and Coyle, J.T. (1979). Specific binding of [3H]kainic acid to 
receptor sites in rat brain. Mol Pharmacol 15, 492–505. 
 
Lopes da Silva, F.H., and Arnolds, D.E. (1978). Physiology of the hippocampus 
and related structures. Annu Rev Physiol 40, 185–216. 
 
Lucas, D., and Newhouse, J. (1957). The toxic effect of sodium L-glutamate on 
the inner layers of the retina. AMA Arch Ophthalmol 58, 193–201. 
 
Lucifora, S., Willcockson, H.H., Lu, C.-R., Darstein, M., Phend, K.D., 
Valtschanoff, J.G., and Rustioni, A. (2006). Presynaptic low- and high-affinity 
kainate receptors in nociceptive spinal afferents. Pain 120, 97–105. 
 
Maren, S. (2008). Pavlovian fear conditioning as a behavioral assay for 
hippocampus and amygdala function: cautions and caveats. Eur J Neurosci 28, 
1661–1666. 
 
Martin, J.H., Mohit, A.A., and Miller, C.A. (1996). Developmental expression in 
the mouse nervous system of the p493F12 SAP kinase. Brain Res Mol Brain Res 
35, 47–57. 
 
McKhann, G.M., Wenzel, H.J., Robbins, C.A., Sosunov, A.A., and Schwartzkroin, 
P.A. (2003). Mouse strain differences in kainic acid sensitivity, seizure behavior, 
mortality, and hippocampal pathology. Neuroscience 122, 551–561. 
 159 
McLin, J.P., and Steward, O. (2006). Comparison of seizure phenotype and 
neurodegeneration induced by systemic kainic acid in inbred, outbred, and hybrid 
mouse strains. Eur J Neurosci 24, 2191–2202. 
 
McNaughton, B.L., and Morris, R.G.M. (2002). Hippocampal synaptic 
enhancement and information storage within a distributed memory system. 
Trends Neurosci 10, 408–415. 
 
Melyan, Z., and Lancaster, B. (2004). Metabotropic regulation of intrinsic 
excitability by synaptic activation of kainate receptors. The Journal of 
Neuroscience. 
 
Melyan, Z., Wheal, H.V., and Lancaster, B. (2002). Metabotropic-mediated 
kainate receptor regulation of IsAHP and excitability in pyramidal cells. Neuron 
34, 107–114. 
 
Morris, R.G.M. (2003). Long-term potentiation and memory. Philos Trans R Soc 
Lond, B, Biol Sci 358, 643–647. 
 
Mulle, C., Sailer, A., Pérez-Otaño, I., Dickinson-Anson, H., Castillo, P.E., Bureau, 
I., Maron, C., Gage, F.H., Mann, J.R., Bettler, B., et al. (1998). Altered synaptic 
physiology and reduced susceptibility to kainate-induced seizures in GluR6-
deficient mice. Nature 392, 601–605. 
 
Nadler, J.V. (1981). Minireview. Kainic acid as a tool for the study of temporal 
lobe epilepsy. Life Sci. 29, 2031–2042. 
 
Nagata, K.I., Puls, A., Futter, C., Aspenstrom, P., Schaefer, E., Nakata, T., 
Hirokawa, N., and Hall, A. (1998). The MAP kinase kinase kinase MLK2 co-
localizes with activated JNK along microtubules and associates with kinesin 
superfamily motor KIF3. Embo J 17, 149–158. 
 
 
 160 
Nasu-Nishimura, Y., Hurtado, D., Braud, S., Tang, T.T.-T., Isaac, J.T.R., and 
Roche, K.W. (2006). Identification of an endoplasmic reticulum-retention motif in 
an intracellular loop of the kainate receptor subunit KA2. J Neurosci 26, 7014–
7021. 
 
Olney, J.W. (1969). Brain lesions, obesity, and other disturbances in mice treated 
with monosodium glutamate. Science 164, 719–721. 
 
Oswald, R.E., Ahmed, A., Fenwick, M.K., and Loh, A.P. (2007). Structure of 
glutamate receptors. Current Drug Targets 8, 573–582. 
 
Paddock, S., Laje, G., Charney, D., Rush, A.J., Wilson, A.F., Sorant, A.J.M., 
Lipsky, R., Wisniewski, S.R., Manji, H., and McMahon, F.J. (2007). Association of 
GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. The 
American Journal of Psychiatry 164, 1181–1188. 
 
Palomo, T., Kostrzewa, R.M., Beninger, R.J., and Archer, T. (2008). 
Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic 
labyrinths. Neurotoxicity Research 14, 79–96. 
 
Perry, W., and Braff, D.L. (1994). Information-processing deficits and thought 
disorder in schizophrenia. The American Journal of Psychiatry 151, 363–367. 
 
Perry, W., Minassian, A., Feifel, D., and Braff, D.L. (2001). Sensorimotor gating 
deficits in bipolar disorder patients with acute psychotic mania. Biological 
Psychiatry 50, 418–424. 
 
Pfaffl, M.W., Horgan, G.W., and Dempfle, L. (2002). Relative expression software 
tool (REST) for group-wise comparison and statistical analysis of relative 
expression results in real-time PCR. Nucleic Acids Res 30, e36. 
 
 
 161 
Pickard, B.S., Knight, H.M., Hamilton, R.S., Soares, D.C., Walker, R., Boyd, 
J.K.F., Machell, J., Maclean, A., McGhee, K.A., Condie, A., et al. (2008). A 
common variant in the 3'UTR of the GRIK4 glutamate receptor gene affects 
transcript abundance and protects against bipolar disorder. Proc Natl Acad Sci 
USA 105, 14940–14945. 
 
Pickard, B.S., Malloy, M.P., Christoforou, A., Thomson, P.A., Evans, K.L., Morris, 
S.W., Hampson, M., Porteous, D.J., Blackwood, D.H.R., and Muir, W.J. (2006). 
Cytogenetic and genetic evidence supports a role for the kainate-type glutamate 
receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol Psychiatry 11, 
847–857. 
 
Porsolt, R.D., Bertin, A., and Jalfre, M. (1977). Behavioral despair in mice: a 
primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229, 
327–336. 
 
Porter, R.H., Eastwood, S.L., and Harrison, P.J. (1997). Distribution of kainate 
receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and 
bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. 
Brain Res 751, 217–231. 
 
Racine, R.J. (1972). Modification of seizure activity by electrical stimulation. II. 
Motor seizure. Electroencephalogr Clin Neurophysiol 32, 281–294. 
 
Reijmers, L.G., Vanderheyden, P.M., and Peeters, B.W. (1995). Changes in 
prepulse inhibition after local administration of NMDA receptor ligands in the core 
region of the rat nucleus accumbens. Eur J Pharmacol 272, 131–138. 
 
Ren, Z., Riley, N.J., Needleman, L.A., Sanders, J.M., Swanson, G.T., and 
Marshall, J. (2003). Cell surface expression of GluR5 kainate receptors is 
regulated by an endoplasmic reticulum retention signal. J Biol Chem 278, 52700–
52709. 
 
 
 162 
Risbrough, V.B., Hauger, R.L., Pelleymounter, M.A., and Geyer, M.A. (2003). 
Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated 
acoustic startle in mice. Psychopharmacology (Berl) 170, 178–187. 
 
Rodriguez-Moreno, A., Herreras, O., and Lerma, J. (1997). Kainate receptors 
presynaptically downregulate GABAergic inhibition in the rat hippocampus. 
Neuron 19, 893–901. 
 
Rodríguez-Moreno, A., and Sihra, T.S. (2011). Metabotropic actions of kainate 
receptors in the control of glutamate release in the hippocampus. Adv Exp Med 
Biol 717, 39–48. 
 
Sakimura, K., Morita, T., Kushiya, E., and Mishina, M. (1992). Primary structure 
and expression of the gamma 2 subunit of the glutamate receptor channel 
selective for kainate. Neuron 8, 267–274. 
 
Schaeffer, H.J., and Weber, M.J. (1999). Mitogen-activated protein kinases: 
specific messages from ubiquitous messengers. Mol. Cell. Biol. 19, 2435–2444. 
 
Schmitz, D., Frerking, M., and Nicoll, R.A. (2000). Synaptic activation of 
presynaptic kainate receptors on hippocampal mossy fiber synapses. Neuron 27, 
327–338. 
 
Schmued, L.C., Stowers, C.C., Scallet, A.C., and Xu, L. (2005). Fluoro-Jade C 
results in ultra high resolution and contrast labeling of degenerating neurons. 
Brain Res 1035, 24–31. 
 
Shaltiel, G., Maeng, S., Malkesman, O., Pearson, B., Schloesser, R.J., Tragon, 
T., Rogawski, M., Gasior, M., Luckenbaugh, D., Chen, G., et al. (2008). Evidence 
for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating 
behavioral displays related to behavioral symptoms of mania. Mol Psychiatry 13, 
858–872. 
 
 163 
Sharma, A.K., Reams, R.Y., Jordan, W.H., Miller, M.A., Thacker, H.L., and 
Snyder, P.W. (2007). Mesial temporal lobe epilepsy: pathogenesis, induced 
rodent models and lesions. Toxicologic Pathology 35, 984–999. 
 
Sihra, T.S., and Rodríguez-Moreno, A. (2011). Metabotropic actions of kainate 
receptors in the control of GABA release. Adv Exp Med Biol 717, 1–10. 
 
Sokolov, B.P. (1998). Expression of NMDAR1, GluR1, GluR7, and KA1 
glutamate receptor mRNAs is decreased in frontal cortex of “neuroleptic-free” 
schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J 
Neurochem 71, 2454–2464. 
 
Steffenach, H.-A., Sloviter, R.S., Moser, E.I., and Moser, M.-B. (2002). Impaired 
retention of spatial memory after transection of longitudinally oriented axons of 
hippocampal CA3 pyramidal cells. Proc Natl Acad Sci USA 99, 3194–3198. 
 
Stone, M., Gabrieli, J.D., Stebbins, G.T., and Sullivan, E.V. (1998). Working and 
strategic memory deficits in schizophrenia. Neuropsychology 12, 278–288. 
 
Stupien, G., Florian, C., and Roullet, P. (2003). Involvement of the hippocampal 
CA3-region in acquisition and in memory consolidation of spatial but not in object 
information in mice. Neurobiol Learn Mem 80, 32–41. 
 
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, 
M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). 
Gene set enrichment analysis: a knowledge-based approach for interpreting 
genome-wide expression profiles. Proc Natl Acad Sci USA 102, 15545–15550. 
 
Telfeian, A.E., Federoff, H.J., Leone, P., During, M.J., and Williamson, A. (2000). 
Overexpression of GluR6 in rat hippocampus produces seizures and 
spontaneous nonsynaptic bursting in vitro. Neurobiol Dis 7, 362–374. 
 
 
 164 
Tian, H., Zhang, Q.-G., Zhu, G.-X., Pei, D.-S., Guan, Q.-H., and Zhang, G.-Y. 
(2005). Activation of c-Jun NH2-terminal kinase 3 is mediated by the GluR6.PSD-
95.MLK3 signaling module following cerebral ischemia in rat hippocampus. Brain 
Res 1061, 57–66. 
 
Tokuhara, D., Sakuma, S., Hattori, H., Matsuoka, O., and Yamano, T. (2007). 
Kainic acid dose affects delayed cell death mechanism after status epilepticus. 
Brain Dev. 29, 2–8. 
 
Tournier, C., Hess, P., Yang, D.D., Xu, J., Turner, T.K., Nimnual, A., Bar-Sagi, 
D., Jones, S.N., Flavell, R.A., and Davis, R.J. (2000). Requirement of JNK for 
stress-induced activation of the cytochrome c-mediated death pathway. Science 
288, 870–874. 
 
Valluru, L., Xu, J., Zhu, Y., Yan, S., Contractor, A., and Swanson, G.T. (2005). 
Ligand binding is a critical requirement for plasma membrane expression of 
heteromeric kainate receptors. J Biol Chem 280, 6085–6093. 
 
van den Buuse, M. (2010). Modeling the positive symptoms of schizophrenia in 
genetically modified mice: pharmacology and methodology aspects. Schizophr 
Bull 36, 246–270. 
 
van der Kooij, M.A., Groenendaal, F., Kavelaars, A., Heijnen, C.J., and van Bel, 
F. (2008). Neuroprotective properties and mechanisms of erythropoietin in in vitro 
and in vivo experimental models for hypoxia/ischemia. Brain Res Rev 59, 22–33. 
 
van der Weerd, L., Tariq Akbar, M., Aron Badin, R., Valentim, L.M., Thomas, 
D.L., Wells, D.J., Latchman, D.S., Gadian, D.G., Lythgoe, M.F., and de 
Belleroche, J.S. (2010). Overexpression of heat shock protein 27 reduces cortical 
damage after cerebral ischemia. J Cereb Blood Flow Metab 30, 849–856. 
 
Vannucci, S.J., Willing, L.B., Goto, S., Alkayed, N.J., Brucklacher, R.M., Wood, 
T.L., Towfighi, J., Hurn, P.D., and Simpson, I.A. (2001). Experimental stroke in 
the female diabetic, db/db, mouse. J Cereb Blood Flow Metab 21, 52–60. 
 165 
Vignes, M., and Collingridge, G.L. (1997). The synaptic activation of kainate 
receptors. Nature 388, 179–182. 
 
Vincent, P., and Mulle, C. (2009). Kainate receptors in epilepsy and 
excitotoxicity. Neuroscience 158, 309–323. 
 
Vivithanaporn, P., Yan, S., and Swanson, G.T. (2006). Intracellular trafficking of 
KA2 kainate receptors mediated by interactions with coatomer protein complex I 
(COPI) and 14-3-3 chaperone systems. J Biol Chem 281, 15475–15484. 
 
Wang, Q., Yu, S., Simonyi, A., Sun, G.Y., and Sun, A.Y. (2005). Kainic acid-
mediated excitotoxicity as a model for neurodegeneration. Mol Neurobiol 31, 3–
16. 
 
Werner, P., Voigt, M., Keinänen, K., Wisden, W., and Seeburg, P.H. (1991). 
Cloning of a putative high-affinity kainate receptor expressed predominantly in 
hippocampal CA3 cells. Nature 351, 742–744. 
 
Whalley, H.C., Pickard, B.S., McIntosh, A.M., Zuliani, R., Johnstone, E.C., 
Blackwood, D.H.R., Lawrie, S.M., Muir, W.J., and Hall, J. (2009a). A GRIK4 
variant conferring protection against bipolar disorder modulates hippocampal 
function. Mol Psychiatry 14, 467–468. 
 
Whalley, H.C., Pickard, B.S., McIntosh, A.M., Zuliani, R., Johnstone, E.C., 
Blackwood, D.H.R., Lawrie, S.M., Muir, W.J., and Hall, J. (2009b). Modulation of 
hippocampal activation by genetic variation in the GRIK4 gene. Mol Psychiatry 
14, 465. 
 
Whitmarsh, A.J., and Davis, R.J. (1996). Transcription factor AP-1 regulation by 
mitogen-activated protein kinase signal transduction pathways. J. Mol. Med. 74, 
589–607. 
 
 
 166 
Wo, Z.G., and Oswald, R.E. (1994). Transmembrane topology of two kainate 
receptor subunits revealed by N-glycosylation. Proc Natl Acad Sci USA 91, 
7154–7158. 
 
Yan, S., Sanders, J.M., Xu, J., Zhu, Y., Contractor, A., and Swanson, G. (2004). 
A C-Terminal Determinant of GluR6 Kainate Receptor Trafficking. J Neurosci 24, 
679–691. 
 
Yang, L., Mao, L., Chen, H., Catavsan, M., Kozinn, J., Arora, A., Liu, X., and 
Wang, J.Q. (2006). A signaling mechanism from G alpha q-protein-coupled 
metabotropic glutamate receptors to gene expression: role of the c-Jun N-
terminal kinase pathway. Journal of Neuroscience 26, 971–980. 
 
 
